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1. SUMMARY (ZUSAMMENFASSUNG) 
 
1.1. Summary 
Protein interactions as mediated by catalytic or non-catalytic protein domains 
contribute to cellular signal transduction processes by covalent protein modification of or non-
covalent binding to interaction partners. Ena/VASP homology 1 (EVH1) domains are found in 
different signal transduction proteins as N-terminal non-catalytic adaptor modules of ~ 115 amino 
acids sharing a common fold. By targeting their host proteins to subcellular sites of action they are 
involved in several signalling cascades which include protein phosphorylation and cytoskeletal 
reorganisation. In this study, protein interactions of the two EVH1 domain containing proteins 
VASP and Spred2 were studied according to their involvement in different and non-overlapping 
signal transduction pathways of the cell. 
EVH1 domains were first described in the Ena/VASP protein family with the 
Vasodilator-stimulated phosphoprotein VASP being its founding member. As a cytoskeleton-
associated protein VASP not only interacts with different proteins of the actin network but it is also 
a substrate for cAMP- and cGMP-dependent protein kinases. However the full complement of 
protein kinases targeting VASP as their substrate is still unknown. Here we used mouse cardiac 
fibroblast (MCFB) cells in order to study the phosphorylation status of VASP and identify new 
candidate protein kinases involved after serum stimulation of these cells. Using phosphosite-
specific antibodies we found that serum stimulation induces a phosphorylation of VASP at Ser-157 
in a time-dependent manner reaching its maximum after 90 min of stimulation. We developed an 
interaction graph model of possible candidate protein kinases involved. Using a pharmacological 
perturbation analysis with different combinations of specific protein kinase inhibitors and 
activators we excluded any contribution of cGMP-dependent protein kinase and Rho kinases to this 
process and identified a combined action of classical isoforms of PKCs and PKA in serum-
stimulated VASP phosphorylation at Ser-157 positioning PKC upstream of PKA in this signalling 
pathway. We hypothesise that PKC receives an external stimulatory signal upon serum stimulation 
of MCFB cells which is passed either directly or indirectly to PKA which finally phosphorylates 
VASP at Ser-157. 
A new EVH1 domain has been described recently in the Spred proteins (Sprouty 
related proteins containing an EVH1 domain) which are inhibitors of the Ras/Raf/MAP kinase 
pathway. Our laboratory has been involved in the elucidation of the atomic structure of the human 
Spred2 EVH1 domain by protein NMR spectroscopy (PDB 2JP2; 2007). A positively charged 
binding interface of this EVH1 domain suggests an interaction with negatively charged ligands; 
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however no interaction partners of this domain have been described so far. In the second part of 
this study, we used different genetic and biochemical screening methods to search for ligands of 
the Spred2 EVH1 domain. A bacterial two-hybrid system was established using a physically well 
characterized interaction of the VASP EVH1 domain with a panel of its ActA binding peptides as 
positive controls to screen a human brain cDNA expression library at different stringencies for 
candidate Spred2 EVH1 interaction partners. However none of the clones isolated could be 
genetically and physically validated to support Spred2 EVH1 specific interactions. An in-vitro 
screening of a 9-mer phage display peptide library using purified GST-Spred2 EVH1 fusion protein 
was performed together with a Fyn-SH3 fusion protein as a positive control. In contrast to the Fyn-
SH3 domain the majority of phages isolated with the Spred2 EVH1 domain either carried no inserts 
or inserts with stop codons suggesting a highly non-specific interaction of the phage coat protein 
with the latter domain but neither the Fyn-SH3 domain nor the GST moiety. Isolation of a 13-mer 
proline-rich sequence was particularly surprising in this context. In order to address possible 
interactions of the Spred2 EVH1 domain with non-peptidergic ligands protein-lipid interaction 
assays were performed. Quantitative binding studies to purified Spred2 EVH1 using a liposome 
sedimentation assay however excluded any interaction of candidate phospholipids of the 
phosphatidyl inositol phosphate class with the Spred2 EVH1 domain. A natively folded and thus 
binding-competent conformation of the purified proteins used was assessed independently by 1H 
protein NMR spectroscopy. In summary the cumulative evidence of our genetic and biochemical 
screening experiments suggests that the still elusive Spred2 EVH1 ligand(s) may be formed of 
hydrophobic peptide epitopes larger than nine amino acids in size and carrying negative charge(s). 
A phosphorylation of Spred2 EVH1 binding epitopes by a post-translational modification should 
be seriously considered in future experiments.  
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1.2. Zusammenfassung 
Proteininteraktionen, wie sie durch katalytisch oder nicht-katalytisch wirksame 
Proteindomänen vermittelt werden können, spielen eine wesentliche Rolle in zellulären 
Signaltransduktionsprozessen durch die kovalente Modifikation oder nicht-kovalente Bindung von 
Interaktionspartnern. Ena/VASP Homologie 1 (EVH1) Domänen finden sich als N-terminale, 
nicht-katalytische, etwa 115 Aminosäuren große und konserviert gefaltete Adaptormodule in vielen 
verschiedenen Signaltransduktionsproteinen. Indem sie ihre jeweiligen Wirtsproteine an deren 
subzellulärem Wirkort verankern helfen, sind sie an vielen verschiedenen Signalkaskaden wie z.B. 
Proteinphosphorylierungen oder Umbauprozessen des Zytoskeletts beteiligt. In dieser Arbeiten 
wurden Proteininteraktionen der beiden EVH1 domänen-haltigen Proteine VASP and Spred2 
untersucht, die in nicht überlappenden Signaltransduktionswegen der Zelle vorkommen.  
EVH1 Domänen wurden zuerst innerhalb der Ena/VASP-Proteinfamilie 
beschrieben, deren Gründungsmitglied das Vasodilator-stimulierte Phosphoprotein VASP ist. Als 
zytoskelett-assoziiertes Protein wechselwirkt VASP nicht nur mit verschiedenen Aktin-bindenden 
Proteinen, sondern ist auch ein Substrat der cAMP- und cGMP-abhängigen Proteinkinasen. Der 
vollständige Satz jener Proteinkinasen, die VASP als eines ihrer Substrate aufweisen, ist immer 
noch unbekannt. Hier haben wir kardiale Mausfibroblasten (MCFB) Zellen verwendet, um nach 
Serum-Stimulation dieser Zellen den Phosphorylierungsstatus von VASP zu bestimmen und daran 
beteiligte, neue Kandidaten-Proteinkinasen zu identifizieren. Mit Hilfe von 
Phosphorylierungsstellen-spezifischen Antikörpern konnten wir zeigen, dass eine Serum-
Stimulation eine zeitabhängige Phosphorylierung von VASP an Serin 157 induziert, die ein 
Maximum 90 min nach Stimulation erreicht. Wir entwickelten ein Interaktionsgraphen-Modell 
möglicher Kandidaten-Proteinkinasen, die an diesem Prozess beteiligt sein könnten. Mit Hilfe 
pharmakologischer Perturbationsexperimente auf der Grundlage spezifischer Proteinkinase-
Inhibitoren und Aktivatoren konnten wir einerseits eine Beteiligung der löslichen cGMP-
abhängigen Proteinkinase und von Rho-Kinasen an diesem Prozess ausschliessen und anderseits 
die gemeinsame Beteiligung der klassischen Proteinkinase C Isoform(en) und der cAMP-
abhängigen Proteinkinase nachweisen. In diesem Signalweg liegt dabei die Proteinkinase C 
stromaufwärts vor letzterer. Nach unserer Interpretation der Daten wird die PKC nach Serum-
Stimulation der MCFB-Zellen aktiviert und aktiviert ihrerseits direkt oder indirekt die cAMP-
abhängige Proteinkinase, die schliesslich VASP als proximales Substrat am Serin 157 
phosphoryliert. 
Eine neue EVH1 Domäne wurde kürzlich in den Spred Proteinen (Sprouty related 
proteins containing an EVH1 domain) beschrieben, die neue Inhibitoren im Ras/Raf/MAP-Kinase-
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Signalweg darstellen. Unser Labor war an der NMR-gestützten Aufklärung der atomaren Struktur 
der Spred2 EVH1 Domäne beteiligt (PDB 2JP2; 2007). Die positiv geladene Bindungsfurche dieser 
EVH1 Domäne legt eine Interaktion mit anionischen Liganden nahe. Interaktionspartner für diese 
Domäne sind bisher jedoch nicht beschrieben worden. Im zweiten Teil dieser Arbeit verwendeten 
wir verschiedene genetische und biochemische Suchverfahren zur Identifizierung möglicher 
Spred2 EVH1 Liganden. Ein bakterielles Two-Hybrid-System mit der Spred2 EVH1 Domäne als 
Köderprotein wurde dazu etabliert unter Verwendung der physikalisch gut charakterisierten 
Wechselwirkung der VASP EVH1 Domäne mit ihren ActA Bindungspeptiden als eines positiven 
Kontroll-Interaktionspaars und zum verschieden stringenten Durchmustern einer humanen cDNA 
Expressionsgenbank aus Gehirn eingesetzt. Keiner der isolierten Klone ließ sich jedoch genetisch 
oder nach Sequenzierung in Hinblick auf eine Spred2 EVH1 spezifische Wechselwirkung 
validieren. Mittels gereinigtem GST-Spred2 EVH1 Protein wurde daher eine 9-mer Peptid-
Genbank im Phage-Display-Verfahren durchgemustert unter Verwendung eines Fyn-SH3 
Fusionsproteins als positiver Kontrolle. Im Gegensatz zu den Ergebnissen mit letzterer trugen die 
mit der Spred2 EVH1 Domäne isolierten Phagen überwiegend keine Inserts oder solche mit Stop-
Codons, was eine unspezifische Wechselwirkung mit den Phagen-Hüllenproteinen dieser Domäne 
nicht jedoch der Fyn-SH3 Domäne oder des GST-Partners nahelegt. Die Isolierung einer 13-mer 
großen prolin-reichen Bindesequenz war in diesem Zusammenhang besonders überraschend. Um 
eine mögliche Wechselwirkung von Spred2 EVH1 mit nicht-peptidergen Liganden zu untersuchen, 
wurden Protein-Phospholipid-Interaktionsassays durchgeführt. Mittels quantitativer 
Bindungsstudien unter Verwendung der isolierten Domäne konnte eine Interaktion mit Kandidaten-
Phospholipiden aus der Klasse der Phosphatidylinositolphosphate in einem Liposomen-
Sedimentationsassay ausgeschlossen werden. Eine native Faltung und damit prinzipiell 
bindungskompetente Konformation(en) der gereinigten Proteine konnten mittels 1H Protein-NMR-
Spektroskopie sichergestellt werden. Zusammengenommen lassen unsere Experimente vermuten, 
dass es sich bei den noch immer nicht dingfest gemachten Spred2 EVH1 Liganden um hydrophobe, 
negative geladene, mehr als neun Aminosäuren umfassende Peptidepitope handeln könnte. Bei 
deren Identifizierung in zukünftigen Experimenten sollte mit ihrer Phosphorylierung durch post-
translationale Modifikationen gerechnet werden. 
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2. INTRODUCTION 
 
2.1. A portrait of VASP and Spred proteins which share a conserved EVH1 adapter domain 
but are involved in distinct signal transduction pathways 
 
2.1.1. VASP - a cytoskeletal phosphoprotein harboring an EVH1 domain 
 VAsodilator Stimulated Phosphoprotein (VASP) was first characterized by 
Halbrügge and Walter [1] as a major cyclic nucleotide dependent phosphorylated protein in 
platelets and endothelial cells on stimulation with vasodilators. Referring to this observation it has 
been named as “vasodilator stimulated phosphoprotein”. VASP acts as a molecular adaptor 
associated with areas of dynamic membrane activity and is involved in cell adhesion and migration. 
It has binding sites for various proteins and is a well established substrate protein for protein kinase 
A (PKA or cAK) and protein kinase G (PKG or cGK) [2] along with other kinases as found 
recently [3, 4].  
  VASP is the founding member of Ena/VASP protein family comprising actin 
regulatory proteins harboring an N-terminal Ena/VASP homology 1 (EVH1) domain. VASP is 
expressed in almost all mammalian cell types with high levels of expression in platelets, blood 
vessels, spleen, stomach, intestine and lung. VASP is subcellularly highly concentrated at focal 
adhesions and stress fibres. Moreover, VASP localizes at cell-cell contacts of various cultured cells 
and is associated with highly dynamic membrane structures such as the leading edge. In both 
mouse and humans, the coding gene is composed of 13 exons with conserved exon-intron positions 
and the predicted amino acid sequences are 89% identical. The human VASP gene has been 
assigned to chromosome 19q13.2-q13.3, an extended region with homology to mouse chromosome 
7 [5]. 
 
2.1.1.1. Domain organisation 
  Human VASP is a 39 kDa protein containing 380 amino acids and running as a 46 
kDa band in SDS-PAGE. Phosphorylation induced by vasodilator agents in intact cells or 
performed with purified components in-vitro shifts the molecular weight to an apparent molecular 
mass of 50 kDa [6]. VASP shows a tripartite domain organisation. In VASP, the N-terminal 
domain of about 115 amino acids is called Ena/VASP homology 1 domain (EVH1 domain) and the 
C-terminal domain is called Ena/VASP homology 2 domain (EVH2 domain) comprising about 
130-190 amino acids separated by a low complexity regions including a proline-rich central region 
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of 60 to 90 amino acids in length (Fig.1). VASP harbors three phosphorylation sites at Ser-157, 
Ser-239 and Thr-278 which have been well characterized in-vivo and in-vitro [2, 7]. 
 
PKGPKA
PRR EVH2EVH1 - COOHNH2 -
Ser-157 Ser-239 Thr-278
Binding domain 
for FP4 motifs of 
Vinculin, Zyxin 
and ActA
Binds to Profilin, 
SH3 and WW 
domain proteins
Contains binding sites 
for G- and F-actin and 
also a coiled coil motif 
for tetramerization
 
Figure 1: Structural organization of human VASP, localization of phosphorylation sites and overview of binding 
partners. EVH1 domain binds to FP4 motifs, the proline-rich region (PRR) binds with SH3, WW domains and profilin 
and the EVH2 domain binds to G-actin, F-actin and is responsible for tetramerization. VASP is a substrate for both 
PKA and PKG. PKA preferentially phosphorylates Ser-157 and PKG preferentially Ser-239. 
 
The proline-rich central region of VASP contains four copies of a GPPPPP (GP5) 
motif with three of them arranged in tandem. This proline-rich region binds to proteins containing 
Src Homology 3 (SH3) domains [8], WW domains [9] and profilin, an actin binding protein [10-
12]. It is not clear which of these interactions are shared among all members of the Ena/VASP 
family. Profilin undergoes dimerization upon binding to the proline-rich region of VASP and 
promotes actin filament formation [10]. These data support a model of an action of VASP in the 
process of actin filament formation [13-15]. The phosphorylation sites for PKA and PKG in the 
central proline region of VASP do not seem to alter microfilament formation upon their 
phosphorylation. 
The C-terminal EVH2 domain of VASP harbors three conserved blocks viz., a G-
actin binding site, an F-actin binding site and a coiled coil region necessary for tetramerization [16-
19]. The C-terminal oligomerization region of 45 residues is highly conserved and has been 
implicated in the oligomerization of individual members of Ena/VASP family. VASP behaves as 
tetramer and the conserved C-terminal block in the EVH2 domain is necessary and sufficient to 
mediate tetramer formation [16, 17]. The 1.3 Å resolution crystal structure of the tetramerization 
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domain reveals a parallel right-handed coiled-coil structure formed due to a 15-residue repeat in its 
amino acid sequence. Thus full-length tetrameric VASP adopts a ‘‘bouquet-like’’ quarternary 
structure [19]. The EVH2 domain harbors two phosphorylation sites (Ser-239 and Thr-278) which 
are suspected to regulate the functions of this domain [20-22]. Further characteristic functions of 
this domain have to be determined yet even though partial information has been disclosed 
including those on its role in subcellular localization and formation of multimers [11, 23]. 
 
2.1.1.2. VASP EVH1 domain 
  The N-terminal EVH1 domain of Ena/VASP family members is necessary for 
binding of VASP to the focal adhesions [11, 21] at the ventral cell surface by connecting with 
FPPPP proline-rich motifs [24, 25] present in its binding partners vinculin [26], zyxin [27, 28] and 
also in the Listeria actin binding protein, ActA [29, 30] among others. These interactions of the 
EVH1 domain are likely to be important in a number of cellular processes that require regulated 
actin filament assembly [25] and recruitment of Ena/VASP proteins to specific sites within the cell. 
The EVH1 domain structure of Ena/VASP family members has been elucidated both 
by X-ray crystallography [31, 32] and by NMR [24]. The EVH1 domain folds into a seven-
stranded β-barrel with a single C-terminal α-helix thus resembling a fold found in pleckstrin 
homology (PH), phospho tyrosine binding (PTB) and ran-binding domains (RanBD) [31-33]. 
VASP EVH1 domain shares structural homology with the WH1 (WASP homology 1) domain of 
another cytoskeletal protein Wiskott-Aldrich syndrome protein (WASP) and with N-terminal 
EVH1 domain of synaptic scaffold proteins (Homer/Vesl) and Sprouty related EVH1 domain 
containing (Spred) proteins [33] (see Chapter 2.2.2 for details). 
Detailed binding studies showed that the phenylalanine and the first and final proline 
residues in the proline-rich FPXФP motifs (X = any amino acid, Ф = hydrophobic amino acid) of 
VASP EVH1 binding partners are highly conserved which can not be replaced with natural amino 
acids without damaging the binding affinity (see Chapter 2.2.1). Recent substitution studies of 
these conserved residues with non-native amino acid derivatives (peptoide building blocks) may 
open up the way for designing selective modulators of VASP function for biological studies and for 
the development of novel therapeutics for diseases involving pathologically altered cell adhesion or 
cell motility. Well characterized binding partners for the EVH1 domain of VASP which provide 
surface exposed proline-rich motifs to bind specifically are vinculin [34], zyxin [27] and other 
binding partners known so far viz., T-cell signalling Fyn-binding protein/SLP-76-associated protein 
(Fyb/SLAP) [35], the lipoma preferred partner LPP protein [36] and recently found paladin [37]. 
VASP interacts with its EVH1 domain directly with ActA, a bacterial protein from Listeria 
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monocytogenesis required for the recruitment and assembly of host actin filaments around the 
intracellular bacteria [12, 30, 38, 39].  
 
2.1.1.3. Family members 
Ena/VASP proteins are major constituents of signal transduction pathways 
regulating organization of the cytoskeleton. These proteins are a conserved family of actin 
regulatory proteins, which have been implicated in actin based process such as fibroblast migration 
[40], axon guidance and T-cell polarization, phagocytosis, migration of neutrophils and are also 
important for the actin based motility of the intracellular pathogen, Listeria monocytogenesis [12] 
as mentioned above. They localize to highly dynamic areas of actin reorganization, such as the 
leading edge of lamellipodia, the tips of filopodia; adherens type cell matrix, cell–cell junctions and 
other dynamic membrane regions [8, 40]. These regulator proteins of cell motility and actin 
assembly are found in a variety of organisms and cell types [8, 15]. VASP is the founding member 
of Ena/VASP family. Drosophila enabled (Ena), another member of this family, was discovered in 
a genetic screen for extragenic suppressors of Drosophila Abelson tyrosine kinase (D-Abl) mutants 
[41]. Ena has an important role in guiding axonal connections in the central and peripheral nervous 
system and embryonic epithelial morphogenesis of the fly [42, 43]. Later, in addition to Ena, other 
members of this family from vertebrates, namely Mammalian enabled (Mena), and Ena/VASP–like 
(EVL) protein were identified [44, 45]. 
Proteins of the Ena/VASP family are characterized by a common overall domain 
organization consisting of the conserved amino terminal EVH1 and carboxyl terminal EVH2 
domains separated by a less conserved central proline-rich region as explained in Chapter 2.1.1.1 
(see Fig.1) [8, 15, 46]. Mena contains two phosphorylation sites (Ser-236, Tyr-296) the first one is 
equivalent to the first site in VASP (Ser-157), EVL has only this site. Interestingly, Drosophila Ena 
lacks a clear equivalent of this VASP Ser-157 phosphorylation site which is only conserved among 
the vertebrate members of this family [8]. Phosphorylation of Mena and EVL at the position 
equivalent to VASP Ser-157 also induces band shifts in their mobility [15]. 
 
2.1.1.4. Signalling pathways 
All Ena/VASP proteins are well characterized substrates of cAMP and cGMP 
dependent protein kinases (cAK; cGK or PKA; PKG) [7, 45], but these proteins harbor conserved 
and divergent sites for phosphorylation at different regions (see above). VASP harbors three 
phosphorylation sites viz., Ser-157, Ser-239, and Thr-278 and is one of the major substrates for 
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PKA and PKG (Fig.1) [2]. VASP acts thus as a major effector molecule in cyclic nucleotide 
dependent pathway(s) and impacts many cellular functions. 
In VASP, the preferred phosphorylation site for PKA is Ser-157, which leads to the 
above mentioned retardation of VASP mobility during SDS-gel electrophoresis, resulting in an 
apparent shift in molecular weight of VASP from 46 to 50 kDa [2] indicating that this 
phosphorylation may cause a change in structure of the molecule and/or in SDS detergent binding 
to the protein. The preferred site for PKG on VASP is Ser-239 while Thr-278 is a less favoured site 
for both PKA and PKG, but recent studies have shown that Thr-278 is a preferred site for AMP 
activated protein kinase (AMPK) [3]. Phosphorylation of these later two sites does not shift the 
apparent molecular weight of VASP as assayed by SDS-PAGE. To date, the exact functional role 
of any of the three phosphorylation sites is unclear at a mechanistic level. However, a positive 
correlation between phosphorylation of VASP at Ser-157 and the inhibition of fibrinogen receptor 
(integrin αIIbβ3) activity was reported [47]. In endothelial cells, PKG induced-phosphorylation 
resulted in the detachment from focal adhesions of wild type VASP, but not of mutant VASP 
containing Ser/Thr to Ala substitutions at all three phosphorylation sites [20, 48]. It was also 
hypothesized that VASP interacts with mammalian Diaphanous (mDia) protein(s) to regulate the 
cytoskeletal actin dynamics [21, 49]. Also, recent in-vivo and in-vitro studies have proved a role of 
PKC either directly or indirectly in phosphorylation of VASP [4, 50-52] which is in correlation 
with our studies submitted in this thesis. Also, a serine threonine kinase, AMP activated protein 
kinase (AMPK) was shown to be a new kinase activity phosphorylating VASP specifically at Thr-
278 and effecting cell morphology [3]. Work presented in this thesis is focused on elucidating new 
signalling networks involved in regulation of VASP phosphorylation. However open questions still 
concern the molecular mechanisms by which phosphorylation effects Ena/VASP protein’s 
function. 
 
2.1.1.5. Physiological functions  
  VASP is a crucial factor in regulating actin dynamics and associated processes such 
as cell-cell adhesion, platelet function and actin-based motility of both cytopathogenic Listeria and 
its eukaryotic host cells. Although biochemical mechanisms emerged depicting VASP as enhancer 
of actin filament formation at the subcellular level increasing evidences suggest that these proteins 
have inhibitory functions at the cellular level in integrin regulation, cell motility and axon guidance 
[15, 53-55].  
  An important putative function of VASP is to promote actin filament assembly 
which depends on the ability of VASP to recruit the G-actin binding protein, profilin through its 
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GP5 motif to strengthen the binding capacity with G-actin [12]. The G-actin binds to profilin and 
VASP at the leading edge of the cell and results in ruffling and extension of F-actin filaments. The 
control of F-actin assembly could be exerted at the level of availability of free barbed ends through 
nucleation, uncapping or severing by actin depolymerising factor (ADF) and the stabilization of 
VASP-profilin binding. AMPK mediated VASP phosphorylation at Thr-278 reduces F-actin fiber 
assembly and impairs stress fiber formation [3]. The direct interaction of VASP with monomeric 
actin [18, 56] was also suggesting the same and the phosphorylation of VASP would effect this 
interaction by changing the actin binding properties [20]. The effects of VASP deletion/over-
expression on the motile behaviour of living cells [54, 57, 58] and actin based propulsion of 
Listeria [12, 38, 39] has given cumulative evidence for a role of VASP in cell motility. It was 
shown that VASP also seem to compete with capping proteins to bind at the barbed ends [59] and it 
enhances branched actin polymerization when ActA protein is immobilized on beads or Listeria 
[60]. VASP increases the rate of dissociation of the branch junction from immobilized ActA, which 
was found to be the rate–limiting step in the catalytic cycle of site directed filament branching [60]. 
The signalling pathways induced by vasodilators phosphorylate VASP in smooth 
muscles and platelets and are mediated by PKA and PKG [7]. Since both PKA and PKG signalling 
cascades relax smooth muscle cells and inhibit platelet activation [61, 62], it was speculated that 
phosphorylation of VASP by these cascades mediates the respective effects by modulating actin 
filament dynamics and integrin activation. At the same time, it was shown in VASP null mice 
studies that PKG and PKA mediated inhibition of calcium mobilization and granule secretions in 
platelets are independent of VASP [63] and it is a negative modulator of platelet and integrin αIIbβ3 
activation [64]. This suggests that the cellular role of VASP in the mediation of effects of 
vasodilators might be an indirect one. Phosphorylation of Ser-157 in VASP appears to correlate 
with their activity in cell motility [40]. It seems likely that this phosphorylation relieves either intra 
or inter-molecular inhibitory interactions.  
Further, recent research developments are suggesting the role of protein kinase C in 
phosphorylation of VASP, cytoskeletal regulation and focal adhesion induction [4, 51, 52]. This 
interconnectivity can be elucidated by inhibiting growth hormone or serum activated kinases and 
looking at the phosphorylation of VASP. This approach can reveal new signalling networks that 
might contribute to phosphorylation of VASP. 
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2.1.2. Spred - an inhibitor of the Ras/Raf/MAP kinase pathway harboring a new class of 
EVH1 domains 
Spred proteins are recently described Sprouty-related proteins with an EVH1 
domain (Spred) establishing a new class of EVH1 domains. They are membrane-associated 
suppressors of tyrosine kinases and act as negative regulators of the Ras/Raf/MAP kinase pathway 
upon growth factor stimulation. These proteins are involved in regulation of differentiation in 
neuronal cells and myocytes. All members of the Spred protein family contain an N-terminal 
EVH1 domain and a Sprouty-related C-terminal cysteine-rich SPR domain (Fig.2) which is 
responsible for translocation of Spred proteins to the plasma membrane [65].  
To date, three mammalian Spreds are identified: Spred-1, Spred-2 [66], and a third 
isoform discovered through nucleic acid homology, called Spred-3 [67]. All Spred proteins that 
have been described so far localize to the plasma membrane [67]. Recent studies have disclosed the 
localization of Spred-1 and Spred-2 proteins in different organs and cell types which depicts their 
role in tissue development and organisation. Comparison of the mRNA expression profile of Spred 
family members in developing rat lung revealed that expression of Spred was found predominantly 
in mesenchymal cells [68]. The Spred-2 isoform was studied in this thesis determining its EVH1 
domain structure and interacting partners. 
 
2.1.2.1. Domain organisation 
Similar to VASP, Spred proteins also show a tripartite domain organisation albeit 
with different elements harboring besides a conserved N-terminal EVH1 domain, a central c-Kit 
binding domain (KBD) and a C-terminal Sprouty-like cysteine-rich domain (SPR domain) (Fig.2) 
[33, 66, 67]. 
The c-Kit binding domain in the middle part of the Spred proteins consists of about 
50 amino acids first described in Spred. This domain is not related to any previously identified 
tyrosine kinase interaction domain [66]. It has been shown to be responsible for the interaction with 
the receptor tyrosine kinases c-kit and c-fms. Spred-3 with a non-functional KBD and deletion 
mutants of Spred-1 in this region revealed that this internal region is involved but not essential for 
ERK suppression [66, 67, 69]. This raises the question of what the physiological function of this 
domain might be. 
Similar to Sprouty proteins Spred proteins harbor a well conserved cysteine-rich 
SPR domain at the C terminus. In the case of Spred-2, it is required for efficient suppression of 
stem cell factor-induced ERK phosphorylation and suppression of hematopoietic cell development 
[70]. This domain is involved in binding to phosphatidylinositol 4, 5-bisphosphate [71] and for the 
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interaction with Raf1 [72]. A C-terminal deletion mutant of Spred-1 was shown to act as a 
dominant negative form and augments growth factor-induced ERK activation [66, 73]. Spred-2 
with a deletion of the Sprouty domain was unable to suppress ERK activation but similar loss in 
Spred-1 and Eve-3 were still functional in suppressing ERK activation raising a controversial 
discussion [74, 75]. Therefore, future work has to be done, elucidating the physiological function of 
the SPR domain. 
 
EVH1 - COOHNH2 - KBD SPD
c-Kit, c-Fms 
binding domain, 
site for thyrosine 
phosphoryaltion
Raf, caveolin-1 
binding domain, 
domain for 
heterodimerization 
and palmitylation
Unknown 
interaction 
partner
 
Figure 2: Structural organization of human Spred2 and overview of binding partners. Binding partners for EVH1 
domain is not known yet, c-Kit binding domain (KBD) is a site for thyrosine phosphorylation and binds to c-Kit and c-
Fms domains and the well-conserved cysteine-rich Sprouty-related domain (SPD) binds to Raf, caveolin-1 and is 
responsible for heterodimerization and palmitylation.  
 
2.1.2.2. Spred EVH1 domain 
A new family of proteins also containing a new class of N-terminal EVH1 domains 
was described by Yoshimura and co-workers [66], called Spred protein. EVH1 domains of mouse 
and human Spred are identical, named as the human Spred-1a and mouse Spred-1 EVH1 domains. 
The human Spred-1 EVH1 domain is also very closely related to the other two domains with only 
two conservative mutations in comparison. The human Spred-3 EVH1 domain shows much less 
conservative mutations and an insertion [67]. 
The typical aromatic triad present on the surface of EVH1 domains formed by Arg-
Trp-Phe in case of Spred is certainly an important factor for determining ligand specificity [33] 
(Table.1). The recently determined crystal structure of the Spred1 EVH1 domain from Xenopus 
tropicalis solved to 1.15 Å resolution suggests that dislocation of one of the peptide-binding groove 
beta-strands might narrow the putative ligand binding groove although one end of the groove 
shows structural flexibility. Based on these observations, it was proposed that Spred EVH1 might 
bind peptides that are less proline-rich than other EVH1 domain binding motifs with 
conformational changes indicating an induced fit [76]. The specific binding partner of the Spred 
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EVH1 domain is currently unknown for any of its isoforms although the limited expression 
patterns and non-overlapping functional roles in signal transduction of its host proteins suggest 
specific binding partner different from other EVH1 domain classes. Recently, the NMR structure of 
human Spred2 EVH1 domain which been determined in a collaborative effort of this Institute and 
the Structural Genomic Consortium (SGC), Oxford has been submitted to the PDB database with 
access code 2JP2 and can be accessed from http://www.sgc.ox.ac.uk/ structures/ SPRED2A_2jp2. 
html [77]. 
The EVH1 domains of the three mammalian Spred paralogues are functionally 
interchangeable [67]. Involvement of the Spred EVH1 domain in Raf inhibition was proved by the 
studies in which replacement of the murine Spred1 EVH1 domain with the Wiskott–Aldrich 
syndrome protein (WASP) EVH1 domain was not sufficient to inhibit the MAPK pathway [66]. 
Moreover, Eve-3 consisting only EVH1 domain is potent in inhibiting the MAP kinase pathway 
[75]. However, deletion of the EVH1 domain in Spred-2 (ΔN-Spred-2) was shown to be competent 
to inhibit differentiation of murine haematopoietic cell lines [70]. But, sprouty domain deletion in 
Spred-1 shown negative dominance behaviour in EVH1 domain regulated activities [73]. These 
observations suggest that the different Spred proteins use different mechanisms to induce inhibition 
of the MAPK pathway. 
 
2.1.2.3. Family members 
The Spred proteins can be divided into four members as so far described in the 
literature including three mammalian homologous isoforms Spred-1, Spred-2, Spred-3 and a 
Drosophila founder member AE33. Recently, a splice variant of Spred-3 named Eve-3 was 
identified [75]. All of them bear an N-terminal EVH1 domain and Eve-3 contains merely a single 
EVH1 domain whereas Spred-3 lacks a functional c-Kit binding domain but maintains the 
inhibitory action on Raf suggesting that the KBD is not required for this action [67]. So far, four 
binding partners of Spred proteins were described, namely Raf1, caveolin-1, Ras, and RhoA [66, 
69, 72, 78]. The former two bind to the Spred SPR domain, but the binding property of the latter 
two members with Spred proteins is unknown so far although their signal transduction cascades 
have been studied. The Spred-1 protein interacts with both Ras and Raf, probably through the 
Sprouty domain [66]. Spred-1 is expressed predominantly in adult brain and in some fetal tissues, 
suggesting a role during development [79]. Spred-2 isoform express ubiquitously in adults; 
especially strong expression was seen in neural tissues and different glandular epithelia, but not in 
fetal tissues. Spred-3 isoform was detected only in brain [67, 79], whereas Eve-3 was limited to the 
developing liver [75].  
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2.1.2.4. Signalling pathways 
Spred proteins were first described as suppressors of the Ras/Raf/MAPK signalling 
pathway [66] [80] which regulates proliferation and differentiation of cells in response to 
extracellular signals but they suppress ERK signalling by a different mechanism [81]. Spred 
proteins are potent inhibitors of a wide range of mitogenic stimuli like different growth factors, 
cytokines, and chemokines, but the suppressing effect seems to be restricted to the 
Ras/ERK/MAPK pathway [67, 73, 74, 78, 81] [80]. Endogenous Spred constitutively associates 
with Ras and inhibits the activation of MAPK by suppressing the phosphorylation and activation of 
Raf [66]. This mechanism prevents neither Ras activation nor membrane translocation of Raf, but 
reduces the threshold of growth factor sensitivity for differentiation [66]. In Spred-2–/– 
midgestation mouse embryos, Spred-2 suppresses hematopoietic processes by inhibiting MAPK 
activation [70] and stem cell factor or interleukin-3 stimulation of mature Spred-1–/– bone marrow-
derived mast cells resulted in increased cell proliferation and MAPK activation [73]. Therefore, 
Spred-2 could serve as a negative regulator of embryonic [70] and Spred-1 of mature late phase 
hematopoiesis, respectively [73]. However, the EVH1 domain mediated protein interactions of 
Spred are not yet known which would disclose its role in cell signalling cascades. 
 
2.1.2.5. Physiological functions 
As mentioned above, the knock-out studies uncovered the physiological functions of 
Spred proteins. Spred proteins are not necessary for fertility and development, and young adult 
mice of Spred knock-out are viable and show no apparent abnormalities [82]. However, loss of 
functional Spred-2 protein causes a dwarf phenotype, similar to hypochondroplasia, a common 
form of human dwarfism [82]. In this context, Spred-2 seems to be an important modulator of bone 
morphogenesis by inhibiting the fibroblast growth factor-induced MAPK pathway [82]. Similarly, 
Spred-1 negatively regulates allergen-induced airway eosinophilia and hyperresponsiveness 
without affecting helper T cell differentiation [83]. Recently, Spred-1 and Spred-2 have been 
shown to down regulate cell motility by suppressing activated RhoA induced stress fiber formation 
[78]. Furthermore as already mentioned above, Spreds seem to be important for hematopoiesis. 
Expression levels of Spred-1 and Spred-2 in human hepatocellular carcinoma tissue were 
frequently decreased compared to non-tumour tissue and their expression levels are inversely 
correlated with the process of invasion and metastasis [84]. Expression of Spred-1 inhibited 
carcinoma cell motility and proliferation in-vivo and in-vitro which is associated with ERK down 
regulation [84]. A specific function of Spred-3 which is expressed exclusively in brain [67] is not 
known yet. Physiological functions of Spred proteins are not completely known due to lack of well 
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characterized interaction partners. Determination of the Spred EVH1 domain binding motifs will 
disclose Spred proteins further regulated physiological functions.  
 
2.2. A classification scheme of EVH1 domains: portrait of a conserved domain family 
Enabled (Ena)/vasodilator-stimulated phosphoprotein (VASP) homology 1 (EVH1) 
domains, sometimes referred to as Wiskott–Aldrich syndrome protein homology 1 (WH1) 
domains, are a family of small (~115 residues; ~13 kDa), non-catalytic, protein–protein interaction 
adaptor modules essential for their host proteins in subcellular localisation and connecting to 
various signalling pathways. EVH1 domains occur in single copies located exclusively at the N-
termini of their host proteins (Fig.3). This conserved, unique N-terminal location appears to be a 
characteristic feature of EVH1 domains, which categorizes them clearly apart from structurally 
related domains such as RanBDs, PTB, and PH domains (Fig.3). The EVH1 domains may confer a 
segmental polarity to their host proteins that is required for functional or biogenetic reasons, 
resulting in the topological separation of this exposed terminal adaptor domain from the different 
types of genetically fused effector domains with which they co-exist and lodging a specific binding 
socket for its interaction partners [33]. In all EVH1 domains, a highly conserved cluster of three, 
surface-exposed aromatic side chains forms the recognition triad for their target specific proline-
rich sequence ligands and classified these domains into different classes based on these 
interactions. The predicted phylogenetic evolutionary relationship enlighten that EVH1 domains 
within a class are more related than within the same species suggesting that the homology among 
specific sub-family members reflects similar functional and binding specificities (Fig.3). The 
possible divergence of a common ancestor of EVH1 domains into the different classes would 
probably predate the divergence of the Bilateria.  
EVH1 domains mediate protein–protein interactions in a diverse range of signalling 
cascades, depending on their host protein and site of action [33]. The protein–protein interactions 
mediated by EVH1 domains are highly important for the regulation of signal transduction events, 
re-organization of the actin cytoskeleton, and modulation of actin dynamics and actin-based 
motility. Many EVH1 containing proteins are associated closely with actin-based structures and are 
involved in re-organization of the actin cytoskeleton. EVH1 domains are also present in proteins 
enriched in neuronal tissue, thus implicating them as potential mediators of synaptic plasticity, 
linking them to memory formation and learning.  
 
2.2.1. EVH1 domains recognize proline-rich sequences in their binding partners in a stereo-
specific manner 
Introduction 
 
16 
Like Src homology 3, WW and GYF domains and profilin, EVH1 domains 
recognize and bind specifically to core proline-rich motifs (PRMs) in peptides exposed on the 
surfaces of their binding partners [24, 25, 33, 85]. A small PRMs of 4–6 amino acids in the target 
peptides (6-12 amino acids) bind the recognition pocket on the domain surface which is unique for 
each class of EVH1 family due to their characteristic so called aromatic triad formed by three 
surface exposed amino acids (Table.1). Often, the target core PRMs occur in close tandem repeats 
in the sequence of the binding partner which could provide an additional mechanism for increasing 
binding affinity. The binding affinities of the core motifs in isolation are extremely low (Kd values 
in the millimolar range), but are increased to biologically significant levels by the presence of core-
flanking epitopes, which make additional contacts with the domain surface [85]. The three-
dimensional structures of EVH1: peptide complexes reveal the most important features of these 
interactions and explain the origins of specificity, ligand orientation and sequence degeneracy of 
target peptides in the low affinity signalling complexes (for review see [24, 33]). 
 
(a) (b)
 
Figure 3: Occurrence, distribution and phylogenetic classification of EVH1 domains. (a) Domain organisation in 
proteins containing EVH1 domain: The EVH1 domain occur in single copies located exclusively at the N-terminus (b) 
Phylogenetic tree of EVH1, RanBD, PH and PTB domain sequences derived from a structure-based sequence 
alignment with branch lengths indicating sequence similarity. Clustering of sequences on this tree identified four 
distinct classes of EVH1 domains. Source: [33] 
 
In the EVH1: peptide complexes, the surface exposed Trp side chain (Trp23; VASP 
numbering) is usually located at the centre of the aromatic triad and is oriented in a plane almost 
perpendicular to the domain surface. On one or both sides, at approximately 90° to this plane and 
almost parallel to the domain surface, lie the flat rings of either Tyr or Phe side chains [33]. This 
perpendicular arrangement of aromatic rings results in rectangular organized hydrophobic pockets 
on each side of the central Trp, well-suited to the recognition of peptide ligands that adopt 
structures close to that of a left-handed poly proline-II (PP-II) helix [33]. The FPXXP containing 
peptides bound by the Ena/VASP EVH1 domains and the LPPPEP region of the WIP peptide 
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bound by the N-WASP EVH1 domain are good examples of this. The indole proton of the central 
Trp forms a hydrogen bond to one of the backbone carbonyl oxygens in the peptide, which further 
anchors the ligand into place [33, 86]. The side chains of the peptide residues surrounding this 
carbonyl trunk (usually prolines) then pack closely into the rectangular shaped hydrophobic 
pockets on either side of the central Trp side chain. In the Ena/VASP EVH1 domains, Tyr16 and 
Phe79 (VASP numbering) comprise the Trp flanking aromatic residues, and the proline residues P 
(2) and P (5) of the Class 1 EVH1-binding motif FPPPP binds to either side of Trp23 [24, 33]. The 
N-terminal Phe(1) of this sequence makes a further close hydrophobic contact with the domain, 
which is important for anchoring the peptide and for determining the orientation of a highly 
symmetric ligand [85].  
Variations in the geometries of the PRM binding sites give rise to the observed 
differences in ligand preference between the different domain sub-families. Nevertheless, they are 
critically placed and provide sufficient external variation to tailor the different classes of EVH1 
domains to recognize highly specific target sequences [85]. This allows EVH1 domains to be used 
as versatile molecular adaptors by diverse families of host proteins to mediate their localization to 
very different signalling proteins. Recent substitution studies have incorporated peptoid building 
blocks (non-natural amino acids) into binding peptides derived from proline-rich regions and were 
able to substitute the most highly conserved residues without altering the EVH1 binding affinity to 
the corresponding partner [29]. This approach may open up the way for designing selective 
modulators for biological signalling studies and for the development of new therapeutics. 
Interestingly, the PRM-binding interfaces of the EVH1 domains described above have many 
features in common with those of the other protein interaction domains that bind specifically to 
proline-rich sequences viz., SH3, WW, GYF, and UEV domains, as well as the small, actin-
binding, profilin protein. The described stereochemical mechanism for proline-rich peptide 
recognition is therefore not specific to EVH1 domains, but is rather widely used in many different 
types of adaptor modules involved in several signalling pathways [33]. 
 
2.2.2. EVH1 domains are classified into four groups based on similarity of their sequences 
and recognition pattern of their ligands  
EVH1 domain family proteins can be classified by a phylogenetic analysis of 
structural similarities based on their sequence conservation, domain co-occurrence, and ligand 
binding preferences. The EVH1 domains are categorised into four main groups, named after their 
primary host proteins viz., the Ena/VASP class, the Homer/Vesl class, the WASP/N-WASP class, 
and the Spred class. 
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2.2.2.1. Class 1: The Ena/VASP class  
The EVH1 domains were first identified in host proteins comprising of the 
Ena/VASP protein family which includes Drosophila Ena, its mammalian orthologs (VASP, Mena, 
and EVL), C. elegans Unc-34, and Dictyostelium discoideum DdVASP [8, 87] (for more details, 
see Chapter 2.1.1.3). As explained above the domain structure of this class and the characteristic 
aromatic triad formed by the class-specific amino acids Tyr, Trp and Phe specifically recognizes 
the consensus binding motif FPxφP (Table.1) (where φ is a hydrophobic residue) in vinculin [26], 
zyxin [27, 28] the Listeria actin binding protein, ActA [29, 30], the intracellular axon guidance 
receptors in Drosophila and C.elegans, Robo [42] and SAX-3 proteins [88] respectively, the fyn-
binding / SLP-76- associated protein (Fyb-SLAP) [35], the lipoma preferred partner LPP protein 
[36], semaphoring 6A-1 protein (SEMA6A-1) with a zyxin like carboxy terminal domain [89], and 
paladin [37]. Proline residues at positions (2) and (5) (FPPPP) are essential for EVH1 binding and 
the prolines at positions (3) and (4) (FPPPP) are highly variable [85]. Position (3) is completely 
non-specific and could be replaced by almost any other residue, whereas position (4) required a 
hydrophobic residue in order to determine EVH1 binding [24, 31, 32]. 
 
EVH1 class Host protein 
3D-structure 
PDB code Aromatic Triad 
Consensus ligand 
Motif 
VASP 1EGX Tyr16 Trp23 Phe79 FPXXP 
Class 1 
Mena 1EVH Tyr16 Trp23 Phe77 FPXXP 
Class 2 Homer 1DDV Ile16 Trp24 Phe74 TPPXXF 
Class 3 N-WASP 1MKE Ala48 Trp54 Phe104 DLPPPEPYNQT 
Class 4 Spred 2JP2 Arg23 Trp30 Phe88 This study 
 
Table 1: The classification of EVH1 domain family members. Summary of different classes of the EVH1 domain 
family featuring the highly conserved triad of aromatic amino acid residues and specific proline-rich ligand motifs are 
shown in the table (for details see Chapter 2.2.2). The protein database (PDB) code for the respective EVH1 domain’s 
atomic structure is also given here. 
 
2.2.2.2. Class 2: The Homer/Vesl class 
The Homer/Vesl proteins are a family of synaptic scaffolding proteins that are 
constitutively expressed in brain and enriched at excitatory synapses representing the class 2 of 
EVH1 domain family [90]. The domain architecture of the Homer/Vesl family is variable. Homer 1 
contains only an N-terminal EVH1 domain followed by a low complexity region. In contrast, its 
close relative Homer 2 consists of an N-terminal EVH1 domain, a low complexity linker region, 
and a leucine zipper motif at the C-terminus responsible for clustering (Fig.3) [91, 92]. In the 
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Homer/Vesl proteins, Ile replaces Tyr to offer a characteristic aromatic triad (Table.1) which alters 
the structural basis and geometry of the PRM recognition mode from that of Ena/VASP EVH1 
domains, thereby recognising the class 2 specific EVH1-binding motif TPPxxF in a very different 
binding mode [85, 90, 93]. The two consecutive prolines and the terminal Phe of the TPPxxF motif 
make the closest hydrophobic contacts to the Homer EVH1 domain surface, with the exposed 
indole proton of Trp24 (numbering according to VASP) forming a hydrogen bond to the carbonyl 
oxygen of the N-terminal Thr [85, 90, 91, 93, 94].  
The Homer-Vesl proteins show no obvious connection to the actin assembly 
machinery and are found enriched in neuronal tissue. These proteins are proposed to play a role in 
long-term potentiation in excitatory synapses, with implications for memory formation [95]. 
Homer-Vesl EVH1 domains bind selectively to PPxxF containing motifs found in the C-termini of 
group I metabotropic glutamate receptors (mGluRs), inositol-1, 4, 5-trisphosphate receptors 
(IP3Rs), ryanodine receptors (RyRs) and the Shank family proteins [92]. The EVH1 domain of 
Homer 1 also interacts with its own proline-rich motif in the linking region [91]. 
 
2.2.2.3. Class 3: The WASP/N-WASP class  
The WASP/N-WASP family exhibits a more complex domain structure, comprising 
an N-terminal EVH1 domain (sometimes referred to as WH1 domains) [96], a short basic motif, a 
GTPase binding domain (GBD), a proline-rich region, and a C-terminal region containing either a 
verprolin homology (VPH) and cofilin-acidic (CA) domain (WASP) or two tandem VPH domains 
followed by a single CA domain (N-WASP) (Fig.3). The N-terminal EVH1 domain binds 
specifically a proline-rich sequence LPPPEPY in the WASP interacting protein (WIP), CR16 and 
verprolin [96]. The PRM binding triad of N-WASP is most closely related to that of Homer and 
conserved Tyr16 of the Ena/VASP class (equivalent to Ile16 in Homer) is replaced by Ala 48 and 
thus it is no longer part of the peptide binding site. Instead, a groove comprising of Trp54, Phe104 
and Thr106 in the N-WASP EVH1 domain contributes to form an identical aromatic cluster for 
WIP peptide contact (Table.1). In contrast to the other EVH1 domains the N-WASP EVH1 domain 
binds a much longer proline-rich peptide, having a minimum length of 25 residues. It does not bind 
a 10-residue ligand of the Mena EVH1 domain from ActA, which contains a PRM (DFPPPPT) 
very similar to that found in the WIP peptide (DLPPPEP) [30]. It has recently been proved that this 
domain needs multiple recognition motifs for its functional activity [97] and binds to WIP in a 
reverse orientation to that observed in other classes of EVH1 domains [33, 96]. Similar to 
Ena/VASP proteins, the WASP family proteins are closely associated with cytoskeleton regulation. 
They are believed to regulate actin assembly downstream of Cdc42 and phosphatidylinositol 4, 5-
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bisphosphate signalling pathways [98]. Mis-sense mutants in their N-terminal EVH1 domains 
result in the X-linked recessive disorder Wiscott – Aldrich syndrome (WAS), characterized by 
immunodeficiency, eczema, and thrombocytopenia [96]. 
 
2.2.2.4. Class 4: The Spred class  
The Spred proteins possess as mentioned above a domain structure comprising an N-
terminal EVH1 domain, a central c-Kit binding domain (KBD) and a C-terminal cysteine-rich 
Sprouty-related (SPR) domain (Fig.3) [67, 80]. As described in Chapter 2.1.2.2, a characteristic 
aromatic triad (Table.1) is expected to determine the specific ligand preference of this EVH1 
domain class [33]. Binding studies have shown that the Spred EVH1 domain does not bind the 
FPPPP motif recognized by the Ena/VASP EVH1 domains and no binding partner has been 
identified for this EVH1 domain so far. Yet the fairly restricted tissue distribution of some Spred 
isoforms suggests that their binding partners may be significantly different from those of the other 
EVH1 domains. Recently, The SGC group (Oxford) in collaboration with our Institute has solved 
the NMR structure of the human Spred2 EVH1 domain and deposited it in the data base under 
accession code “2JP2”. The study of binding motifs for this new class of EVH1 domains is a part 
of this thesis work. 
 
2.3. Approaches for identification and characterization of interaction partners of protein 
kinases and adaptor proteins 
  The study of protein interactions are vital in understanding how proteins function 
within the cell. The ability to identify and characterize the physical and biological interactions in a 
living cell is essential for developing a detailed system level model of cellular functions [99]. Since 
50 years, after discovering the enigma of phosphorylation, many of the signalling pathways 
involved in the regulation of normal cells were revealed with a major break through in the most 
recent interaction studies [100]. Previously interaction studies were limited to known targets in 
which novel protein partners or kinases were studied with specific drugs like activators and 
inhibitors by using biochemical and pharmacological approaches. Advancements in deciphering of 
the human genome and subsequent proteomics-based protein profiling studies have catalyzed 
resurgence in these interaction studies at a new scale using various new molecular, cellular and 
genetic technologies. Well known protein interaction databases based on different domain 
recognition motifs are now available together with the experimental data for compiling interaction 
data and even predicting unknown signalling interactions in a cell [101]. They are helpful to some 
extent in determining predictive protein interactions and giving models of the signalling network of 
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a specific cell type (Table.1a) [102]. Such databases are DOMINO (http://mint.bio.uniroma2.it/ 
domino/), a database of interactions mediated by protein recognition modules [103], MINT 
(http://mint.bio.uniroma2.it/mint/ ), a Molecular INTeraction database [103] and the DIP database 
(http://dip.doe-mbi.ucla.edu/), which catalogues experimentally determined interactions between 
proteins [104]. The success of exploring global signalling networks of a cell has shifted the 
research focus to an understanding of the system’s level regulation of a biological system creating 
the new discipline of systems biology [105]. Systems biology comprises the study of the 
interactions between the components of biological systems, and how these interactions give rise to 
the function and behaviour of the cellular or even the organismic system. By revealing the 
molecular logic that underlies cellular processes the genomic revolution of sequencing and 
analysing whole genomes has now captured molecular biology into the realm of systems biology 
[106, 107]. Systems biology approaches also promise to improve rational decision making in drug 
discovery [108]. Further more the data driven modelling approaches using mathematical techniques 
like principle component analysis, clustering and partial least squares have addressed the huge 
experimental data of recent cell signalling studies to understand and help to derive algorithmic 
ways of analysis of cell signalling networks [109]. Thus recent advancements in interaction 
analysis strategies are reviewed below in context of our studies performed to determine the 
substrate specificity of new protein kinases for VASP and the identification of interacting peptides 
for the EVH1 domain of Spred proteins. 
 
 
Query string 
 
Spred binding proteins 
AE331/Spred 
(D. 
melanogaster) 
ANGEL1(2,3)[Q9UNK9] 
Spred1 
ANGEL1(5) [Q9UNK9]    KIT(1,4,5)[ P10721];     HRAS(6)[ P01112]; 
ANGEL2(5) [Q5VTE6]                                         RhoA(6)[ P61586]; 
 
                                                                                                                 PPP1CA(1,3,5)[ P62136] 
                                                                                                                Caveolin-1(6)[ Q03135] 
Spred 
(M. musculus)                                            KIT
(1)      [ P10721] 
Spred2                                            KIT
(1,4,5) [ P10721]     RAS(4,6)[ P01112] 
                                          RhoA(1,4,5,6)[ P61586] 
 
Table: Spred binding proteins as identified by interaction database searches. The table shows a list of potential 
Spred binding candidates as derived from in-silico database and literature searches using Spred protein sequences as 
the query. UniProt ID of the respective hits is given in brackets. The majority of the databases did not provide any 
experimental evidence for the hits listed. The databases in which the hits were identified are given as follows (1)HPRD, 
(2)Biogrid, (3)Mint, (4)String, (5)UniHI, (6)literature search.  
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2.3.1. The role of protein interactions in biological signal transduction networks 
In multicellular organisms, a multitude of different signal transduction processes are 
required for co-ordinating the behaviour of individual cells to support the function of the organism 
as a whole. Signal transduction as a key process refers to any activity by which a cell organises the 
transmission of a signal or stimulus from its receptors to the targets in the cytoplasm and nucleus, 
most often by an ordered sequence of biochemical reactions involving secondary messengers, 
proteins kinases and effector proteins. These signal transduction pathways are governed by an 
intricate web of physical and functional links between protein ligand molecules forming a 
signalling network. The comprehensive description of this network structure is referred to in recent 
days as the “interactome” of a cell [110]. Many disease processes such as diabetes, heart disease, 
autoimmunity and cancer arise from defects in this web of signal transduction pathways, further 
highlighting the critical importance of signal transduction to biology as well as medicine. 
The reception of a signal on the surface of a cell often results in signal transduction 
cascades that include transmembrane and intracellular receptor proteins, protein kinases and 
phosphatases, binding proteins for secondary messengers and many intracellular protein 
interactions of different specificity to downstream effector molecules that finally execute the cell’s 
response [111]. Information from the receptor-ligand complex formed by cell surface receptor and 
external signalling ligand activates those small molecules called secondary messengers which often 
constitute early steps in the signal transduction cascades. The most well-known secondary 
messengers include cyclic AMP and cyclic GMP, NO, calcium ion, inositol 1, 4, 5-trisphosphate 
(IP3), and diacylglycerol (DAG). Second messengers are often free to diffuse to other 
compartments of the cell, such as the nucleus, where they can influence gene expression and other 
processes by amplifying a signal significantly for effective transmission. Many secondary 
messengers elicit responses by activating protein kinases which transfers the γ-phosphate group 
from ATP to specific serine, threonine or tyrosine residues in substrate proteins by the process of 
protein phosphorylation [112]. This signal continues to function until protein phosphatases are 
activated to shut off its transmission to the targets. Protein phosphatases thus play an important role 
in the termination of protein phosphorylation signalling processes by hydrolytically removing the 
specific phosphate groups from the modified proteins. Thereby changes in the concentration of free 
secondary messengers could induce changes in the covalent structures of proteins. In animal cells, 
these cascades are mediated by two types of protein kinases: serine/threonine kinases (which 
phosphorylate serine and threonine amino acid side chains) and tyrosine kinases (which 
phosphorylate tyrosine amino acid side chains). In-vivo phosphorylation patterns thus transmit 
signals among various proteins being either phosphorylated or dephosphorylated resulting in 
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various changes of cellular behaviour. Many of these cascades are studied and modelled as 
phosphorylation networks for a computational, in-silico prediction of unknown substrates for 
different protein kinases [102, 113]. 
Protein-protein interactions are intrinsic to virtually every cellular process with their 
effects mediated by different multi-domain protein complexes. Many of the protein-protein 
interactions involved in signalling networks frequently make use of signalling adaptor proteins 
composed of conserved, non-catalytic, interacting adaptor domains and their cognate binding 
peptide motifs which in turn connect to specific signalling cell surface receptors and their 
downstream effectors [99, 112, 114]. The functional regulation of adaptor proteins is done by 
several mechanisms including intra-molecular interactions, conformational reorganisation, post 
translational modification and co-operative and combinatorial binding reactions where individual 
adaptor domains regulate divergent signalling networks by utilizing distinct combinations of 
binding partners to carry out complex developmental and physiological processes [111, 114]. Thus, 
the domain interacting network could be explicated by considering the modular nature of their host 
proteins [115]. These networks can be viewed as molecular circuits for mediating sensing and 
processing of stimuli. They could detect, amplify, and integrate diverse external signals to generate 
responses such as changes in enzyme activity, gene expression, or ion-channel activity. Specificity 
in protein interactions during signal transduction is regulated by different biochemical mechanism 
like exclusive binding of stimulating factors to the receptor complex, preferred recognition of 
protein kinase substrates and adaptor domain binding peptide motifs [111, 112]. Paradoxically, a 
similar signalling pathway often regulates very different cellular processes, for example the same 
signal and receptor in different cells can promote responses as diverse as proliferation, 
differentiation or death. Conversely, activation of the same signal-transduction component in the 
same cell through different receptors often elicits different cellular responses. We can anticipate 
that similar genetic and molecular studies in flies, worms, and mice will lead to an understanding 
of the interplay between different pathway components and the underlying regulatory principles 
controlling specificity in multicellular organisms. 
One specific group of modular recognition adaptor domains, including SH3, WW 
and EVH1 domains play a crucial role in the assembly and regulation of many intracellular 
signalling complexes by a common proline rich recognition mechanism [116]. The EVH1 domain 
host proteins regulate a large number of transient interactions in events involving actin 
cytoskeleton dynamics [25] or postsynaptic signalling cascades [85] through their proline rich 
specific binding interactions. Knowledge of the molecular determinants of structural and 
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biochemical specificity of these proteins is necessary for a rational understanding of their role in 
signalling cascades.  
Not only protein-protein interaction, but also lipid–protein interactions play a crucial 
role besides maintaining the structure and function of biological membranes where lipid–protein 
interactions are implicated in the assembly, stability and function of membrane proteins [117] 
[118]. Of the known adaptor domain proteins interacting with lipids, Pleckstrin homology (PH) 
domains [119] and Src homology3 domains [120] are well characterised for their lipid interaction 
and show some structural homology with EVH1 domains. Many of the EVH1 family proteins are 
localised to or near the cell membrane and are involved in cytoskeletal signalling cascades, but 
their interaction with negatively charged phospholipids has not been detected so far. The recently 
discovered positively charged surface of Spred EVH1 domains and their unique structure opens up 
the possibility of an interaction with negatively charged biological molecules.  
 
2.3.2. Identification of candidate protein kinases for VASP and elucidation of 
phosphorylation pathways in serum stimulated cells 
The above described information has given a detailed view of how signals are 
transmitted from the cell surface and transduced into changes in cellular behaviour via protein 
kinases and protein interactions. The combination of biochemistry, structural biology and genetics 
has developed different tools like immunodetection studies with polyclonal and monoclonal 
antibodies for phospho and non-phospho forms of the target proteins, NMR studies, transgenic and 
knock out studies which are very helpful in characterizing the functional role of these protein 
molecules in different signalling pathways. Despite the close structural relationship among 
different signalling molecules such as protein kinases, recent studies suggest that activators and 
inhibitors selective for specific subclasses can be designed to activate or block the responses of 
these molecules thus up- or down-regulating these signalling pathways. Such up- and down-
regulation of signalling pathways could be studied by looking at a specific end substrate or target 
molecule participated in that pathway. These activators and inhibitors are thus useful 
pharmacological tools to trace out the order and role of signal transduction molecules in a specific 
pathway. Recently, the development of peptide inhibitors for specific kinase isozymes has been 
started depending on the structural variations of isozymes. Especially, protein kinases are the most 
exploited targets in pharmacological studies due to the key roles of these enzymes in many human 
diseases including cancer [121]. Recently, the in-silico virtual screening of large scale chemical 
databases with different docking procedures for protein kinase inhibitors depicts their demand in 
drug designing [122]. Transgenic methodologies have also provided further evidence for 
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involvement of biological molecules in regulation of signalling pathways. Knock out models are 
thus well known tools for elucidation of signalling pathways. In some cases like studies of VASP, 
even though a knock out model may not show any apparent gross phenotype, there might be 
alterations at the cellular level in the signalling molecule’s recruitment for signal transduction. 
Hence, knock out technology is a valuable approach to elucidate the role of specific molecules in a 
particular signalling pathway complementary to pharmacological and biochemical studies. 
Activation of cyclic nucleotide dependent signalling pathways regulates the 
phosphorylation of VASP via PKA and PKG (see Chapter 2.1.1.4). Inhibition of PKA and PKG 
activity by cyclic AMP and cyclic GMP antagonists thus down regulates the phosphorylation of 
VASP which can be detected by using monoclonal or polyclonal phosphorylation site-specific anti-
VASP antibodies [48, 123]. Furthermore, it is possible to activate cyclic nucleotide dependent 
signalling pathways by adenylyl and guanylyl cyclase activators or agonists thus modulating the 
phosphorylation of VASP. Also, external stimulation of cells by growth hormones or serum 
proteins may interconnect and regulate not only the cyclic nucleotide dependent signalling 
pathways but also other cascades that directly or indirectly phosphorylate VASP by protein kinases 
participating in cytoskeletal regulation and focal adhesion induction. The interconnectivity of these 
pathways can be elucidated by either inhibiting or activating various candidate protein kinases 
including growth hormone or serum activated protein kinases followed by assaying the 
phosphorylation status of VASP.  
As versatile molecular tools for these signalling assays that address the extent and 
function of VASP phosphorylation after different stimuli and activation of specific kinases, specific 
antibodies had been developed. A polyclonal anti-VASP antiserum for detecting phospho and non-
phospho VASP based on the mobility shift from 46 kDa to 50 kDa in SDS gel electrophoresis [6] 
and more specifically, monoclonal antibodies for the individual phosphorylation sites of VASP had 
been raised and characterized previously namely, anti-phospho-Ser-157 VASP (5C6 mAB) and 
anti-phospho-Ser-239 VASP (16C2 mAB) monoclonal antibodies [48, 124]. Immunohistochemical 
experiments are also possible with these mABs to find out the role of these phosphorylation sites in 
localization of VASP to its various binding partners. They are also very useful tools to differentiate 
among PKA and PKG action as assayed by VASP phosphorylation in signal transduction pathways 
known to engage these protein kinases in relation to different stimuli. It is possible with these 
phosphorylation site-specific mABs to trace out the involvement of effective phosphorylation at 
these acceptor sites by various protein kinases which may have direct or indirect actions on VASP 
as a substrate. Genetic tools like site-specific mutations are advanced techniques that can also be 
used to dissect the function of individual phosphorylation sites in VASP. De-phospho mutant 
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VASP proteins consisting of serine substituted by alanine at both phosphorylation sites namely Ser-
157-Ala and Ser-239-Ala are convenient tools to evaluate the function of these VASP 
phosphorylation sites on the cell’s behaviour [3]. Clarification of the complex relationship between 
secondary messengers (especially cyclic nucleotides), protein kinases and cytoskeleton-associated 
proteins (like VASP, WASP and others) may lead to future diagnostic and therapeutic implications 
for haemostasis, cardiovascular diseases and cancer. 
 
2.3.3. Identification of interaction partners for a new EVH1 domain of the Spred2 protein 
A substantial proportion of intracellular signalling pathways and physical interaction 
complexes in a cell are mediated by short peptide binding domains like EVH1 domains and their 
multidomain scaffold, anchoring or adaptor proteins [112]. Many of these non-covalent interactions 
are of relatively low affinity and with a transient impact on signal transduction. Comprehensive 
characterization of their interacting peptides and substrate specificity is critical for understanding 
the mechanisms and signalling networks involved in many cellular functions. 
As described by Fields et al many types of physical, molecular biological and 
genetic screening approaches are available to identify binding partners of a protein or a domain 
[125, 126]. The conventional approaches of protein interaction-motif detection can be distinguished 
into three categories viz., affinity-elution methods, genomic library screening (both in-vivo and in-
vitro) methods and synthetic peptide library screening methods. Of the affinity-elution approaches, 
protein affinity chromatography is a popular method where cell extract proteins are passed over a 
bait protein immobilized to a column matrix and the bound ligands are eluted after washing off 
unbound extract proteins [126]. Immunoprecipitation and tandem affinity purification (TAP)-tag-
based co-precipitation experiments represent further powerful tools to isolate proteins of interest 
and their associated interaction partners from cell extracts using the immobilized N- and C-
terminally tagged bait protein in a batch-type protocol [125, 127, 128]. Prey proteins co-purified by 
these affinity-chromatography based approaches are subsequently identified by immunodetection 
or mass spectrometry. The recent advances in mass spectrometry have allowed the molecular 
characterization of large protein complexes and even an analysis of protein interaction networks on 
a proteomic scale [129]. 
 One of the most commonly used genetic systems today is the two-hybrid system, 
which was originally described by Fields and Song in yeast [130-134]. Two-hybrid systems are 
extremely powerful approaches of detecting protein-protein interactions in-vivo in a heterologous 
host organism. The two-hybrid system approach is mostly employed in yeast or E. coli, though it 
has also been developed for mammalian cells [135]. The modular domain organisation of certain 
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transcription factors forms the genetic basis for two-hybrid systems which use transcriptional 
activity of a reporter gene suitable for screening or selection as a measure of productive protein-
protein interactions. The modular nature of these site specific transcriptional activators consists of a 
DNA binding domain and a transcriptional activation domain which could be fused with bait and 
target proteins to be tested in the genetic system for their interaction [126, 136-139]. We decided to 
use an in-vivo genetic library screening approach based on a bacterial two hybrid system to search 
for the Spred EVH1 domain binding epitopes. The coding sequence of the bait protein, human 
Spred2 EVH1 domain was cloned to a respective plasmid vector to express the recombinant DNA 
binding domain as a fusion protein to genetically screen proteins fused to a transcriptional activator 
domain of RNA polymerase for binding epitopes. Thus selected epitope guides in disclosing the 
interacting protein of the Spred2 EVH1 domain through a genomic sequence blast search. After 
completion of many genome studies for various organisms including human, by application of two-
hybrid systems in yeast or bacteria in-vivo screening of libraries of genes or fragments thereof 
identified recognition motifs which interact with a protein of interest [126, 140-144]. Complete 
protein-protein interactions network thus determined by identification of the domain recognition 
motifs in a given cellular proteome, referred to as the “interactome” would thus be the next 
milestone along a deeper understanding of cellular signalling networks of the cell [145] [110, 146, 
147]. 
 The in-vitro peptide library screening for specific domain interaction based on 
exposing libraries of peptides on the surface of phages is a complementary and orthogonal tool in 
screening for peptide or even antibody binding motifs [148, 149]. Since the last few years, 
advances in molecular biology allowed this phage display technology to dominate even hybridoma 
technology to serve as an advanced tool in antibody engineering [150] [151, 152]. Phage display 
technique uses an in-vitro selection method in which a peptide or protein is genetically fused to a 
coat protein of a bacteriophage resulting in the display of the fused protein on the exterior of the 
phage virion which contains its gene thus providing a link between phenotype and genotype for 
selection of desirable peptides from large collections of variants [153]. The phage display 
screening process occurs in several repetitive cycles of affinity selection and subsequent 
amplification of enriched phage populations by host bacteria. This is opposed to other methods 
described above which comprise only single selection rounds [154]. One of the most advanced 
features of phage display is to make large sized libraries of mutants for a given protein, particularly 
focused to a limited region of the protein so that a small number of amino acid residues can be 
mutated [155, 156]. Despite the relatively large size of libraries that can be constructed by phage 
display, the randomization of more than six residues (≈ 6X107 variants) often already exceeds the 
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ability to construct a complete library with all possible combinations of sequences [157]. Phage 
display libraries screened for peptide binding adaptor domains contain few fixed amino acids, 
which are often indispensable for binding and the rest of the residues is randomized by maintaining 
a number of “degenerated” positions. Completely randomized 9mer peptide phage display libraries 
(X9mer) have gained more popularity for selecting affinity ligand motifs from a set of peptides 
[158]. Phagemids containing one of the genes encoding the fusion capsid protein, beside a 
resistance gene and the large intergenic region of the phage (IR) have all necessary elements for 
DNA replication and packaging required to clone and express proteins/peptides of interest as 
capsid fusion proteins in E. coli (Fig.19) [153]. To display peptides or proteins on viral particles 
using this phagemid system, bacteria have to be infected further with packaging-defective helper 
phages. These helper phages supply an almost complete viral genome in trans, but its large IR 
region is engineered with the DNA-packaging function impaired. In the absence of a helper phage 
the phagemid is propagated as a plasmid. While after infection of the phagemid-harboring E. coli 
cells with them, both the fusion version of a capsid protein from phagemid and the wild type copies 
of all capsid proteins from the helper phages are expressed. Phage assembly of all fusion and wild 
type capsid proteins together thus forms encapsulated phage virion particles which are extruded 
from the host cells and can be harvested for screening. The protein of interest immobilized on a 
solid phase is incubated with this phage display library to allow binding between the protein and 
the appropriate phages by a special in-vitro selection procedure called “bio-Panning” (Fig.20) 
[159]. Phage display has been shown to be a successful tool for selection of short proline rich 
motifs (6-15 amino acids) for peptide binding adaptor domains like SH3 domain, EVH1 domains, 
WW domains and for refining of designed proteins with only a small part of the protein being 
subjected to the evolution at each step [154]. Therefore, phage display peptide library screening 
was used as a second experimental approach for binding epitope identification of the Spred2 EVH1 
domain in the studies submitted by this thesis. 
Complimentary to phage display biochemical methods which are based on screening 
of chemically synthesised peptide libraries have been utilized extensively to identify binding sites 
or refine recognition motifs of many proteins. SPOT synthesis, the highly parallel chemical 
synthesis of biological molecules on cellulose membranes by position specific application of 
defined building blocks in each synthesis cycle [160, 161], has therefore become a widely used tool 
for studying biological molecular recognition in-vitro. These tests are important tool in biochemical 
identification of the protein-ligand binding interactions and enable to generate an enormous 
sequence diversity of custom peptide libraries for mapping applications. SPOT technology was 
originally developed as a system for easily determining the amino acid sequence of peptide 
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antigens. Peptide sequences corresponding to the specificity of an antibody are identified by 
conventional enzyme linked or autoradiographic detection methods. Such technology has since 
progressed to include a variety of new applications for research in the areas of peptide chemistry, 
molecular biology, cell biology and immunology for studies like protein-protein and protein-
phospholipid interactions, phosphorylation studies, nucleic acid binding and combinatorial peptide 
library screening [162]. Thus, it has been utilized successfully for epitope mapping (also known as 
peptide walking) [27, 30], alanine scanning [163], substitution analysis [24, 30],[164], screening of 
potential peptide ligands derived from genomic sequences [165] or mutational analysis of binding 
domains [166]. Ligand molecules other than peptides like phospholipids are also capable of being 
screened with similar SPOT methods by spotting and immobilizing the target molecules on a solid 
phase membrane. Incubation of the spotted membrane with the protein of interest determines 
complex formation with the interacting molecules and further solid phase studies using fine-
tailored ligand forms reveal the chemical details for binding of these pairs [120]. Experiments like 
the whole interactome scanning experiment (WISE) uses a selective combinatorial approach of 
SPOT scans and phage display screening to reveal all the peptides in a proteome that have the 
potential to bind to any domain of interest [115, 167]. 
The preferred binding motifs for individual domains identified by the methods 
described above can be used to blast genome data for identification of the proteins holding these 
binding sequences. Finally, such information aims at exploring the proteome of a whole organism 
for the candidate binding partners and thus forming network models of multi protein complexes. 
Hence, understanding and identification of specific motifs and the recognition code of individual 
domain classes gives an interactome of the complete signalling network for a cell. As recognition 
motif specificity is an important basis for signal transduction regulation, determination of such 
specific motifs for every adaptor domain is an essential step in finally describing a functional 
global interactome.  
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3. AIM OF THE WORK 
Ena/VASP homology (EVH1) domains are found in different signal-transduction 
proteins as N-terminal non-catalytic, adaptor modules of ~ 115 amino acids sharing a common 
fold. By targeting their host proteins to subcellular sites of action EVH1 domains are involved in 
protein-protein interactions in a diverse range of signalling cascades several of them include 
protein phosphorylation. These interactions takes place through a recognition pocket formed by a 
highly conserved cluster of three surface exposed aromatic side chains in EVH1 domains with 
proline rich specific sequences of the target proteins. 
EVH1 domains were first described in the name giving Ena/VASP protein family 
with the Vasodilator-stimulated phosphoprotein VASP being its founding member. Several EVH1 
binding proteins of VASP have been described being responsible for localisation of VASP to 
different regions of the cytoskeleton including the microfilaments and focal adhesions. As a 
cytoskeleton associated protein VASP has been found to be a substrate of cAMP- and cGMP- 
dependent protein kinases and implemented in regulation of cytoskeletal reorganisation. Besides 
cyclonucleotide dependent protein kinases however many other protein kinases are known to be 
involved in regulation of cytoskeletal remodelling in particular during serum stimulation of cells. 
Using a combined cell biological and pharmacological approach, in the first part of this thesis 
several candidate protein kinases are analysed with regard to their specificity towards VASP as a 
substrate of phosphorylation during serum stimulation of cells. Specifically the following topics 
were addressed: 
 
1. Analysis of the effect of serum stimulation on VASP in terms of its phosphorylation. 
2. Identification of the candidate protein kinases participating in serum stimulated VASP 
phosphorylation and elucidation of their order of action involved in these pathways. 
 
A new EVH1 domain has been described in the recently discovered Spred proteins 
(Sprouty related proteins containing an EVH1 domain) which are membrane-associated 
suppressors of tyrosine kinases and act as proximal negative regulators of the Ras/Raf/MAPK 
signalling pathway. This new EVH1 domain harbours a characteristic recognition pocket different 
from all the other EVH1 domains suggesting binding to unique ligand(s) which have not been 
discovered so far. Using different screening methods in combination with in-vitro binding assays to 
candidate ligands, in the second part of this thesis a search for ligands of the Spred EVH1 domain 
was performed. Specifically, the following topics were addressed: 
Aim of the work 
 
31 
1. Genetic screening of a cDNA expression library using an in-vivo interaction cloning approach 
for candidate sequences harbouring binding peptide motifs of the Spred EVH1 domain  
2. Genetic screening of a phage display library using an in-vitro affinity selection approach for 
oligopeptide binding motifs of the Spred EVH1 domain. 
3. Biochemical screening using in-vitro binding assays for studying the interaction of the Spred 
EVH1 domain with phospholipid candidate ligands.  
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4. MATERIALS AND METHODS 
 
4.1. Materials 
 
4.1.1. Chemicals 
3-AT ……………………………………………………………………….. Sigma, 
8-pCPT-cGMP............................................................................................... Biolog 
Adenine HCL………………………………………………………………. Sigma, 
Antibiotic & Antimycotic solution (100 X)……………………................... Sigma 
Bisindolylmaleimide I (Bis I) ........................................................................Calbiochem 
Bisindolylmaleimide V (Bis V) ..........................…........................................Calbiochem 
Dimethyl Sulfoxide (DMSO)……………………….................................. ...Calbiochem 
Dulbecco’s Modified Eagle Medium (DMEM)............................................. Invitrogen 
Falcon tubes …………………………...…………………………………….BD-biosciences 
Foetal Calf Serum (FCS).................................................................................Biospa 
Forskolin  .................................................................................................…...Calbiochem 
Glutathione Sepharose® 4B matrix.................................................................Amarsham 
GSH................................................................................................................. Amarsham 
H 89................................................................................................................ .Calbiochem 
His drop out supplements…………………………………………………….BD-biosciences 
Insulin-Transferrin Sodium selenate (ITS) growth supplements .....................Sigma 
M9 salts ………………………………………………………………………Q biogen 
PEG....................................................................................................................Fulka 
Phorbol 12-Myristate 13-Acetate (PMA)..........................................................Sigma 
Phosphate Buffer Saline (PBS).........................................................................Biochrome AG 
Ro-31-8220...................................................................................................... Calbiochem 
RPMI 1640 Medium.................................................................................... ….PAN 
Thiamine HCL...................................................................................................Sigma 
Trypsin EDTA...................................................................................................PAN 
Trypsin...............................................................................................................Invitrogen 
Y-27632.......................................................................................................... ..Calbiochem 
   
  All the standard chemicals of highest purity were obtained from Sigma, Calbiochem 
and other chemicals were of analytical grade. 
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4.1.2. Primary antibodies 
Name Antigen Type Origin Supplier Dilution
M4 VASP Polyclonal Rabbit immunoGlobe (cat# 0016-05) 1:3000 
5C6 VASP epitope with Ser-157P-VASP  Monoclonal Mouse 
Nanoo tools 
(cat# VASP 5C6) 1:100 
16C2 Ser-239P-VASP epitope-KVpSKQE Monoclonal Mouse 
Nanoo tools     
(cat# VASP 16C2) 1:100 
Anti PKG cGMP dependent protein kinase 1α Polyclonal Rabbit -                 1:1500 
Anti GST - Polyclonal Rabbit 
Santa cruz 
biotechnology 
(cat# sc-33613) 
1:5000 
Anti Spred 
EVH1 - Polyclonal Rabbit - 1:5000 
Anti VASP 
EVH1  Polyclonal Rabbit - 1:5000 
Anti λcI 
N-terminal 
polypeptide  
(aa 21–36) 
Polyclonal Rabbit Stratagene (Cat#240110) 1:5000 
 
Table 2: Primary antibodies used in the experiments. The information known about recognition motif, type, 
supplier’s details and dilution used in the experiments are described in the table for each primary antibody. 
 
4.1.3. Secondary antibodies 
Name Label Supplier Dilution Detects 
Goat-anti -Rabbit Ig Horse Radish Peroxidase 
Amersham 
biosciences 
NA 934V 
1:5000 
M4, anti PKG, 
Anti Spred EVH1, 
Anti VASP 
EVH1, Anti GST, 
AntiλcI 
Goat-anti- Mouse Ig Horse Radish Peroxidase 
Amersham 
biosciences 
NA 931V 
1:5000 5C6 and 16C2 
 
Table 3: Secondary antibodies used in the experiments.  
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4.2. Methods 
 
4.2.1. Cell culture 
 
4.2.1.1. Solutions 
Phosphate buffer saline (PBS): 8.19 g/L NaCl, 0.2 g/L KCl, 1.45 g/L Na2HPO4,  0.2 g/L 
KH2PO4, pH 7.4 
Earl’s buffer:  6.8 g/L NaCl, 0.4 g/L KCl, 0.125 g/L NaH2PO4, 1 g/L Glucose, 
0.05 g/L Phenol Red, 2.45 g/L Tris,  pH 7.5 
Sample buffer: 0.062 M Tris HCl (pH= 6.8), 2% (w/v) SDS, 10% (v/v) Glycerol, 10% (v/v) β–
Mercaptoethanol, 0.001% (w/v) Bromophenol Blue  
 
4.2.1.2. Cell lines 
  Wild type Mouse Cardiac Fibroblast Cells (MCFB (+/+)) were used as the biological 
model for all the experiments to look for serum stimulated VASP phosphorylation. Cardiac 
fibroblasts localize at the connecting regions of tissues to organs and blood vessels. These cells 
were preferred as they express high levels of VASP, commonly used for cytoskeletal studies and 
are easy to handle in cell culture laboratory and a well established methodology is available in our 
laboratory [58]. Mouse mesangial cell  lines (+/+) were also used for positive control 
experiments to rule out any cell  specific activity in serum stimulated VASP 
phosphorylation. 
 
4.2.1.3. Isolation of MCFB Cells (+/+)  
  Two months old mice of both sexes were anasthetised with ether. Hearts were 
excised, submerged in cold PBS and cut into pieces (2-3 mm size) with tissue chopper. The pieces 
were washed with Earl buffer and cells were dissociated with 1mg/ml collagenase/dispase for 30 
min at 37˚C in incubator. When the tissue pieces sank in Earl buffer, the tissue pieces that had 
sedimented were discarded and the supernatant containing the isolated cells was taken out and 
spinned down at 800xg for 5 min to isolate cardiac fibroblast cells. The pelleted cells were 
resuspended in DMEM, 10% FCS and transferred to a 25 cm2 culture flask to grow at 37˚C in the 
incubator. Later, the cells were trypsinized for every 3 days, (0.1% Trypsin), counted (CASY®1 
cells counter, Schärfe system, Germany) and transferred to a new flask at a density of 5 x 103 
cells/cm2. After continuous growth of the cells in the same medium for 3 to 4 weeks, the isolated 
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cells from this culture spontaneously became immortalized and then started to grow in 6 cm petri 
dishes with the same nutrient medium [168]. 
 
4.2.1.4. Cell  passage, counting, freezing and storage 
  The cells grow up to 80% confluence in 6-cm dish with DMEM and 
10% FCS within 3 days. Then medium was drained out from the dish and cells 
were washed twice with warm PBS. Then trypsinized by adding 0.1% Trypsin in 
PBS for 3 to 4 min and incubated at 37˚C in incubator until  the cells adopted 
rounded shape. The trypsinized cells were resuspended in DMEM with 10% FCS 
and 1. 5 x 105 cells were replated on 6 cm dishes containing 5 ml of DMEM with 10% FCS. 
Passages from 20 to 40 of this cell line were preferred to use for signal transduction experiments. 
Mouse mesangial cells (+/+) were cultured in 7.5 cm2 cell  culture flask in RPMI 1640 
medium containing 20% FCS, 0.1% ITS growth supplements and 10% antibiotic and 
antimycotic solution (100X). Cell passaging was carried out for mouse mesangial cells also as 
described above with the help of warm PBS-EDTA and Trypsin-EDTA after cells were grown to 
80% confluent. Cells from passages 4 to 10 were preferably used for the experiments because these 
cells showed faster growth during these passages. 
A 100 µL volume of cell suspension was diluted in 10 mL of PBS and counted with 
CASY® 1 cell counter (Schärfe system, Germany) as described by the manufacturer. Trypsinized 
cells were collected in warm DMEM with 10% FCS, then counted and pelleted by centrifugation at 
5000xg for 5 min at room temperature. The pellet was resuspended in freezing medium (DMSO + 
10% FCS) to a final concentration of 106 cells/mL, and aliquoted into 1 mL cryotubes. The aliquots 
were frozen for 48 hours at - 80˚C and then stored in liquid nitrogen. 
 
4.2.1.5. Cell culture experimental set up 
  MCFB cells (+/+) were plated at 1 x 10 4 cells per well in six well plates, and grown 
up to 80% confluent in DMEM containing 10% FCS (Fig.4). Then the medium was drained and 
cells were washed twice with warm PBS to counter the effect of any remaining serum. To these 
cells only DMEM was added and kept for starvation overnight in order to synchronise these cells in 
the same phase of cell cycle. Some of the synchronised quiescent cells were stimulated with 10% 
FCS and/or activators PMA (1 µM) and Forskolin (10 µM) (see Table.6) depending on the 
experimental question to be solved for the respective stimulated signalling pathway’s effect on 
VASP phosphorylation. Synchronised cells were also separately incubated with specific inhibitors 
namely Y-27630 (10 µM), Ro-31-8220 (10 µM), and Bis I (10 µM) and H 89 (10 µM) (see 
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Table.6) for 30 min before stimulating with respective activators either individually or in 
combination (PMA, Forskolin and 10% serum). In all the experiments, after incubating the cells 
with specific activators for respective incubation periods (4 hours for FCS, 8 min for PMA and 30 
min for Forskolin), cells were washed twice with cold PBS and then cell lysates were collected in 
sample buffer containing 10% β-mercaptoethanol with the help of a cell scraper. Overnight starved 
cells without any stimulation were collected as unstimulated controls and Bis V was used as a 
negative control for the inhibition activity of Bis I. DMSO was used as a solubilisation vehicle in 
all the experiments that treat the cells with the above mentioned activators and inhibitors. The 
collected samples were boiled immediately at 100˚C for 5 min and stored at -20˚C. 
 
 
Analysis by immunoblotting 
Harvest the cell lysates 
(Sample buffer + 10 % β - Mercaptoethanol) 
Stimulate with 10% serum 
or/and protein kinase activator(s) 
80% confluent
Overnight starvation to synchronise the cells 
with only DMEM (no FCS)
Seed cells in 6 well plates 
(DMEM + 10% FCS)
Protein kinase  
Inhibitor(s) 30 min 
 £
 
Figure 4: Scheme of the general experimental set up used in the cell culture work. MCFB cells (+/+) were grown 
in a six well plate with DMEM and 10% serum until they grow up to 80% confluence. Then the cells were starved for 
overnight using only DMEM medium without FCS for synchronization of cells. These synchronized cells were used 
for the experiments with activation or inhibition of different protein kinases. Before stimulating the cells with serum 
or/and a specific activator, some of the cells were incubated for 30 min with a single protein kinase inhibitor or a 
combination of different ones which are needed to inhibit the corresponding pathways in that experiment. Details are 
given in the figure legends in the results section. After incubation for the respective time period, the cells were lysed in 
sample buffer containing 10% β-mercaptoethanol and boiled for 5 min at 100 °C before storing at -20 °C. These 
samples were used for immunoblotting experiments for detecting VASP phosphorylation. 
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4.2.2. Protein biochemistry 
 
4.2.2.1. Solutions  
Stacking gel buffer: 0.5 M Tris HCl, 0.4% (w/v) SDS (pH 6.8 ) 
Resolving gel buffer: 1.5 M Tris HCl, 0.4% (w/v) SDS (pH 8.8) 
Electrode buffer (1X): 3 g/L Tris base, 14.4 g/L Glycine, 1 g/L SDS 
Sample buffer (2X): 0.062 M Tris HCl (pH= 6.8), 2% (w/v) SDS, 10% (v/v) Glycerol, 10% (v/v) 
β–Mercaptoethanol, 0.001% (w/v) Bromophenol Blue 
Acrylamide 4x solution (mix= 37.5:1): 29.22% Acrylamide, 0.78% Bis-acrylamide 
Transfer Buffer: 25 mM Tris base, 150 mM Glycine, 10% (v/v) Methanol (pH 8.3) 
10% Ammonium per sulfate (APS): 1 gm in 10 mL H2O 
 
4.2.2.2. SDS- polyacrylamide gel electrophoresis (PAGE) 
  Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed using 9% (w/v) polyacrylamide separating gels [169]. Cell lysates collected in sample 
buffer containing 10% β-mercaptoethanol after cell treatment experiments were loaded into the 
slots of the gel and separated with a voltage of 100 volt until the samples reached the resolving gel 
and then separated under 150 volt for the rest of the experiment.  
 
Composition for 9 % SDS poly acrylamide gel electrophoresis:  
Resolving gel (total volume= 8 mL)   Stacking gel (total volume= 3 mL) 
Acrylamide 4x solution..... 3.0 mL   Acrylamide 4x solution…..0.52 mL 
Resolving gel buffer……...2.5 mL  Stacking gel buffer ………1 mL 
 H2O....................................3.7 mL   H2O ……………………...2.48 mL 
TEMED…………………...40 µL  TEMED..............................10 µL 
10% (w/v) APS …………..100 µL   10% (w/v) APS .................40 µL 
 
4.2.2.3. Immunoblotting 
Proteins resolved on SDS–PAGE were transferred to Nitrocellulose transfer 
membrane (PROTRAN BA83; pore size = 0.2 μm) in a Semi Dry Transfer Device (Fast Blot B33, 
Biometra, Germany) by transfer buffer at 260-280 mA current for 1 hour, according to 
manufacturer’s description. After transfer, the membranes were stained with Ponceau solution 
(0.1% (w/v) Ponceau in 5% (v/v) CH3COOH) for 2-3 min and then washed with tap water. 
Ponceau solution would stain all the proteins present on the membrane. So, it could be helpful to 
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confirm the perfect transfer of protein from SDS gels to the membrane. Subsequently, the 
membranes were incubated with blocking solution for one hour (4% (w/v) milk powder in PBS + 
0.025% (v/v) Tween-20 + 0.15% (v/v) Triton X-100). After blocking the non-specific binding sites 
on the membranes, they were incubated with the respective primary antibodies freshly diluted in 
solution containing 4% (w/v) milk powder with PBS (Table.2) for one hour. Membranes were then 
washed 3 times 15 min each with PBS + 0.025% (v/v) Tween-20 + 0.15% (v/v) Triton X-100 and 
incubated for 45 min with the specific secondary antibody (Table.3) diluted at 1:5000 in 4 % (w/v) 
milk with PBS. Then the membranes were again washed twice with PBS + 0.025% (v/v)  Tween-
20 +0.15% (v/v) Triton X-100 for two times 15 min each and then finally with PBS only for 15 
min. The washed membrane was exposed to scientific imaging film (KODAK X-Omat AR film, 
XAR-5) after incubating it in developer solution (Amersham biosciences, Cat# RPN 2106V2) for a 
minute, according to the manufacture’s instructions of the Enhanced Chemiluminescence (ECL) 
method. Developer solution is a highly sensitive chemiluminescent substrate system utilizing a 
novel acridine-based chemistry and horse radish peroxidase, which is tagged with secondary 
antibody, to generate a light signal that is normally detected on exposing the film. 
 
4.2.2.4. Protein expression and purification 
  The GST-Spred EVH1 protein used in this study was expressed and purified from 
the pGEX-4T2-hSpred2 (1-124) construct available in our laboratory. The expression, purification 
and cleaving the GST tag from the Spred2 EVH1 domain was performed as described in [170]. The 
purified GST-Spred2 EVH1 protein and Spred2 EVH1 protein were analysed on SDS gel 
electrophoresis after purification and stored at +4°C. 
 
4.2.2.5. 1H NMR spectroscopy 
  The GST-Spred2 EVH1 protein expressed and purified in our laboratory was tested 
for its biological activity and native folding conformation before using in the interaction studies. A 
100 µM protein sample in PBS was mixed with 1:10 (v/v) ratio of D2O and natively folded 
conformation of the protein was analysed in Bruker XWIN-NMR Spectrophotometer (available at 
FMP, Berlin). 
 
4.2.3. Molecular biology 
The plasmid isolation during this total study was performed by using the mini-prep 
(for small scale), midi-prep (for medium scale) maxi-prep (for large scale) kits supplied by Qiagen 
sample and assay technologies. The volume of o/n culture and procedure was followed as given in 
the product manual. For pBT and pTRG origin plasmids, low-copy number plasmid isolation 
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protocols were employed. The isolated plasmid’s mass determination was done by using 
spectrophotometer (A260) and standard mass rulers on the Agarose gel electrophoresis after 
linearising the plasmid. The standard enzymes supplied by Fermentas life sciences and New 
England Biolabs were used for restriction enzyme digestion analysis and followed their standard 
protocol of enzyme digestion. For cloning experiments, the quick ligation kit provided by New 
England Biolabs was used and the ligation mixtures were performed in 1:3 and 1:5 ratios of vector 
and insert was used.  
 
4.2.4. Bacterial two-hybrid system 
 
4.2.4.1. Solutions 
M9 media additives: Solution I and solution II were prepared separately as shown below by 
mixing the components listed in the order. Solution II was added to solution I to get M9 media 
additives prior to use. 
Solution I: 10 mL of 20% glucose (filter sterilized) 
5 mL of 20 mM adenine HCl (filter sterilized) 
50 mL of 10× His dropout amino acid supplement (autoclaved) 
Solution II: 0.5 mL of 1 M MgSO4 (autoclaved) 
0.5 mL of 1 M Thiamine HCl (filter sterilized) 
0.5 mL of 10 mM ZnSO4 (autoclaved) 
0.5 mL of 100 mM CaCl2 (autoclaved) 
0.5 mL of 50 mM IPTG (filter sterilized) 
10x M9 salts (Qbiogene #3037-032): 112 gm of 10X M9 salts were dissolved in 1 L deionised 
water and autoclaved. 
M9+ His-dropout broth: 50 mL of 10× M9 salts, 67.5 mL M9 media additives and 380 mL of 
sterile deionised water were mixed to prepare M9+ His-dropout Broth. It can be store at 4°C for up 
to one month and brought to room temperature prior to use. 
1 M 3-AT stock solution: 840.8 mg of 3-AT was dissolved in 10 mL of DMSO  
SOB medium: 20.0 gm of tryptone, 5.0 gm of yeast extract and 0.5 gm of NaCl were dissolved in 
deionised water to a final volume of 1 L and sterilized by autoclave. 10 mL of filter-sterilized 1 M 
MgCl2 and 10 mL of filter-sterilized 1 M MgSO4 were added to the autoclaved solution to get 
SOB medium. 
SOC medium: Freshly prepared 2 mL of filter-sterilized 20% (w/v) glucose was added to 98 mL 
of SOB medium (autoclaved) to get SOC medium prior to use. 
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LB agar: 10 g of NaCl, 10 g of tryptone, 5 g of yeast extract and 20 g of agar were dissolved in     
1 L of deionised water and autoclaved to sterilize. Then, poured into plates after adding respective 
antibiotic to the medium.  
 
4.2.4.2. Preparation of different selection medium plates 
The following methods and calculations were used to prepare different types of 
screening medium plates for B2H system experiments. 
Non-selective screening medium (also called as No 3-AT medium) (for 750 mL): 
1. 11.25 gm of Bactoagar added in 570 mL deionised H2O in 1 L flask and autoclaved. 
2. After cooling the agar to 70°C, 75 mL of 10× M9 salts solution was added. 
3. After cooling the agar mixture to 50°C, 101.25 mL of M9 media additives, 0.75 mL of 
Chloramphenicol (25 mg/mL) and 0.75 mL of Tetracycline (12.5 mg/mL) were added and 
poured into petri dishes. The plates were wrapped in aluminium foil and stored in dark place at 
4°C. 
Selective screening medium (also called as 3-AT medium):  
The selective screening medium was prepared as non-selective screening medium. 
After adding both antibiotics, required volume of 1 M 3-AT stock was added to get the desired 
concentration of 3-AT in the screening medium plates and poured into petridishes.  
 
4.2.4.3. The protocol for co-transformation 
1. BacterioMatch II validation reporter strain competent cells (Stratagene, cat # 200192) were 
thawed and gently mixed by tapping the tube. Then, 100 µL aliquots of competent cells were 
prepared in required number of pre-chilled 14 mL BD falcon tubes (one aliquot for each bait 
and target test pair co-transformation reaction). It is critical to use 14 mL BD falcon 
polypropylene round-bottom tubes for this procedure.  
2. 1.7 µL of the β-ME was added to 100 µL aliquot of cells and the tubes were swirled gently. 
3. The tubes were incubated on ice for 10 minutes with swirling for every 2 minutes. 
4. Then respective bait and target plasmid DNA was added to reaction tubes and incubated on ice 
for 30 minutes with gently swirling after the first 15 minutes of incubation. 
5. After incubation, the tubes were swirled gently and heat-pulse shock was given to cells by 
keeping tubes in 42°C water bath for 35 seconds.  
6. Then incubated the tubes on ice for 2 minutes and added 0.9 mL of pre-warmed SOC medium 
to each tube. 
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7. Incubated tubes at 37 °C with continuous shaking at 225 rpm for 90 minutes and then cells 
were collected by centrifugation at 2000 × g for 10 minutes. 
8. Discarded the supernatant and the cells were washed by resuspending the cells in 1 mL of room 
temperature M9+ His-dropout broth to remove the rich medium. 
9. The cells were collected as described in step.7 and gently discarded the supernatant. Then 
resuspend the cells in a fresh 1 mL volume of M9+ His-dropout broth. 
10. Then incubated the cells at 37°C with shaking at 225 rpm for 2 hours. This allows the cells to 
adapt to growth in minimal medium prior to plating 
11. Plated the co-transformation reaction mixtures on the appropriate non-selective and selective 
screening medium plates with the help of sterile glass beads and incubated at 37°C for colony 
growth. 
 
4.2.4.4. Plating method 
All the plates were brought to the room temperature before plating transformation 
mixture to avoid moisture on the surface of the plates which hinders the bacterial cell growth. A 20 
µL volume of co-transformation reaction mixture without any dilution and 20 µL and 200 µL 
aliquots of 1:100 diluted co-transformation reaction mixtures were plated on non-selective 
screening medium plates in triplicates. A 200 µL volume of co-transformation reaction mixture 
without any dilution was plated on desired concentration of 3-AT medium plates in triplicates. 
 
4.2.4.5. Amplification of cDNA library 
Name of the library: Human brain cDNA expression plasmid library (Stratagene, Cat # 982262) 
Cloning details: Uni-directionally cloned into pTRG Vector at XhoI and EcoRI sites 
Host strain: XL-1 Blue MRF` Kan cell;  
Primary colonies: 1.65 x 106 cfu; estimated titer given by Stratagene: 2.5 x 108 cfu / ml 
The glycerol stock of human brain cDNA expression plasmid library was completely 
thawed on ice and 1:10 dilution aliquot were prepared for 200 µL volume with SOC medium. 
Remaining original library stock was immediately re-frozen for future usage. A pool of 248 µL of 
SOC medium and 2 µL volume of 1:10 diluted cDNA library glycerol stock (≈ 50,000 cfu) was 
plated on each 150 mm LB-tetracycline agar plate and spreaded the mixture evenly over the surface 
of the agar using a sterile glass beads. The number of plates required in the experiment depends on 
the number of colonies to be grown in order to harvest the amount of plasmid required for library 
screening. But it should be at least one time more than the complexity of library so that the 
amplified library plasmid pool consists of total complexity of the cDNA library. We amplified 
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cDNA library by streaking on 50 plates (150 mm plate). The total number of colonies grown on 
these 50 plates would yield nearly 250 µg of cDNA plasmid library which can be isolated using 
maxi-prep plasmid isolation kit (≈ 50,000 colonies/plate and each colony contains nearly 1x105 
cells). The plates were incubated at 30°C for 24 hours. Prolongation of incubation time (up to 30 
hours) could increase the recovery of plasmids containing longer cDNA inserts. 
Gently scraped all of the bacterial clones to one edge of the 150 mm plate by using a 
wide, sterile scraper (may be a sterile cell scraper works out better) and the dense paste was 
transferred from the edge of the plate into the chilled, sterile container having a small amount of 
SOC medium. The amplified library clones from all the plates were pooled into the same sterile 
container by performing the same procedure for all the plates and cells were resuspended by 
pipetting up and down repeatedly with enough SOC medium. The volume of resuspended cells was 
measured and 2 µL, 5 µL volumes of the resuspended amplified library were plated on LB 
Tetracycline plates to estimate the titer of the amplified library (cfu/mL) by incubating them at 
30°C for 24 hours. The cDNA library plasmid DNA was isolated from the pooled bacteria using 
Qiagen maxi-prep kit. The mass of the isolated cDNA library pool was determined by 
spectrophotometer and the cDNA library insert present in the isolated cDNA library pool was 
analyzed by digesting with XhoI and EcoRI enzymes. As the insert is a pool of cDNA library, we 
could observe a smear with different sizes of strands all together after linearising on agarose gel. 
The mass of cDNA library plasmid was also estimated with reference to a mass ruler used on 
agarose gel to cross check the mass estimated from spectrophotometer. 
 
4.2.4.6. Library screening 
Pilot co-transformation experiment was performed to find out the the number of co-
transformation reactions required to cover the complete amplified cDNA library in library 
screening experiment. The recombinant pBT bait vector [i.e. pBT-Spred2 (1-124)] and the pTRG-
cDNA library plasmid were co-transformed into BacterioMatch II screening reporter competent 
cells (Stratagene, Cat # 200190). After evaluating the results from the pilot co-transformation 
experiment, the number of co-transformation reactions to be performed during library screening to 
cover the complete complexity of cDNA library was determined. Then, a large scale cDNA library 
screening was performed by transforming pBT–Spred2 (1-124) and pTRG-cDNA library plasmid 
DNA for those many of 500 µL volume transformation reactions using BacterioMatch II screening 
reporter competent cells. A negative control plasmid pair (pBT–Spred2 (1-124) and pTRG empty 
plasmid) were also co-transformed in the experiment. 
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The following protocol was used to perform co-transformation for large scale library screening: 
1. Pre warmed SOC medium to 42°C. 
2. Required number of aliquots each of 500 µL volume of the BacterioMatch II screening reporter 
competent cells were thawed on ice and gently mixed the cells by tapping the tube. After 
thawing, each 500 µL volume of cells was transferred into pre-chilled 14 mL BD Falcon tubes. 
Note: It is critical to use 14 mL BD Falcon polypropylene round-bottom tubes for this 
procedure.  
3. Added 8.5 µL of the β-ME to each tube and incubated the tubes on ice for 10 minutes by 
swirling for every 2 minutes. 
4. To each tube, 200 ng of the pTRG-cDNA library and 200 ng of pBT-Spred2 (1-124) plasmids 
were added and swirled the tubes gently to mix. Incubated the tubes on ice for 30 minutes by 
swirling the tubes gently after the first 15 minutes of incubation.  
5. After 30 min, swirled the tubes gently again and given heat shock to the reactions at 42°C for 
55 seconds and incubated the tubes on ice for 2 minutes and then 2.5 ml of pre-warmed SOC 
medium (at 42°C) was added to the tubes.  
6. Transferred each of the cell suspensions from each falcon tube into separate 50 mL conical 
bottom tubes for outgrowth and incubated the at 37°C with shaking at 225 RPM for 90 min. 
7. The cells were spun down at 2000 × g for 10 minutes and the supernatant was discarded gently 
by taking care to avoid disturbing the pellet.  
8. In order to remove residual rich medium, the cells were washed twice by resuspending the cells 
in 3 mL of room temperature M9+ His-dropout broth and collected the cells as described in 
step.6. 
9. After washing steps, the cell pellets were resuspended in 1.5 mL of M9+ His-dropout broth and 
incubated at 37°C with shaking at 225 rpm for 2 hours. This allows the cells to adapt growth in 
minimal medium prior to plating.  
10. The adapted outgrowth cultures from step. 9 were pooled together into one tube and swirled the 
tube to mix well. The final reaction volume after pooling all the co-transformation reactions is 
7.5 ml. 
During the adaptation period in step.9, agar plates were labeled and the surface 
moisture was dried. A 100 µL volume of 1:100 dilutions of reaction mixture from step.10 in M9+ 
His d/o broth was plated on 100 mm non-selective screening medium plates (no 3-AT plates) in 
triplicates to determine the co-transformation efficiency as well as the total number of colonies 
screened was determined from these plates. The rest of the reaction pool was plated in 300 µL 
aliquots onto 150 mm 3-AT selective screening medium plates of desired 3-AT concentration for 
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the library screening. For negative control pair, 100 µL of undiluted reaction mixture from step.10 
was plated on non 3-AT and 3-AT plates in triplicates. All the plates were incubated at 37 °C and 
observed colony growth at every 24 hours. The colony growth with different time points was 
noticed to study their difference in behavior. Depending on the need of the experiment, 3-AT 
resistant colonies were replica plated on to higher 3-AT concentration selection medium plates by 
using sterile tooth picks. 
The colonies from the 3-AT screening medium plates were replicated onto dual 
selective screening medium (5 mM 3-AT + Streptomycin) plate and LB-
Tetracycline/Chloramphenicol plate by using sterile tooth picks for secondary screening and colony 
preservation respectively. The positive control co-transformants of pBT-LGF2 / pTRG-Gal11P, 
pBT-VASP / pTRG-ActA (332-344)W plasmid pairs and negative control co-transformants were 
also included on the same plates on the dual selective screening medium to confirm the 
effectiveness of the plates. The plates were incubated at 37°C for 24 hours and then transferred to 
room temperature to incubate for additional 15–18 hrs in a dark location. The growth pattern of the 
colonies was recorded. 
 
4.2.4.7. Physical characterization of dual resistant clones 
  The identified dual resistant colonies from the secondary screening medium were 
further characterized for the target plasmid insert coding sequences by colony PCR and enzyme 
digestion. The replica colony of the positive colony was picked from the maintenance plate and 
dissolved in 25 µL of sterile water by pipetting up and down. Then stirred the tube gently with 
stirrer and cooked for 5 min at 45°C. Then centrifuged the sample at high speed for 2 min and 3 µl 
of the supernatant was used as DNA template in the PCR reaction. The pTRG-Gal11P was used 
positive control in colony PCR. 
Forward primer (5’-3’) = TGGCTGAACAACTGGAAGCT 
  Reverse primer (5’-3’) = ATTCGTCGCCCGCCATAA  
 
PCR reaction mixture (for 20 µL volume): 
Reaction component Volume 
Template DNA = 3 µL 
Forward primer (10 µM) = 0.5 µL 
Reverse primer (10 µM) = 0.5 µL 
dNTP mix (2.5 mM) = 1 µL 
Taq polymerase (New England biolabs) = 0.5 µL 
NEB 10X reaction buffer = 2 µL 
H2O = 12.5 µL 
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PCR programme: 
 
Process Temperature Time Number of cycles 
Initial denaturation 94°C 2 min - 
Denaturation 94°C 30 sec 
Annealing 50°C 30 sec 
Extension 72°C 90 sec 
30 cycles 
End 12°C - - 
 
The amplified PCR reaction product was analysed on 1% agarose gel electrophoresis 
and the colonies having target insert coding sequence in the target plasmid were identified by 
finding the respective amplified product. From such positive colonies, the target plasmid was 
isolated by physically separating from the bait plasmid using antibiotic selection facility. The total 
plasmid was isolated from the positive colony by mini-prep plasmid isolation kit from 2 mL 
overnight cultures. The isolated total plasmid was transformed in to the BacterioMatch II validation 
reporter strain competent cells and co-transformants were plated on LB-tetracycline plates. After 
overnight incubation of the plates at 37°C, the colonies grown were replica plated on to the LB-
Chloramphenicol plate (which selects the cells carrying bait plasmids) and incubated at 37°C for 
overnight. The cells which were grown on LB-tetracycline plates but not on LB-Chloramphenicol 
plates were identified as the colonies carrying only the target plasmid and isolated target plasmid. 
The isolated target plasmid was analysed by enzyme digestion with EcoRI and XhoI and the 
cleaved insert target coding sequences were analysed on 1% agarose gel electrophoresis. The 
positive target plasmids identified from colony PCR were sequenced for further study and also 
used for the panel of genetic assays. 
 
4.2.5. Phage display technology 
 
4.2.5.1. Solutions 
PBS buffer: 140 mM NaCl, 2.7 mM KCl, 20 mM Na2HPO4, pH = 7.3 
PBS + 0.1% Tween 20: 0.1 mL Tween 20 + 1 litre PBS buffer 
0.1 M Glycin: Dissolved 1.1 gm glycin in 100 mL distilled water and adjusted pH to 2.2 
2 M Tris: Dissolved 24.2 gm Tris HCl in 100 mL distilled water and adjusted pH to 1.1 
20% PEG + 2.5 M NaCl: Dissolved 200 gm PEG (PEG-6000 from Fulka # 81253) and 146 gm 
NaCl in 1 litre distilled water  
2YT medium: Dissolved 31 gm of 2YT cock tail powder (Roth # X966.2) in 1 litre Millipore 
water and autoclaved after adjusting the pH to 7.4. 
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4.2.5.2. Helper phage amplification 
One litre fresh culture of E. coli XL-1 blue MRF´ cells grown up to 0.5 OD600 in 
presence of 1:500 dilution of Tetracycline (10 mg/mL) at 37°C with continuous shaking was 
infected with 100 µL of helper phages (VCSM13 Interference-Resistant Helper Phages, Stratagene, 
cat # 200251) and further incubated for 30 min. After two hours of incubation, 1:333 dilution of 
Kanamycin (35 mg/mL) and 1:500 dilution of Tetracycline (10 mg/mL) were added to suppress the 
un-infected cells and then incubated for overnight at 30°C with continuous shaking. The overnight 
grown turbid culture was centrifuged at 10,000 RPM for 10 min and the supernatant was collected 
in to fresh bottles. The supernatant was incubated with 1/4th its volume of 20% PEG + 2.5 M NaCl 
solution [171] in ice to chill down the solution until a transparent cloudy smear appears due to 
dense phage particles in PEG solution. The chilled dense solution was centrifuged at 10,000 RPM 
for 30 min at 4°C to pellet down the phage particles. The pellet was dissolved in a small volume of 
PBS (3 to 4 mL) and collected into a fresh eppendorf tube. The solution was mixed by pipetting up 
and down to dissolve the pellet uniformly and centrifuged at high speed for 5 min to get rid of the 
cell lysate particles. The supernatant was collected in fresh tubes and added 20% PEG + 2.5 M 
NaCl solution at the rate of 150 µL/1 mL volume of supernatant. Then incubated on ice for 30 min 
and centrifuged to pellet down the particles at high speed for 5 min in table top centrifuge. The 
supernatant was discarded and centrifuged again for few seconds to remove the supernatant 
completely. The pellet was dissolved in PBS in a small volume and centrifuged for 5 min at high 
speed in table top centrifuge. The clear white supernatant is the amplified helper phage solution 
which was collected in a fresh sterile tube and preserved at -20°C by adding 30% (v/v) of the 
sterile 100% glycerol. 
 
4.2.5.3. The protocol for panning 
1. 65 µL of 80% of Glutathione Sepharose® 4B matrix (i.e. ≈ 50 µL) was taken in a fresh 1.5 mL 
eppendorf tube and centrifuged at 3000 RPM for 30 sec by using table top centrifuge 
2. The pellet was dissolved in 1 mL PBS + 0.1 % Tween 20 to wash out ethanol after discarding 
the supernatant very carefully and centrifuged for 5 sec at high speed 
3. Repeated step 2 
4. Repeated step 2 again with only PBS. 
5. The supernatant was removed carefully by leaving few drops to make sure that the pellet was 
not disturbed and thus the volume of slurry at this stage is 50 to 60 µL after removing the 
ethanol. Then, added 60 µL of only PBS to it for preparing 50 % diluted matrix and dissolved 
uniformly which results in 50 % slurry and 50 % PBS in total solution.  
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6. The total slurry was made into two parts of each ≈ 60 µL fresh 1.5 mL eppendorf tubes and 
labelled them as aliquot 1 and aliquot 2 (Aliquot 1 was used for query test and aliquot 2 was 
used for negative control panning). 
7. Added 0.4 mg of GST fusion protein i.e. GST-Spred2 EVH1 to aliquot 1 and 0.25 mg of GST 
alone (as negative control) to aliquot 2.  
8. Both the aliquots were incubated at 4°C for 10 min after vortexing the tubes thoroughly to mix 
protein and matrix uniformly and then centrifuged at 3000 RPM for 30 sec. 
9. The supernatant was discarded carefully and the pellets were washed for 5 times by dissolving 
each time in 1 mL PBS + 0.1% Tween 20 followed by centrifugation to get rid of the unbound 
protein remained in between the beads. 
10. After final wash, the pellets were dissolved in 25 µL of PBS + 0.1 % Tween 20 and the total 
volume would be 50 µL (including 25 µL of matrix with bound protein and 25 µL PBS + 0.1 % 
Tween 20). 10 µL of slurry (i.e. 5 µL of matrix) was collected from each aliquot and prepared 
SDS sample by adding 10 µL of 2X SDS buffer and heating at 100°C for 5 min. This SDS 
sample would be useful to determine whether the protein is bound to the beads to further 
quantify the same. 
11. The remaining matrix slurry volume of both aliquots was increased from 40 µL to 400 µL by 
adding the following components  
 
Component End con / proportion 
Final composition 
(for 400 µL) 
Matrix - 40 µL 
BSA (50 mg/mL) 5 mg/ml 40 µL 
PBS + 0.1% Tween 
20 
Half of the final 
volume 200 µL 
PBS Rest of the volume 120 µL 
 
12. 50 µL of M13 phage display X9 library (titre: 2 X 1011 Pfu/ml) was added to each of the 400 
µL of matrix and incubated at 4°C with 360° rotation for overnight. 
13. After overnight incubation, the samples were centrifuged for 30 sec at 3000 RPM in table top 
centrifuge and discarded the supernatant carefully without disturbing pellet. 
14. The pellet was then dissolved in 1 mL PBS + 0.1% Tween 20 and centrifuged for 30 sec at 
3000 RPM in table top centrifuge  
15. Step 14 was repeated for two more times and the pellet was dissolved in 1 mL PBS + 0.1% 
Tween 20 and incubated for 1 hour at room temperature. 
16. steps 13, 14 and 15 were repeated for two more times. 
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17. After final incubation, the solution was centrifuged and supernatant was discarded. The pellet 
was dissolved in only PBS and centrifuged for 30 sec at 3000 RPM in table top centrifuge. The 
supernatant was discarded carefully without disturbing the pellet. 
18. The pellet was dissolved completely in 350 µL of 0.1 M glycin (pH = 2.2) and incubated for 20 
min at room temperature. 
19. Then centrifuged for 30 sec at 3000 RPM at table top centrifuge and collected the supernatant 
in new tube. 
20. 20 µL of 2 M Tris was added to the collected supernatant to neutralize the solution and stored 
at 4°C. This is the eluted bound phages of the respective protein during this panning round. At 
the end of each panning round, we got the elute phages against both query protein and negative 
control (i.e. GST alone) which were titrated to estimate the total number of phages eluted in 
each panning round. 
 
4.2.5.4. Titration of phages 
Titration of phages was performed after every panning round and amplified to 
estimate the titre (pfu/mL) of the phages. The phages to be titrated (either elute phages or amplified 
phages) were diluted by serial dilution method up to desirable dilution by taking 45 µL of fresh 
2YT medium and 5 µL of phages from previous dilution. 50 µL of fresh 0.5 OD600 E. coli XL-1 
blue MRF´ culture was added to the 50 µL volume of all phage dilutions. The cells were incubated 
with phages for infection at 37°C for 10 min and then centrifuged for 3 min at 5000 RPM to pellet 
down the infected cells. Then, 50 µL of the supernatant was discarded and the pellet was dissolved 
in the rest of the supernatant. Each of these infected cells were plated on LB-AMP at 37°C for 
overnight. A control was also made by plating 50 µL of cells without any phage infection. The 
number of colonies grown from every dilution were normalised to one dilution factor and the 
average colony count gives titre value of the phage sample tested. The following formula was used 
to calculate the titre of the phages tested. 
Phage titre (pfu/mL) = Number of colonies X 10X dilution factor X 1000 / 45 
 
4.2.5.5. Enrichment factor  
The enrichment factor was calculated after determining the titre of elutes of GST 
fused protein and GST alone from a panning round. Enrichment factor of a panning round gives the 
rate of the bound phages enriched against the GST fused protein in that round. 
Enrichment factor = Net outcome for GST fusion protein / Net outcome for GST alone 
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(Net outcome = Number of bound phages eluted/ Number of phages given as input in the panning 
round) 
 
4.2.5.6. Amplification 
Amplification was performed with enriched positive phage population given from a 
panning round against GST fusion protein. We used different protocols for the amplification of 
enriched positive phages without loosing the consistency of phage representation.  
Protocol 1: 
1. 2 mL of 0.5 OD600 culture of E. coli XL-1 blue MRF´ was infected with 100 µL of eluates of 
GST fusion protein and incubated at 37°C for 15 min with continuous shaking. 
2. 6 mL of fresh 2YT medium, 3.2 µL Ampicillin (100 mg/mL), and 16 µl of Tetracycline (10 
mg/mL) was added and incubated for one hour at 37°C with continuous shaking.  
3. After incubation, 4.8 µL of Ampicillin (100 mg/mL) was added to increase the specific 
selection for recombinant phage infected cells and incubated for one hour with continuous 
shaking.  
4. After incubation, the cells were super infected with 100 µL of helper phages (VCSM13 
Interference-Resistant Helper Phage from Stratagene, cat # 200251) and incubated at 37°C for 
30 min with continuous shaking. 
5. After incubation, the super infected culture volume was increased to 500 mL by adding fresh 
2YT medium along with 460 µL of Ampicillin (100 mg/mL) and 920 µL of Tetracycline (10 
mg/mL) and incubated for 2 hours at 37°C with continuous shaking. 
6. After incubation, the culture looked turbid due to growth of super infected cells. Then 1: 500 
dilution of Kanamycin (35 mg/mL) was added and incubated overnight with continuous 
shaking at 37°C. The super infected cells do not grow fast and sometimes we do not see any 
turbidity even after many hours of super infections. In such cases, we used 1:1000 dilution of 
Kanamycin (35 mg/mL) and incubated overnight. 
7. The overnight grown turbid culture was centrifuged at 10,000 RPM for 10 min. The 
supernatant was collected and 1/4th of its volume of 20% PEG + 2.5 M NaCl solution was 
added to the supernatant. This was incubated on in ice to harvest the amplified phages at least 
for 2 hours. We observed a transparent cloudy smear due to dense phage particles in PEG 
solution.  
8. After dense solution was centrifuged at 10,000 RPM for 30 min at 4°C to pellet down the phage 
particles. 
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9. The pellet was dissolved in small volume of PBS (≈1.5 mL) uniformly and transferred into a 
fresh eppendorf and centrifuged at high speed for 5 min to get rid of the un-dissolved particles. 
The supernatant was collected in a fresh tube. 
10. 20% PEG + 2.5M NaCl solution was added at the rate of 150 µL/ mL of the supernatant and 
incubated on ice for 30 min. 
11. After incubation, the solution was centrifuged to pellet down the phage particles at high speed 
for 5 min. The supernatant was discarded and centrifuged again for few seconds to discard the 
remnants of the supernatant. 
12. The pellet was dissolved in PBS and centrifuged for 5 min at high speed. The supernatant was 
collected in a fresh tube which is the amplified phage sample and preserved at -20°C by adding 
30% (v/v) of the sterile 100% glycerol. 
13. Amplified phages were titrated to know the titre of the phages amplified in this amplification 
process. 
Protocol 2: 
1. 500 mL fresh culture of E. coli XL-1 blue MRF´ was grown up to 0.5 OD600 in presence of 1: 
500 dilution of Tetracycline (10 mg/mL) and then infected with 100 µL of eluates of GST 
fusion protein. The infected culture was incubated at 37°C for 30 min with continuous shaking. 
2. After incubation, 200 µL Ampicillin (100 mg/mL) and 1 mL of Tetracycline (10 mg/mL) was 
added and incubated for one hour at 37°C with continuous shaking. 
3. After incubation, 300 µL of Ampicillin (100 mg/mL) was added and again incubated for one 
hour with continuous shaking.  
4. After incubation, the cells were super infected with 100 µL of helper phages (Technical name: 
VCSM13 Interference-Resistant Helper Phage from Stratagene, cat # 200251) and 1 mL 
Ampicillin (100 mg/mL), 1 mL of Tetracycline (10 mg/mL) were supplied. Then incubated at 
37°C for 2 hours with continuous shaking. 
5. Rest of the method was same as in protocol 1, from step.6 onwards. 
Protocol 3: 
1. 2 ml fresh culture of E. coli XL-1 blue MRF´ grown up to 0.5 OD600 in presence of 1:500 
dilution of Tetracycline (10 mg/mL) was infected with 100 µL of elute phages of GST fusion 
protein and incubated at room temperature for 15 min without shaking 
2. Then, 6 mL of fresh 2YT medium, 2 µL Ampicillin (100 mg/mL), 8 µL of Tetracycline (10 
mg/mL) were added and incubated for 1 hour at 37°C in a water bath without shaking. 
3. After incubation, 4.8 µL of Ampicillin (100 mg/mL) was added and incubated for 1 hour with 
continuous shaking. 
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4. After incubation, the cells were super infected with 100 µL of helper phages and incubated at 
room temperature for 30 min without shaking. 
5. After incubation, the 8 mL culture of super infected cells was upgraded to 500 mL by fresh 
2YT medium along with 500 µL of Ampicillin (100 mg/mL) and 1 mL of Tetracycline (10 
mg/mL) and incubated for 2 hours at 37°C with continuous shaking. 
6. Rest of the method was same as in protocol 1, from step.6 onwards. 
Protocol 4: 
1. 25 mL fresh culture of E. coli XL-1 blue MRF´ was grown up to 0.5 OD600 in presence of 1: 
500 dilution of Tetracycline (10 mg/mL) was infected with 100 µL of elute phages of GST 
fusion protein and incubated at 37°C for 30 min without shaking. 
2. 100 mL of fresh 2YT medium, 125 µL Ampicillin (100 mg/mL) and 125 µL of Tetracycline 
(10 mg/mL) were then added and incubated at 37°C with continuous shaking until OD600 of the 
culture reaches 0.5. 
3. 100 µL of helper phages was used to super infect and incubated at room temperature for 30 min 
without shaking and then incubated with shaking at 37°C for 30 min. 
4. These cultures were centrifuged and the cells were resuspended in 500 mL of fresh 2YT 
medium, 0.75 mL Ampicillin (100 mg/mL), 1.5 mL of Tetracycline (10 mg/mL) and 1.5 ml 
Kanamycin (35 mg/mL) and grown overnight with continuous shaking at 37°C. 
5. Isolation of amplified phages was performed as described in protocol 1, from step.7 onwards 
 
4.2.5.7. Characterization of phagemids by colony PCR 
Colony PCR was performed to determine the phagemids carrying insert coding 
sequences from the phage population eluted in the panning rounds against query GST fusion 
protein. The respective phage infected cells plated on LB-Ampicillin plates for selecting single 
colonies. Colony PCR was performed to identify the amplified insert coding regions in the 
phagemids. 
1. Single colony was picked by using a sterile yellow tip and dissolved in 15 µL of sterile water 
by pipetting up and down and vortexing. 
2. 5 µL of the cells were collected in a fresh tube for back up.  
3. Rest of the sample was boiled at 100°C for 5 min to lyse the cells and centrifuged at high speed 
for 5 min to pellet down the cell debris. 
4. The supernatant was used as template for colony PCR. 
Forward primer (5’-3’): TACCCTCGTTCCGATGCTG 
 Reverse primer (5’-3’): GCTGAGGCTTGCAGGGAG 
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PCR reaction mixture: 
 
Reaction component Volume 
Template DNA 3 µL 
Forward primer (50 µM) 0.3 µL 
Reverse primer (50 µM) 0.3 µL 
dNTP mix (2.5 mM) 2 µL 
Taq polymerase (New England biolabs) 0.18 µL 
NEB 10X reaction buffer 1.5 µL 
H2O 7.7 µL 
                                                      Total reaction volume = 15 µL 
  
PCR programme: 
 
 Process Temperature Time Number of cycles 
Initial denaturation 94°C 2 min - 
Denaturation 94°C 20 sec 
Annealing 65°C 20 sec 
Extension 72°C 20 sec 
30 cycles 
End 4°C - - 
 
The amplified PCR products were analysed on 2% agarose gel. An empty and recombinant 
phagemids were used as positive and negative control in PCR reaction. Loading both of those 
amplified products together on a 2% agarose gel gives a double band of very low molecular weight 
difference (≈ 50 kDa) which could help us to identify positive and negative phagemids. 
 
4.2.6. Protein-phospholipid interaction assays 
 
4.2.6.1. Solutions 
Washing solution (TBS-T): 10 mM Tris, 150 mM NaCl, 0.1% (v/v) Tween-20, pH 8.0  
Blocking solution (TBS-T + 3% BSA): 3 g fatty acid free BSA + 100 mL TBS-T 
MLV buffer (Liposome buffer): 100 mM NaCl, 10 mM MOPS, pH = 7.2 
LUV buffer (Sucrose buffer): 176 mM sucrose, 10 mM MOPS, pH = 7.2 
 
4.2.6.2. Solid phase overlay assay 
PIP Strip™ membranes (Echelon, cat # P-6001) containing phospholipids spotted 
onto Hybond-C membranes were used for phospholipid membrane screening in solid phase overlay 
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assay to identify Spred2 EVH1-phospholipid interactions. GST-ADAP SH3-N fusion protein was 
used as positive control for phospholipid membrane screening experiments. 
1. Blocking: Blocked the membrane with TBS-T+ 3% BSA solution and gently agitated for one 
hour at room temperature.  
2. Add protein of interest: Discarded blocking solution and incubated the membrane with 10 
μg/mL GST-Spred2 EVH1 fusion protein in fresh blocking solution for overnight at 4 ºC with 
shaking. 
3. Washing: The membrane was washed three times with TBS-T with gentle agitation for 10 min 
each.  
4. Anti-GST antibody: Incubated the membrane for 2 hours at RT with anti-GST polyclonal 
antibody (dil 1:1,000 (v/v)) in blocking solution. 
5. Washing: as in step 3  
6. Anti-rabbit HRP antibody: Incubated the membrane for 1 hour at RT with anti-rabbit IgG-
HRP (dil1:10,000 (v/v)) in blocking solution.  
7. Washing: as in step 3  
8. Detection: The protein bound phospholipids were detected using enhanced chemiluminescence 
(SuperSignal West Pico, PierceIllinois). The membrane was incubated in developer solution 
(solution A = 2 mL and solution B = 50 µL) for few minutes and drained off before exposing the 
membrane in scientific image illuminator which detects the signal and produces an electronic 
image in computer. 
 
4.2.6.3. Preparation of multilamellar vesicles (MLVs) 
The synthetic lipids phosphatidylcholine (PC), phosphatidylserine (PS), which 
contain palmitic and oleic acid esterified at the sn-1 and 2 positions of the glycerol backbone, 
PI(4)P (Cat No. 840045) and PI(4,5)P2 (Cat No. 840046) were purchased from Avanti Polar Lipids. 
PI (3) P, PI (5) P, and PI (3, 5) P2 (Cat No. P-3016, P-5016, P-3516 respectively) were obtained 
from Echelon Inc. To prepare MLVs, PC, PS and different phosphoinositides (PIPs) were dissolved 
in chloroform or chloroform: methanol: water solutions (as per product description by supplier) in 
desired ratios as shown in the Table.4. This was dried on a rotating evaporator to get the require 
liposome composition. Liposomes (4 mM) were prepared in the proportion of 52 mol% PC, 46 
mol% PS and 2 mol% of the mono-PIs or 54 mol % PC, 44 mol % PS and 2 mol% of the bis-PIs 
[172].  
Total volume of vesicle Stock = 1200 µL (Enough for two binding assay experiments) 
End concentration of phospholipid in the liposome vesicle stock = 4 mM 
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 POPC POPS PI(X)P DiC16*   PI(3,5)P2, DiC16 
PI(4,5)P2, 
Di 18:1 
Con. Stock (µg/µL) 20 20 1 1 1 
MW 760.1 784 956.96 1080.9 1074.17 
      
POPC:POPS      
Portion (%)/ mol 50.0 % 50.0 %    
Vol. Stock (µL) 91.2 94.1    
Mass (µg) 1824.2 1881.6    
      
POPC:POPS:PI(3)P      
Portion (%)/ mol 52.0% 46.0% 2.0%   
Vol. Stock (µL) 94.8 86.6 91.8   
Mass (µg) 1897.2 1731.0 91.8   
      
POPC:POPS:PI(4)P      
Portion (%)/ mol 52.0% 46.0% 2.0%   
Vol. Stock (µL) 94.9 86.6 96.1   
Mass (µg) 1897.2 1731.1 96.1   
      
POPC:POPS:PI(5)P      
Portion (%)/ mol 52.0% 46.0% 2.0%   
Vol. Stock (µL) 94.9 86.6 91.9   
Mass (µg) 1897.2 1731.1 91.9   
      
POPC:POPS:PI(3,5)P2      
Portion (%)/ mol 54.0% 44.0%  2.0%  
Vol. Stock (µL) 98.5 82.8  103.8  
Mass (µg) 1970.2 1655.8  103.8  
      
POPC:POPS:PI(4,5)P2      
Portion (%)/ mol 54.0% 44.0%   2.0% 
Vol. Stock (µL) 98.5 82.8   103.1 
Mass (µg) 1970.2 1655.8   103.1 
X = monophospho lipids 
Table 4: Composition of the liposome vesicles. The phospholipids of different phosphorylation sites were mixed 
along with the respective amounts as shown in the table to get the 4 mM end vesicle stock concentration. The ratio/ 
mol were calculated to compose the liposomes such that the overall surface charge of the liposome is equilibrated.  
 
1. The phospholipids were dissolved in chloroform or methanol as per the supplier’s description 
to achieve desired concentration and kept on ice. 
2. The glass tubes were washed with methanol and chloroform each two times thoroughly by 
vortexing to rinse the sides perfectly. After washing, few drops of chloroform was added to the 
tube for easy pipetting of phospholipids. 
3. By using glass Hamilton syringe, phospholipids were mixed in the appropriate ratio as shown 
in the table.4 to prepare MLVs 
Note: After mixing the phospholipids together in glass test tube, they should be colourless. If 
phospholipid mixture looks like white cloudy, it can be dissolved further by adding few drops 
methanol further. 
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4. The organic solvents were carefully evaporated by using rotating vacuum pump for 1 hour. The 
evaporation was extended further for few phospholipids when the solvent was not completely 
evaporated. If the evaporation is not taking place at all for any phospholipids in such cases we 
left them over night for evaporation to get rid of solvents completely or used nitrogen stream to 
remove rest of the solvent. 
5. The multi lamellar vesicles were resuspended in 400 µL of LUV buffer and incubated for 30 
min in a dark place at RT by closing the test tubes with parafilm. 
6. Then the volume was split into two equal halves (200 µL each) which is the final required 
amount for one phospholipid-protein sedimentation assay as per our experimental plan (used 
safe lock eppendorf tubes for MLVs). 
7. MLVs were made by passing through five cycles of freezing (liquid nitrogen) and thawing 
(37 °C water bath) and then final round of frozen MLVs were stored at -80°C. 
 
4.2.6.4. Preparation of large unilamellar vesicles (LUVs) 
1. MLVs of required phospholipids were thawed by keeping on ice for few minutes. 
2. During thawing MLVs, mini-extruder (Avantis, cat # 610000) was assembled as per the 
instructions given at http://www.avantilipids.com/ExtruderAssembly.html (Fig.5). Four filter 
supports (Avanti #610014) and one polycarbonate membrane (100 nm diameter, Avanti # 
800309) was used in the mini extruder for our experiments. 
3. Once the MLVs solution is fully thawed the sample was loaded into one of the gas-tight 
Hamilton syringes and carefully placed it into one end of the mini-extruder.  
4. The empty gas-tight syringe was placed into the other end of the mini-extruder. 
Note: Make sure that the empty syringe plunger is set to zero and the syringe will be filled 
automatically as the MLVs are extruded through the membrane.  
5. the plunger of the filled syringe gently pushed until the solution was completely transferred to 
the alternate syringe through the extruder.  
6. The plunger of the alternate syringe was pushed gently to transfer the solution back to the 
original syringe.  
Note: The MLVs suspension should begin to show transparent colour after passing through the 
extruder.  
7. Repeated steps 5 & 6 for 4 times.        
8. Taken care to fill the final extrusion in the alternate syringe (the receiver in the step 5) at the 
end of extrusion to reduce the chances of contamination with larger particles or foreign 
material. 
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Figure 5: The design of mini-extruder. The mini-extruder for the preparation of LUVs is made up of extruder casings 
on both sides and a bi-layer of filter supports to the polycarbonate membrane to support the pressure created during 
extrusion. The content and arrangement of components of the mini-extruder is depicted in this diagram. 
 
9. The filled syringe was removed from the extruder and injected the LUVs solution into a clean 
eppendorf tube.  
10. The extruder was cleaned by passing the LUV buffer for 5 times before using for a new LUVs 
preparation.  
11. The volume of the extruded LUVs was measured and filled with the rest of the volume with 
MLV buffer to get final volume of 1400 µL (it gives nearly 1:8 dilution) to exchange the 
suspension buffer.  
12. The LUVs were centrifuged at 45,000 RPM at 10° C for one hour in Beckman TLA-45 rotor.  
13. The supernatant was discarded by leaving 50 µL in the tube to avoid pellet damage.  
14. The pellet was dissolved in required volume of MLV buffer by considering 50 µL already left 
in the tube to get final phospholipid concentration of 4 mM. 
 
4.2.6.5. Liposome sedimentation assay 
1. Binding assays were performed with 2 μM of ultra purified and natively folded Spred2 EVH1 
protein. The protein was added to LUVs of serial dilutions in a total reaction mixture volume of 
500 µL as shown in the table.5. The ADAP SH3-C protein was used as a positive control for 
protein-phospholipid sedimentation assay. 
2. The binding assay mixtures were incubated at RT in dark place for 30 min. 
3. Then centrifuged at 45,000 RPM for 1 hour at 10° C in ultracentrifuge to sediment the bound 
protein-phospholipid interacting complex. 
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4. The supernatant was removed immediately and protein amount present in the supernatant was 
determined by tryptophan fluorescence emission in a luminescence spectrophotometer. Also, 
the equivalent aliquots of supernatant and pellet samples were analysed by SDS-PAGE to 
detect the protein present in the respective proportions. 
5. The reaction mixture without liposomes (zero concentration reaction mixture) is used as the 
blind value giving the protein concentration maximally to be present in the supernatant if no 
binding at all occurs in other reaction mixtures. 
 
End con of phospholipid (µM) 0 100 300 600 900 1600 
Liposome, LUVs (4 mM) to be 
taken in µL 0 12.5 37.5 75 112.5 200 
MLV buffer (in µL) 490 477.5 452.5 415 377.5 290 
Protein (End con = 2 µM)         
Stock = 0.1 mM 10 µL 10 µL 10 µL 10 µL 10 µL 10 µL 
 
Table 5: The composition of sedimentation assay reaction mixture. The LUVs of different phospholipid 
compositions were incubated with query protein in presence of MLV buffer in the proportions as shown in the table. 
The reactions were performed at different concentrations of liposomes to assay the binding affinity quantitatively 
against the query protein. The reaction mixture without phospholipid would show a base line interaction behaviour 
since one of the interaction partner is missing. This would serve as a negative control in our experiments. 
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5. RESULTS 
 
5.1. Identification of protein kinases participating in serum-stimulated phosphorylation of 
VASP and elucidation of their order of action 
 
5.1.1. Serum treatment of MCFB cells stimulates phosphorylation of VASP at Ser-157 but not 
at Ser-239 
Serum stimulation of cells is known to induce several signalling cascades including 
those involved in regulation of the cytoskeleton. Many protein kinases are serum sensitive and 
effect components of the cytoskeleton. However, not much is known about the role of serum on 
phosphorylation of the cytoskeletal protein, VASP. Hence we have examined the effects of serum 
stimulation on the phosphorylation status of VASP. Overnight starved quiescent Mouse Cardiac 
Fibroblast (MCFB) cells (+/+) were stimulated with 10% serum and assayed in cell lysates for 
alterations in VASP at different time points according to the general experimental scheme as given 
in Chapter 4.2.1.5. Western blot analysis by using polyclonal anti-VASP antiserum M4 after 
protein separation on SDS-PAGE showed that serum stimulation induced phosphorylation of 
VASP as indicated by a shift in apparent molecular weight from 46 kDa to 50 kDa (Fig.6a) which 
was not seen in unstimulated quiescent cells. The M4 antiserum detected also a non-specific 80 
kDa band in western blots which served as a loading control in our experiments. It was found that 
serum stimulation of VASP phosphorylation was time dependent and was prominent as early as 90 
min after serum stimulation (Fig.6b) and persisted even after 10 hours (Fig. 6c). The shift in the 
apparent molecular weight of VASP from 46 kDa to 50 kDa detected by polyclonal M4 antiserum 
indicates a phosphorylation of VASP at Ser-157 [2]. Similar results were seen also in mouse 
mesangial cells (+/+) confirming that the observed activity is not cell specific (Fig.6d). Thus the 
results clearly establish that there is a phosphorylation event occurring at Ser-157 of VASP during 
stimulation of cells by serum. The site specificity of VASP phosphorylation can be determined 
with the use of monoclonal antibodies directed against the three known phosphorylation sites of the 
VASP molecule (see Chapter 2.3.2.3).  
To find out the identity of the VASP phosphorylation sites engaged after serum 
stimulation, lysates of serum stimulated cells were analyzed at different time points for the status of 
individual phosphorylation sites. This was done using monoclonal antibodies 5C6 and 16C2 which 
are specific for the individual phosphorylation sites Ser-157P and Ser-239P on VASP, respectively 
[124]. Western blots with 5C6 and 16C2 showed that serum stimulated VASP phosphorylation 
only at Ser-157 but was not found at Ser-239 (Fig. 7a and b). These experiments confirmed that 
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phosphorylation of VASP induced by serum stimulation was confined to Ser-157. The effect of 
serum stimulation on the regulation of Thr-278, the third phosphorylation site of VASP, could not 
be determined due to a lack of specific antibodies for this site, however recently published research 
articles proposed working antibodies also for this phosphorylation site [3].  
These experimental results show that serum stimulation preferentially induces VASP 
phosphorylation at Ser-157 which causes the shift in molecular weight from 46 kDa to 50 kDa as 
detected by anti-VASP antiserum M4. 
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Figure 6: Serum treatment of cells stimulates VASP phosphorylation. Overnight starved MCFB cells (+/+) were 
stimulated with 10% FCS and VASP phosphorylation was studied at different time periods with an interval of one hour 
(Fig. a and c) and 30 min (Fig. b) each, by immunoblotting using M4-antiserum. Similar experiments were also carried 
out using Mouse mesangial cells (+/+) (Fig. d). In all the blots, 46 kDa and 50 kDa bands represent non-phospho and 
phospho forms of VASP respectively and an upper band at 80 kDa is also recognized by the M4 anti-VASP antiserum, 
which serves as a loading control. Blots shown are representative of four independent experiments. In all blots, C 
represents control samples which are unstimulated cell lysates. 
 
5.1.1.1. An interaction graph model describing serum-stimulated VASP phosphorylation 
forms a conceptual basis for experimental identification of the protein kinases involved 
To summarize the major pathways expected to be involved in serum stimulated 
VASP phosphorylation at Ser-157 a graph model of the interaction network which addresses its 
candidate players and their possible interactions was developed (see Fig.8). This directed 
interaction graph was organized into three major hierarchical layers of protein interactions 
modelled at different resolution (and represented by three different back ground shadow colours in 
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the diagram) that correspond to the major relay stations of the signal transduction cascades under 
study viz., an input signal by external stimulation of the cell, an intermediate processing of the 
signals by signal transduction and signal exchange and finally a targeted output signal as detected 
by a change in the molecular properties of the effector protein VASP. The key players like 
stimulators/receptors, candidate protein kinases, and the substrate protein involved in this signal 
transduction network are represented as nodes. The direct or indirect interaction pathways between 
these nodes either already known or inferred from the literature as described in other biological 
contexts are represented by directed edges (unbroken or broken arrows respectively) in this 
interaction map. The top node at the external layer of this interaction map represents the serum 
added to the cells and is considered here as a collection of unspecified stimuli which by binding to 
an array of cell surface receptors initiate signalling processing. Arrows labelled as a, b, c, d, e, f 
refer to different serum-stimulated intracellular pathways leading to the activation of an 
intermediate network of protein kinases which are represented as nodes in the next layer of 
interaction in our interaction map. These candidate protein kinases do have the propensity to 
downstream phosphorylate VASP (either directly or indirectly as labelled by unbroken or broken 
arrows respectively with numbering 1, 2, 3 and 4 according to the protein kinase specified) or to be 
engaged in phosphorylation reactions among each others (labelled by unbroken arrows with 
apostrophized numbers; for the sake of clarity only nearest-neighbour interactions are shown in the 
diagram). VASP phosphorylation represents the bottom node in the convergent final layer of the 
directed interaction graph. The alphanumerical coding of nodes and edges described here will be 
used throughout the following text while referring to the experimental results in this part of the 
thesis.  
Specifically, stimulation of cells with serum intracellularly activates many 
cytoskeleton-associated protein kinases like MAP kinases (arrow ‘a’ in Fig.8), protein kinases C 
(arrow ‘b’ in Fig.8) or Rho kinases (arrow‘d’ in Fig.8) which are known to play an important role 
in cytoskeletal reorganization. Of these kinases, we hypothesized based on literature knowledge 
that Rho kinases and PKCs may be new candidate protein kinases responsible for mediating serum-
derived signals involved in VASP phosphorylation. Such a phosphorylation event might be either 
the result of a direct interaction with VASP as a proximal substrate for these candidate protein 
kinases or the result of an indirect one involving other protein kinases of the network. Also indirect 
phosphorylation pathways might finally be expected to involve phosphorylation of VASP through 
the cyclic nucleotide dependent protein kinases (PKA and PKG) which are well-known to use 
VASP as one of their direct substrates. Hence PKA and PKG are also considered as member nodes 
of the inter-connecting network layer in our directed interaction graph model. The nodes of the 
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protein kinase network are further labelled in the diagram of Fig.8 by those antagonistic or 
agonistic drugs (specified for the respective kinase and their mode of action on this target) which 
will be used as pharmacological tools to study experimentally the structure of this network in the 
following perturbation experiments with MCFB (+/+) cells. Basically identification of candidate 
protein kinases involved will be achieved by looking at VASP phosphorylation in the presence of 
different combinations of activators or inhibitors complemented by appropriate controls of drug 
specificity. 
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Figure 7: Serum stimulated VASP phosphorylation occurs at Ser-157. In serum stimulated MCFB cells (+/+) after 
different time periods, VASP phosphorylation at Ser-157 (Fig. a) and Ser-239 (Fig. b) was probed using respective 
monoclonal antibodies 5C6 and 16C2. In Fig a and b, C represents unstimulated cell sample and in Fig. b, P represents 
endothelial cells lysates which were used as positive control samples. Blots shown are representative of three 
independent experiments. In Fig. a, an extra band with a molecular weight larger than 50 kDa appeared which 
remained unchanged in intensity during time course of the experiment. Its nature is currently unclear. 
 
5.1.2. Serum activated PKCs, but not Rho kinases are involved in serum stimulated VASP 
phosphorylation at Ser-157 
It is shown above that VASP is phosphorylated at Ser-157 on stimulation of cells by 
serum and we subsequently looked for the type of protein kinases that are involved in this process. 
In general serum stimulation regulates many cytoskeleton-associated protein kinases that are 
responsible in different signalling pathways for cytoskeletal remodelling as shown in the 
interaction network map described above. Of these kinases, PKC and Rho kinases and their 
respective signalling pathways are of great importance in serum-mediated alterations of the cell 
cytoskeleton. VASP is known to participate in such cytoskeletal alterations as a key player. 
Although there are many protein kinases activated during serum stimulation, we focused our 
experiments initially on Rho kinase and PKC in view of the fact that only these kinases might have 
some indirect interactions with VASP. Both of these kinases and VASP for instance are known to 
participate in focal adhesion formation. These kinases might mediate direct or indirect 
phosphorylation of VASP during serum stimulation although VASP has so far been known to be 
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phosphorylated by cyclic nucleotide-dependent kinases only while studying other conditions of 
cellular stimulation. 
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Figure 8: Representation of an interaction graph model compiling possible pathways involved in serum 
stimulated VASP phosphorylation. In the above interaction graph, the following notation was used: arrows labelled 
as a, b, c, d, e, f consider different serum stimulation pathways leading to an activation of the respective kinases. 
Possible pathways down-stream of serum activated PKC, PKA, PKG and Rho kinase are represented by arrows 
labelled with numbers 1, 2, 3 and 4 (and apostrophes) respectively. The same nomenclature was used throughout the 
whole text of this thesis. A set of activator (green) and inhibitor (red) shown at each node are used to modulate the 
respective kinase activity experimentally. 
 
We first tested for an involvement of PKCs and Rho kinases in serum stimulated 
VASP phosphorylation by treating quiescent cells with Ro-31-8220 (10 µM) and Y-27632 (10 
µM), inhibitors of PKCs and Rho kinases respectively (see Table.6), prior to the stimulation with 
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serum according to the general experimental scheme shown in Chapter 4.2.1.5. The samples were 
analyzed by western blot using M4 antiserum. The results were shown in Fig. 9a. Control lanes 1 
and 2 show the unstimulated and serum stimulated samples respectively and thus support the 
phosphorylation of VASP at Ser-157 in this experiment. In the same western blot, in presence of 
the PKC inhibitor (see pathways [1], [1´], [1´´] in Fig.8) there was no phosphorylation of VASP 
upon serum stimulation as seen in lane 4, while with the Rho kinase inhibitor (see pathways [4], 
[4´], [4´´] in Fig.8) VASP phosphorylation still occurred at Ser-157 as seen in lane 3. In presence 
of both inhibitors together lane 5 shows a result which is in line with the results observed in lane 3 
and 4. Taken together these experiments suggest that PKCs mediates serum stimulated VASP 
phosphorylation, but Rho kinases do not. According to the interaction map presented in Fig.8, PKC 
may mediate this process either by a pathway [1] or by the other possible pathways using further 
the intermediate protein kinases PKA or PKG labelled as [1’+2] or [1´´+3] in Fig.8 resulting 
finally in the phosphorylation of VASP at Ser-157. Insensitivity of VASP phosphorylation to the 
action of the Rho kinase inhibitor Y-27632 suggests that pathways [4], [4´] and [4´´] are not 
involved in serum stimulated VASP phosphorylation. The detailed role of PKC in phosphorylation 
of VASP during serum stimulation however can not be elucidated from this type of experiments 
and will be addressed later on. 
To confirm the specificity of the inhibitors used, positive control experiments were 
done to determine whether these substances might unspecifically interrupt known cyclic 
nucleotide-dependent protein kinase mediated signalling pathways that induce VASP 
phosphorylation. In principle the inhibitors used that have been described to inhibit PKC and Rho 
kinase might also interact with the activity of other protein kinases like PKA and PKG which are 
known to phosphorylate VASP independently of serum stimulation. To address this question, the 
quiescent cells were incubated with the above mentioned inhibitors at the same concentration for 
30 min and then stimulated with an adenylate cyclase activator which finally activates PKA 
(Forskolin) or a PKG specific activator (8-pCPT-cGMP). The cell lysates were analyzed by 
western blot using M4 antiserum and assayed for phosphorylation of VASP.  The results showed 
VASP phosphorylation by treatment of the cells with PKA and PKG activators also in the presence 
of each of the inhibitors as it was observed without inhibitors (compare lanes 3 and 4 with lane 2 in 
Fig.9b. Data are not shown for PKG activity). These data rule out that the inhibitors of PKC and 
Rho kinase are unspecifically interrupting PKA- and PKG-mediated signalling pathways leading to 
VASP phosphorylation and thus suggest that they act according to their described specificity also 
under the experimental conditions used here. 
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Compound Activity Concentration used Reference 
Y-27632 
A highly potent, cell-permeable and 
selective inhibitor of Rho-associated 
protein kinases (Ki = 140 nM) 
10 μM [173] 
Ro-31-8220 Competitive and selective inhibitor of protein kinase C (IC50 = 10 nM) 10 μM [174] 
Bis I 
Acts as a competitive inhibitor for the 
ATP-binding site of PKC 
(Ki = 10 nM) 
10 μM [175] 
Bis V 
Negative control compound for protein 
kinase C inhibition studies 
(IC50 > 100 mM) 
10 μM [176] 
H89 
A highly selective cell-permeable potent 
inhibitor of protein kinase A   (Ki = 48 
nM) 
10 μM [177, 178] 
PMA 
Activator of protein kinase C in- vivo 
and in-vitro at nM concentrations.  
Also inhibitor of PKC during long-term 
treatment. 
1 μM [179, 180] 
Forskolin 
Activator adenylate cyclase resulting in 
increased cAMP levels  and activation 
of PKA 
(EC50 = 4 mM) 
10 μM [177] 
 
Table 6: Drugs used in the pharmacological perturbation experiments. Both activators (shown in green colour) 
and inhibitors (shown in red colour) used in this work are listed here. Their mode of action and the concentrations of 
the compounds used in the experiments are listed in the table. 
  
5.1.3. PKA, but not PKG is required for serum stimulated phosphorylation of VASP at Ser-
157 
The above experiments have shown that VASP is phosphorylated at Ser-157 on 
serum stimulation and that in this phosphorylation PKC is involved. It is therefore necessary to 
further elucidate if PKC mediated VASP phosphorylation after serum stimulation is dependent on 
other well known protein kinases which have already been found to phosphorylate VASP in a well 
defined manner (see interaction graph model in Fig.8). In general, PKA and PKG are major protein 
kinases linking cyclic nucleotide-dependent signal transduction with the cytoskeleton. Even though 
PKG preferentially phosphorylates VASP at Ser-239, it can also phosphorylate Ser-157 (see 
Chapter 2.1.1.4) [2]. As serum stimulation via PKC also mediates phosphorylation of Ser-157 on 
VASP, it became an important issue to determine whether PKC phosphorylates VASP at Ser-157 
without any involvement of PKA and PKG (see pathway [1]) or whether its effect depends on PKA 
or PKG either directly or indirectly (see pathways [1´+ 2] and [2´+ 1] or [1´´+ 3] and [3´+ 1] in 
the interaction network model summarized in Fig.8). 
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Figure 9: The protein kinase C inhibitor but not the Rho kinase inhibitor is inhibiting serum stimulated VASP 
phosphorylation. In Fig. a, shows phosphorylation of VASP detected with M4 antiserum in lysates of MCFB cells 
(+/+) incubated with Ro-31-8220 (10 μM), a protein kinase C inhibitor or Y-27632 (10 μM), a Rho kinase inhibitor or 
both for 30 min prior to serum stimulation for 3 hours. In Fig. b, shows the extent of VASP phosphorylation after 
incubating cells for 30 min with inhibitors Ro-31-8220 (10 μM) or Y-27632 (10 μM) followed by activation with 
Forskolin (10 μM), an adenylate cyclase activator that activates PKA, for 10 min. In all the blots, 46 kDa and 50 kDa 
bands represent the non-phospho and phospho forms of VASP respectively and the upper band of 80 kDa which is also 
recognized by the M4 anti-VASP antiserum serves as a loading control. Lane 1 in both blots represent unstimulated 
control cell sample. Blots shown are representative of three independent experiments. 
 
Firstly to examine the role of PKA in the serum stimulated VASP phosphorylation 
at Ser-157, the overnight starved cells were incubated with H89 at a concentration of 10 μM, an 
inhibitor of PKA prior to stimulation with serum. Western blot analysis with M4 antiserum as 
shown in Fig. 10a did not show phosphorylation of VASP at Ser-157 in the presence of H89 (10 
μM) after serum stimulation as seen in lane 6. The same observation was made in lane 4 in the 
presence of the PKC inhibitor, Ro-31-8220 but not in lane 3 in presence of the Rho kinase 
inhibitor, Y-27632 which was already observed in chapter 5.1.2. In lane 5, inhibition of serum 
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stimulated VASP phosphorylation at Ser-157 in presence of both Ro-31-8220 and Y-27632 
together is only due to the activity of Ro-31-8220, according to the results seen in lane 3 and 4 and 
also lanes 3 and 4 in Fig 9a. Lane 1 and 2 show unstimulated and serum stimulated controls 
without and with phosphorylation of VASP at Ser-157 respectively. These results show that serum 
stimulated VASP phosphorylation at Ser-157 is mediated by both PKC and PKA. It suggests 
particularly that PKA is involved in serum stimulated VASP phosphorylation at Ser-157 and that 
this might happen by either pathways [1’+2] or [2’+1] as depicted in Fig.8. However we suspect 
the former pathway to be the most probable one because PKA is well known to directly 
phosphorylate VASP preferentially at Ser-157 (see Fig.1). To establish the sequence of action of 
these two protein kinases this signalling pathway will be elucidated in further detail later on (see 
Chapters 5.1.6). 
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Figure 10: (a) PKA is involved in serum stimulated VASP phosphorylation at Ser-157. MCFB cells (+/+) were 
incubated with Ro-31-8220 (10 μM), a protein kinase C inhibitor, H89 (10 μM), a PKA inhibitor and Y-27632 (10 
μM), a Rho kinase inhibitor for 30 min prior to serum stimulation of 3 hours and blotted for VASP phosphorylation 
with M4 antiserum. In the blot, 46 kDa and 50 kDa bands represent non-phospho and phospho forms of VASP 
respectively and the upper band of 80 kDa which is also recognized by the M4 anti-VASP antiserum serves as a 
loading control. Lane 1 represents unstimulated control. (b) MCFB (+/+) cells lack PKG. The presence of PKG in 
MCFB (+/+) cells was examined by immunoblotting cell lysates (which are collected without any further treatments or 
starvation) with anti PKG antibody. Sodium nitro prusside (SNP) stimulated blood platelet samples which are rich in 
PKG were used as positive control for this experiment. M in the diagram represents protein molecular weight ladder 
and the thick band in the marker near 80 kDa is due to cross-reactivity with the anti-PKG antiserum. The blots shown 
are representative of three independent experiments. 
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It is known that use of an inhibitor for a single protein kinase can also affect other 
protein kinases within the same cell due to its limited specificity. H89 is known to inhibit many 
protein kinases including PKG depending on the concentration used [177]. This will be addressed 
in the following experiments. A reason for this unspecific mode of action is that a major group of 
protein kinase inhibitors are developed on the basis of their competitive inhibitory activity against 
the common substrate of all protein kinases that is ATP. The inhibitory activity of an antagonist for 
a specific protein kinase in an individual cell line is also highly concentration dependent. Therefore 
it is not possible in general to predict the activity spectrum of a given inhibitor type such as H89. In 
preliminary experiments, we have tried to inhibit PKA with other inhibitors which are more 
specific for PKA than H89 and which are cAMP-antagonist. All these inhibitors (for example Rp-
8-Br-cAMPS) were found to be unable to inhibit PKA in our cell lines even at very high 
concentrations or using different batch stocks. We also failed to observe their inhibitory action in 
combination with different types of PKA activators (Forskolin, 8-Br-cAMPS and BIMPS, data not 
shown here). A reason might be that MCFB cells (+/+) might have become impermeable for these 
compounds or that they might have lost their ability to reach their target sites of action. Hence we 
will use compound H89 in further experiments only together with appropriate positive controls to 
make sure that a specific protein kinase inhibition with this drug is observed in every case under 
study. 
 
The above results suggested that serum stimulated VASP phosphorylation at Ser-
157 mediated by PKC involves of another cytoskeleton-associated protein kinase that is PKA. In 
general, PKA and PKG are both major protein kinases linking cyclic nucleotide-dependent signal 
transduction with the cytoskeleton. After we found an involvement of Ser-157 and PKA in serum 
stimulated VASP phosphorylation, it is therefore necessary to examine a possible participation of 
PKG in this process. Even though PKG preferentially phosphorylates VASP at Ser-239, it can also 
phosphorylate at Ser-157 [2]. Moreover the inhibitor used to inhibit PKA in the previous 
experiments can in principle also inhibit PKG. So, the VASP phosphorylation inhibited by H89 in 
the previous experiments might also be due to PKG. Furthermore, it was recently found that there 
is an active interaction between PKC and PKG [181]. All these observations suggest that serum 
stimulation could have been mediated in principle by PKG rather than PKA to result in 
phosphorylation of VASP at Ser-157 (i.e. via pathways [1’’+ 3] or [3´+1] as depicted in Fig.8). To 
address a role of PKG in the serum stimulated VASP phosphorylation, experiments were 
conducted by stimulating overnight starved quiescent cells with serum in the presence of a PKG 
inhibitor (Rp-8-Br-cGMPS). However these experiments had shown no alteration in VASP 
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phosphorylation at Ser-157 after serum stimulation (data not shown). Results from the literature 
suggest that MCFB (+/+) cells may lack PKG [182] which led us to examine the PKG levels in 
these cells directly. Western blots of cell lysates with anti PKG antibody didn’t detect any PKG 
protein (Fig.10b). SNP stimulated platelet samples used as a positive control in this western blot 
showed the expected expression of PKG in this cell type and thus support the activity of the 
antibody used. As there is no detectable PKG level in MCFB (+/+) cells and as there was no 
influence detectable of a PKG inhibitor on serum stimulated VASP phosphorylation, these results 
strongly suggest that serum stimulated VASP phosphorylation is independent of PKG in MCFB 
cells (+/+). Moreover results from a blot with 16C2 antibody (with specificity for VASP phospho-
Ser-239) against serum stimulated cell lysates (Fig.7b) further support this conclusion. 
In summary, these results suggest that along with PKC, PKA but not PKG is 
involved in serum stimulated VASP phosphorylation at Ser-157 and that this might happen by the 
sequential pathways [1’+2] or [2’+1] of the protein kinase network model depicted in Fig.8. 
However according to this model, it could also be possible that PKA and PKC may regulate the 
activity of VASP independently each other. Nevertheless based on known data we suspect the 
former pathway to be the most probable one because PKA is well known to directly phosphorylate 
VASP preferentially at Ser-157 (see Chapter 2.1.1.4 and Fig.8). To establish the sequence of action 
of these two protein kinases the signalling pathway was elucidated further in detail.  
 
5.1.4. Serum stimulated PKCs involved in VASP phosphorylation are members of the Bis I 
sensitive and phorbol ester regulated classical isoforms of protein kinase C  
PKC comprises different isozyme forms and each isozyme is expressed in different 
cell types with a different mode of specific activity [183] [184]. The inhibitor used in the above 
experiments (Ro-31-8220) to inhibit PKC activity is not specific enough to discriminate among 
PKC isozymes individually. An important question therefore is to find out the responsible isozyme 
class of PKC that is involved in serum stimulated VASP phosphorylation at Ser-157. It can be done 
by using isozyme class-specific inhibitors which are commercially available (see Table.6). So 
called classical isoforms of PKC, which are also phorbol ester sensitive, participate in cytoskeletal 
reorganization and serum mediated protein kinase activities [185] [179]. Hence we searched for a 
role of classical isozymes of PKC in serum stimulated VASP phosphorylation by using specific 
inhibitors for this class of PKC, which are generally accepted in the literature and proven to be 
potent inhibitors.  
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Figure 11: Serum stimulated VASP phosphorylation is sensitive to inhibition activity of Bis I and phorbol ester 
treatment. (a) MCFB cells (+/+) were incubated with different concentration of Bis I, an inhibitor of classical protein 
kinase C isozymes, for 30 min prior to serum stimulation for 3 hours and blotted for VASP phosphorylation with M4 
antibody. (b) MCFB cells (+/+) were stimulated with PMA, an activator of classical protein kinase C isozymes, for 
different time periods and blotted for VASP phosphorylation with M4 antibody. (c) MCFB (+/+) cells were also 
stimulated with PMA either alone or prior to stimulation with 10% serum (3 hours) or 10 μM Forskolin (10 min), an 
activator of adenylate cyclase and thus PKA. DMSO was used as vehicle for PMA and thus substituted for PMA in 
positive control experiments. In all the blots, 46 kDa and 50 kDa bands represent non-phospho and phospho forms of 
VASP respectively and the upper band of 80 kDa which is also recognized by the M4 anti-VASP antiserum serves as a 
loading control. In Fig. a, lane 1 and 2 represent unstimulated and stimulated positive controls respectively. In Fig. b, 
US represent an unstimulated control cell sample. Blots shown are representative of three independent experiments. 
 
The experiments were carried out with Bis I, a potent classical PKC isoform 
inhibitor [175], and Bis V [176] which is an inactive version thereof serving as a negative control 
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for inhibition of PKC by this class of drugs. Overnight starved quiescent cells were incubated with 
these two types of inhibitors at different concentrations (1 μM, 5 μM, 10 μM, 20 μM) for 30 min 
and then stimulated with 10% serum according to the general experimental scheme as given in 
chapter 4.2.1.5. The cell lysates analyzed by western blotting with M4 antibody showed that the 
presence of the classical PKC inhibitor, Bis I inhibited the serum stimulated VASP 
phosphorylation at Ser-157 in a concentration dependent manner (shown in Fig. 11a). Lane 1 
shows no VASP phosphorylation at Ser-157 in unstimulated cells but lane 2 does due to serum 
stimulation. Treatment of cells by low concentrations of Bis I did not show a prominent inhibition 
of VASP phosphorylation (in lanes 3 and 4 in Fig.11a). However, 10 μM and 20 μM 
concentrations of Bis I applied to these cells and assayed in lanes 5 and 6 respectively showed a 
prominent inhibition of serum stimulated VASP phosphorylation at Ser-157. From this experiment 
it could be deduced that a concentration of 10 μM of Bis I is optimal in MCFB (+/+) cells to 
interrupt the activity of PKC as assayed by their phosphorylation of VASP (Fig.11a). Moreover 
there was no inhibition of VASP phosphorylation in samples stimulated with serum after 
incubating for 30 min with the corresponding inactive Bis derivative, Bis V, which serves as the 
required negative control compound to asses the specificity of PKC inhibition (data not shown). 
These results show that Bis I sensitive classical isozymes of PKC are among the participants in 
serum stimulated VASP phosphorylation at Ser-157 and these data  further support the results 
obtained with the general PKC inhibitor Ro-31-8220 (see Fig.9a and 10a). 
If the classical isoforms of the PKC are participating in serum stimulated VASP 
phosphorylation, then this pathway(s) should also respond to the effects of phorbol ester activity 
due to the phorbol ester sensitivity of this class of isoforms. Phorbol esters have a characteristic 
mode of regulating activity of PKCs and are highly time dependent in their action spectrum: they 
not only activate PKC for short time intervals but also inhibit the activity of PKC on the longer run 
upon translocation of PKCs to the membrane [185]. Incubation of cells with phorbol esters for 
longer time periods thus down regulates the activity of PKC [186]. Given the involvement of PKC 
in serum induced VASP phosphorylation it should also be affected upon modulation of PKCs with 
phorbol esters. Overnight starved quiescent cells were therefore stimulated with PMA, a well 
known phorbol ester compound, and samples were collected at every two minutes to find out the 
time course of PKC activation and down-regulation. Western blots with M4 antibody showed that 
there is VASP phosphorylation up to 8 min after phorbol ester stimulation and at later time points 
no further increase of VASP phosphorylation was seen (Fig.11b), possibly indicating a down 
regulation of PKC activity by phorbol ester treatment  (data not shown for time periods after 10 
min). It is interesting to note here that VASP phosphorylation occurred nearly after 90 min of 
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serum stimulation (Fig.6b), but an activation of PKC directly with PMA induced VASP 
phosphorylation as early as after 2 min with this activity not further extending beyond 8 min after 
PMA addition. The different time course might be due to differences in the lag time of the signal 
transduction cascades depending on a more proximal or distal activation of the PKC enzymes. 
However these kinetic aspects have not been studied further in this work. 
The above result (Fig.11b) suggests that down-regulation of PKC by phorbol esters 
may have inhibited phosphorylation of VASP. But, for this interpretation, it has to be confirmed 
that the down regulation of the VASP phosphorylating protein kinase activity by phorbol ester 
long-term treatment is indeed only due to PKC but not PKA which is also involved in the serum 
stimulated VASP phosphorylation as shown above in Fig.10a. We therefore performed a control 
experiment in such a way to down regulate the activity of PKC by phorbol ester long-term 
treatment (i.e. more than 8 min) during the activation of PKA via Forskolin which activates 
adenylyl cyclase. In a six well plate, the cells were incubated with PMA for more than 8 min and 
they were then stimulated with either serum (10%) or Forskolin (10 μM).  If the phorbol ester 
would not affect PKA activity, then we would expect a prospective activity of this protein kinase 
i.e. a VASP phosphorylation in Forskolin stimulated cells pre-incubated with PMA. However no 
VASP phosphorylation would be expected in serum stimulated cells during phorbol ester long-term 
treatment as PKC activity is down regulated and the process is dependent of PKC as shown above 
in the results of Fig.11a and b. Cell lysate samples stimulated with either serum or Forskolin were 
used as positive controls in this experiment which are both known to induce VASP 
phosphorylation at Ser-157 as shown in lanes 2 and 3 respectively in Fig.11c and also in the 
previous experiments. The experimental results in Fig. 11c clearly show that there is an inhibition 
of VASP phosphorylation at Ser-157 after phorbol ester long-term treatment as shown in lanes 4 
and 5 either with or without serum stimulation respectively (compare lanes 5 and 4 with lane 2). 
But there is phosphorylation of VASP at Ser-157 after Forskolin treatment in the presence of 
phorbol ester long-term treatment as seen in lane 6. Result in lane 3 show that the vehicle substance 
DMSO does not affect Forskolin stimulation and lane 1 shows the activity of the vehicle (DMSO) 
alone which does not induce phosphorylation of VASP at Ser-157 in the cell line under study. The 
absence of VASP phosphorylation at Ser-157 was observed in lanes 4 and 5 is thus due to the 
phorbol ester (PMA) long-term treatment which finally inactivates PKC. VASP phosphorylation at 
Ser-157 as observed in lane 6 due to a Forskolin treatment after long-term application of PMA 
suggests that the phorbol ester seems to be specific for PKC and is not affecting the PKA mediated 
signalling pathway leading to phosphorylation of VASP at Ser-157. Most important these results 
gave a first cue that PKA activity might act downstream to PKC and therefore PKC inhibition did 
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not oppose an activation of PKA by Forskolin. However, a sequential order of activity as suggested 
from these results has to be further substantiated by using combinations of activators and inhibitors 
as described in the following paragraph (see Chapter 5.1.5).  
In summary, the results of the last three chapters have shown that PKA and Bis I 
sensitive, phorbol ester regulated classical isozymes of PKC are the major cytoskeleton associated 
protein kinases involved in serum stimulated VASP phosphorylation at Ser-157. The combined 
evidence rules out all the other possible pathways involving either PKG or Rho kinases shown in 
the interaction network model of Fig.8. However the experimental evidence obtained so far does 
not allow to conclusively decide between pathways [1’+2], [2’+1] or [1+2] of this model (Fig.8) 
i.e. the order of involvement of PKA and PKC in either a serial or parallel organisation of the 
pathway in serum-stimulated VASP phosphorylation at Ser-157 is still unresolved at this stage of 
the study. In signal transduction research, it is usually only a first step to identify the participating 
biological molecules in a pathway and it is finally important to find out the order of action of these 
biological players in the pathway under study.  
 
5.1.5. Serum stimulated VASP phosphorylation is mediated by a sequential action of classical 
PKC isoforms and PKA 
  From the above results, it has been shown that PKC and PKA are mediating serum 
stimulated VASP phosphorylation. To resolve the order of these participating protein kinases in the 
signalling cascade, it will be necessary to determine the output reaction i.e. VASP phosphorylation 
at Ser-157 in response to simultaneous activations and inhibitions of these protein kinases using 
informative combinations of specific activators and inhibitors during serum stimulation of cells 
(Fig.8). In principle serum stimulation could lead to VASP phosphorylation via PKA and PKC 
either by a parallel or a serial action of these protein kinases (see pathways [1+2] in comparison to 
pathways [1´+2] or [2´+1] in Fig.8 of our interaction network model). A sequential order of PKA 
and PKC action in serum stimulated VASP phosphorylation was determined by using in 
independent experiments instead of serum the specific activators of PKA or PKC, Forskolin or 
PMA in combination with the inhibitors H89 or Bis I which are specific for these protein kinases 
(see Fig.8 for target sites and mode of action of these drugs). Bis V was again used as an inactive 
derivative to control the specificity of inhibition of Bis I in case of PKC (see Table.6). Overnight 
starved quiescent MCFB cells (+/+) were therefore pre-incubated with the inhibitors H89 (10 µM) 
or Bis I (or Bis V) (10 μM) either separately or together in a six well plate for 30 min and then 
stimulated in separate experiments either with serum (10%) (Fig.12a), or the adenylyl cyclase 
activator Forskolin (10 μM) (Fig. 12b) or the PKC activator PMA (1 μM) (Fig.12c) as described in 
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chapter 4.2.1.5 and Fig.4 The general experimental protocol in the combination of the inhibitors 
and activators used in these three independent experiments (labelled as a,b,c) is further summarized 
in the schemes above the gel sections of Fig.12. 
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Figure 12: Serum activated PKC passes a signal to PKA to phosphorylate VASP at Ser-157. MCFB cells (+/+) 
were incubated with Bis I (10 μM), a PKC inhibitor and/or H89 (10 μM), a PKA inhibitor for 30 min prior to 
stimulation with serum (10%) (Fig. a) or Forskolin (10 μM), an activator of adenylyl cyclases thus activates PKA (Fig. 
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b) or PMA (1 μM), a PKC activator (Fig. c) for 3 hours, 10 min and 8 min respectively. Bis V is a negative specificity 
control for PKC inhibition. The samples were blotted for VASP phosphorylation with M4 antibody. In all the blots, 46 
kDa and 50 kDa bands represent non-phospho and phospho forms of VASP respectively and the upper band of 80 kDa 
recognized by the M4 anti-VASP antiserum serves as a loading control. Lane 1 in all the three blots represents 
unstimulated control. Blots shown were representative of three independent experiments. 
 
Upon serum stimulation, lane 1 in Fig. 12a represents the unstimulated control 
showing no VASP phosphorylation and in lane 2 there is VASP phosphorylation observed at Ser-
157 as expected. Lane 3 and 4 show partial inhibition of this serum stimulated VASP 
phosphorylation in the presence of either Bis I or H89. In the presence of Bis I and H89 together, 
lane 5 shows a prominent inhibition of serum stimulated VASP phosphorylation (see lanes 3 and 4 
in comparison to lane 5). Bis V treatment did not effect VASP phosphorylation (see lane 6) and 
thus supports the specificity of Bis I on PKC. These results show that while there is only a partial 
inhibition of serum stimulated VASP phosphorylation by Bis I or H89 when applied separately, a 
prominent inhibition of serum stimulated VASP phosphorylation is observed in the presence of Bis 
I and H89 together. Although from these results it cannot be safely conclude whether PKC and 
PKA act in serum stimulated VASP phosphorylation either in series (see pathways [1´+ 2] or 
[2´+1] in Fig.8) or in parallel (see pathways [1+2] in Fig.8), the data clearly further supports the 
combined involvement of PKC and PKA in this process. Experiments have therefore been carried 
out by using directly instead of serum as a stimulator, activators of PKC or PKA in combination 
with the corresponding inhibitors of these protein kinases to further test the structure of this 
pathway. 
The results of VASP phosphorylation in the presence of the adenylyl cyclase 
activator Forskolin and the different inhibitor combinations are shown in the western blot analysis 
of Fig. 12b using M4 antibody. Lane 1 of Fig.12b shows almost no VASP phosphorylation without 
any Forskolin treatment whereas Forskolin treatment induced prominent VASP phosphorylation at 
Ser-157 in the cells (see lane 2). In lane 3, addition of the PKC inhibitor, Bis I did not interrupt the 
Forskolin activity i.e. VASP phosphorylation upon PKA activation. However in lane 4, the PKA 
inhibitor H89 inhibited this activity as seen by the more prominent appearance of the 46 kDa 
dephospho Ser-157 VASP band in this lane compared to lane 2. This inhibition of Forskolin 
activated PKA activity by H89 is an expected experimental result because both the drugs exert 
opposite effects on the same target (see Table.6 and node ‘PKA’ in Fig 8). Bis I treatment alone 
was found to have no influence on Forskolin stimulated VASP phosphorylation at Ser-157 (lane 3). 
Treatment of cells together with Bis I and H89 results in lane 5 in a more prominent loss of 
Forskolin stimulated VASP phosphorylation at Ser-157 as compared to H89 mediated inhibition 
alone (lane 4). In general, the activity of both inhibitors applied together (lane 5) was expected to 
be similar to the activity of H89 alone (lane 4) because the PKC inhibitor Bis I does not interfere 
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with PKA activity as proved by using Bis V (lane 6). The prominent inhibition of Forskolin 
stimulated VASP phosphorylation in the presence of both Bis I and H89 compared to the activity 
of each one alone was thus an unexpected finding. We have within our experimental limits 
currently no explanation for the enhanced combined action of both inhibitors together. However, 
the insensitivity of Forskolin stimulated VASP phosphorylation at Ser-157 to Bis I alone (lane 3) 
suggests that PKC does not seems to be involved in direct VASP phosphorylation which is 
probably mediated by PKA upon the applied Forskolin stimulation. These data are also in line with 
the experiments described above which showed a Forskolin stimulated VASP phosphorylation at 
Ser-157 being undisturbed by a long term treatment of PMA that will also finally inactivate PKC 
(see Chapter 5.1.4). These data therefore suggests that the possible pathway numbered as [2´+1] in 
our interaction network model of Fig.8 could probably be ruled out.  
Further support for this interpretation is given in the following experiment where the 
results of VASP phosphorylation in the presence of the short term PKC activator PMA and 
different inhibitor combinations are shown in a western blot analysis of Fig. 12c. Lane 1 again 
represents the unstimulated control and lane 2 shows the expected PMA stimulated VASP 
phosphorylation by short-term activation of PKC. Lane 3 and 4 show the inhibition of PMA 
induced VASP phosphorylation in the presence of the inhibitors Bis I or H89 respectively. 
Inhibition of PMA stimulated VASP phosphorylation by Bis I as observed in lane 3 is an expected 
experimental result because also these drugs exert opposite effects on the same target in this case 
PKC (see Table.6 and Fig.8). Most important the PKA inhibitor H89 was found to inhibit the PMA 
stimulation of VASP phosphorylation as it was mediated by PKC (see lane 4). VASP 
phosphorylation after PMA stimulation in presence of both inhibitors Bis I and H89 together is 
completely suppressed. Activity of Bis V in lane 6 again shows the specific inhibitory activity of 
Bis I on PKC also under these experimental conditions. Taken together the experimental results in 
particular the inhibition of PMA activity by H89 in lane 4 suggest that phosphorylation of VASP at 
Ser-157 by PKC seems to be mediated by PKA. This interpretation explains H89 mediated 
inhibition of PMA stimulated VASP phosphorylation at Ser-157 by blocking the PKA activity after 
upstream activity of PKC. It therefore further supports the pathway structure [1’+2] of our 
interaction network model as depicted in Fig.8. This organisation of the pathway states the most 
probable order of events during phosphorylation of VASP by a combined and sequential action of 
PKC and PKA. 
Summarizing the cumulative evidence from the experiments shown in Fig. 12, the 
data suggest that serum stimulated VASP phosphorylation in MCFB cells depends on serial activity 
of PKC and PKA in that order. The inhibitory activity of H89 against PMA stimulated VASP 
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phosphorylation supports an upstream position of PKC to that of PKA in this signalling pathway. 
This interpretation also fully explains the observed inability of Bis I to interrupt Forskolin 
stimulated VASP phosphorylation while using the complementary combination of inhibitors and 
activators. It is also in line with the observation that a long term treatment of cells with PMA does 
not perturb the Forskolin induced VASP phosphorylation. In conclusion, we suggest within the 
limits of the available experimental data that upon serum stimulation of MCFB cells (+/+) cells, a 
classical isoform of PKC receives an external stimulatory signal which is then passed to PKA to 
phosphorylate VASP at Ser-157. According to our data PKA is thus positioned downstream of 
PKC in the pathway under study and located most proximal to its substrate VASP giving a pathway 
structure of serum stimulated VASP phosphorylation as: serum → PKC → PKA → VASP at Ser-
157 (represented as [b+1’+2] in our interaction network model of Fig.8. The internal regulation of 
PKA in this signalling cascade has not been addressed here; so it is still unclear if it depends on a 
cAMP activation or an unknown signal message received indirectly from PKC. 
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5.2. In search for binding epitopes of the Spred2 EVH1 domain: Genetic screening of a cDNA 
expression library using a bacterial two-hybrid system  
 
5.2.1. Motivation for the experimental approach chosen 
The Spred2 EVH1 domain is a member of a new class of EVH1 domains which has 
initially been described in the recently discovered Spred proteins. Its atomic structure has recently 
been determined by NMR spectroscopy in a close collaboration with Linda J. Ball (SGC Oxford 
and FMP Berlin) and our Institute based on the purification of isotopically labelled protein samples 
after recombinant expression in E. coli. The Spred2 EVH1 structure shows the typical fold of an 
EVH1 domain with several unique features among them a characteristic putative binding cleft 
region containing a subfamily-specific triad of surface exposed amino acid residues which by 
homology are expected to be involved in ligand binding. Based on these structural data an 
interaction of the Spred2 EVH1 domain with unique ligand(s) probably comprising short linear 
peptide epitopes is expected. 
Expression and purification of a natively folded Spred2 EVH1 domain in 
Escherichia coli suitable for structure determination by NMR spectroscopy prompted us to take 
further advantage of this host. We therefore decided to use a bacterial two-hybrid selection protocol 
in E. coli to carry out an interaction cloning approach for the identification of candidate peptide 
binding partner(s) of the Spred2 EVH1 domain. 
 
5.2.2. Introduction to the bacterial two-hybrid system and overview of the experimental 
procedure 
A variety of E. coli two-hybrid systems have been described in the literature which 
utilize components of various well-characterized bacterial genetic systems as suitable reporters for 
bait and target protein interactions [136, 187].  For our studies in search of Spred2 EVH1 domain 
binding epitopes, we established the bacterial two-hybrid screening system developed by Joung et 
al [137, 188]. In this genetic method, detection of an in-vivo interaction of a bait and target protein 
is based on transcriptional activation of a bicistronic reporter gene cassette comprised of the yeast 
imidazoleglycerolphosphate dehydratase (HIS3) gene [189] and a bacterial aminoglycoside 3′-
adenyltransferase (aadA) gene [190] which is located on an F′ episome in a hisB mutated E. coli 
strain (Fig.13) [137, 189, 191]. The promoter of this reporter gene cassette is a modified lac 
promoter and contains a single λOR2 operator replacing its endogenous cAMP receptor protein 
(CRP) binding site [188, 192]. Bait and target proteins are expressed separately from two 
compatible expression plasmids. The protein of interest (the bait, represented as X in Fig.13) is 
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fused C-terminally to the dimerization domain of bacteriophage λ cI repressor protein (237 amino 
acids) which tethers to the λOR2 operator via its DNA binding domain (Fig.13). The target proteins 
(represented as Y in Fig.13) are individually fused to the N-terminal domain of the α-subunit of 
RNA polymerase. They are encoded by a cDNA expression plasmid library which is used in the 
search for unknown binding epitopes. When the bait and target hybrid protein encoded by separate 
bait (pBT) and target (pTRG) expression plasmids interact, the λcI-bait hybrid protein at the λOR2 
operator specifically recruits and stabilizes the α-N target hybrid protein at the weak lac promoter 
[192-194] thereby inducing transcription of the downstream HIS3 and aadA reporter genes by RNA 
polymerase (Fig.13) [137]. The magnitude of this transcriptional activation correlates with the 
strength of the interaction between the two chimeric proteins expressed [133]. Expression of the 
yeast HIS3 gene will complement in an auxotrophic E. coli host strain its deficiency of the 
homologous hisB gene and thus allows growth on selective histidine free media even in the 
presence of low concentrations of a competitive inhibitor of the HIS3 enzyme, 3-amino-1, 2, 4-
triazole (3-AT) [189]. The aadA gene confers streptomycin resistance to the cells for further 
selection of any positive protein interactions [190]. This sophisticated bacterial two-hybrid system 
thus allows positive selection by increasing 3-AT concentrations of bacterial clones that exhibit a 
productive interaction between co-expressed bait and target fusion proteins. It offers the ability for 
rapid analysis of gene expression libraries larger than 108 cfu due to the high transformation rate 
possible with highly competent E. coli cells. Expression plasmids for the Spred2 EVH1 and the 
VASP EVH1 domain are constructed and absence of self-activation by these chimeric proteins 
alone is assayed to make sure that transcriptional activation does not take place in the B2H system 
without a productive protein interaction. Before screening a cDNA expression library, it is also 
necessary to calibrate the B2H system with known types of protein interactions for the range of 
required selection intensities by determining the reporter gene expression levels compatible with 
growth in the presence of 3-AT. Therefore, we used as a positive control the VASP EVH1 domain 
in combination with a set of different binding peptides derived from the ActA protein of Listeria 
monocytogenes viz., a wild type peptide and its tighter and non binding mutant peptides [24]. 
These interactions were used to establish and to calibrate the B2H genetic system for detection of 
low affinity target interactions of a well-known adaptor protein domain. A thermodynamic study of 
in-vitro binding of the VASP EVH1 domain with these ActA peptides in our laboratory had 
obtained binding constants (Kd) ranging from 19 to 214 µM for different truncated versions of the 
ActA ligand [24]. In E. coli, this value would correspond to cellular concentrations of 20,000 to 
200,000 molecules per bacterial cell and expression of these levels should be achievable with the 
expression plasmids employed in the B2H system. The dimerization domain of the yeast 
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transcriptional activator Gal4 (referred to as LGF2) and a domain derived from a mutant form of 
the Gal11 protein called Gal11P have been shown to interact strongly in yeast [195-197] and E. coli 
[138]. Hence, this well characterised interaction pair is considered as a further positive control pair 
of the B2H system. After establishing suitable 3-AT selection conditions for detection of low 
affinity EVH1-ligand interactions, a cDNA expression library is screened under these conditions 
for interacting partners of the Spred2 EVH1 domain. The cDNA expression library is derived from 
brain tissue since Spred proteins are known to be expressed predominantly in this and other neural 
tissues [79]. Hence, we had chosen a human brain cDNA library cloned uni-directionally into the 
expression target vector pTRG to represent brain-specific proteins as α-N fusions (Fig.13) for a 
screen of binding epitopes of the Spred2 EVH1 domain. The library screening against this query 
protein is initially based on HIS3 gene transcriptional activation followed by a secondary screening 
based on aadA gene transcriptional activity. A collection of colonies obtained after dual selection is 
physically characterised by colony PCR with primers flanking the cloning sites of the target 
plasmid. Target plasmids were then isolated after genetic and physical separation from the Spred2 
EVH1 bait plasmid for further characterization. These target plasmids should contain putative 
Spred2 EVH1 interaction partners among an unknown fraction of false positive isolates. Individual 
target plasmids from this collection were therefore further characterized after retransformation with 
appropriate bait plasmids by three different types of genetic assays in order to asses (1) their 3-AT 
resistant phenotype, (2) their potential for Spred2 EVH1 independent self activation and (3) their 
interaction specificity to the Spred2 EVH1 domain (Fig.18). After co-transformation of each target 
plasmid isolate with either (1) the Spred2 EVH1 bait, (2) an empty bait or (3) a non-cognate EVH1 
bait plasmid the doubly transformed clones were compared with respect to their plating efficiency 
(PE) in the presence of 3-AT. PE determines the fraction of 3-AT resistant colonies among the total 
co-transformed colonies and correlates with the interaction strength at a defined selection 
stringency for each fusion protein pair [198]. It is calculated by counting the cfu on selective 
screening medium vs. non-selective screening medium normalized to the DNA amount applied for 
transformation. Sequencing of positive target plasmids obtained from these genetic assays would 
reveal consensus motifs of the peptides interacting with the Spred2 EVH1 domain. 
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Figure 13: An overview of bacterial two-hybrid system. A dimeric λcI-bait protein (shown as ‘X’) interacts with a 
RNA polymerase (RNAP) α-subunit-target protein (shown as ‘Y’) containing bait binding epitope at  a λOR2 operator, 
thereby recruiting RNAP to the adjacent promoter that directs expression of a HIS3 and aad reporter gene cassette. The 
bait and target fusion proteins are encoded on two compatible expression plasmids (pBT and pTRG), while the reporter 
gene cassette is located on an F′ episome. 
 
5.2.3. Construction of bait and target expression plasmids and establishment of the bacterial 
two-hybrid system for detection of EVH1 ligand interactions 
  The DNA sequences encoding Spred2 (1-124) and VASP (1-115) i.e. the Spred2 
EVH1 and the VASP EVH1 domains respectively were cloned into the appropriate multiple 
cloning sites of pBT vector by ligation of the respective amplified PCR fragments with the suitable 
sticky ends giving the bait plasmids pBT-Spred2 (1-124) and pBT-VASP (1-115) respectively 
(Table.7). Synthetic codon usage optimized oligonucleotides encoding the wild type ActA peptide 
332SFEFPPPPTEDEL344 and its tighter and non-binding mutants 332SFEWPPPPTEDEL344 and 
332SFEAPPPPTEDEL344 were cloned into the pTRG vector giving the target plasmids pTRG-
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ActA(332-344)F, pTRG-ActA(332-344)W and pTRG-ActA(332-344)A respectively (Table.7). The 
commercially available plasmids pBT-LGF2 and pTRG-Gal11P expressing the LGF2 and Gal11P 
interaction pair were used as a further positive control. All constructs were sequenced to verify the 
insert coding sequence and its in-frame fusion to the acceptor ORFs. These plasmids were purified 
in high mass yields for experimental use.  
 
λcI-Gal4LGF2pBT
αN-Gal11PGal11PpTRG
αN-SFEAPPPPTEDELActA [332SFEAPPPPTEDEL344]pTRG
αN-SFEWPPPPTEDELActA [332SFEWPPPPTEDEL344]pTRG
αN-SFEFPPPPTEDELActA [332SFEFPPPPTEDEL344]pTRG
λcI-VASP EVH1Human VASP (1-124)pBT
λcI-Spred2 EVH1Human Spred2 (1-124)pBT
Expressed fusion 
product Insert coding sequencePlasmid
 
Table 7: Plasmid constructs used in B2H screening experiments. The coding sequences for query bait Spred2 
EVH1 and positive control bait VASP EVH1 domain were cloned into the pBT vector to express λcI-bait fusion 
proteins. The coding sequences of different ActA peptides were cloned into pTRG target vector to express the α-N 
RNA polymerase fusion peptides. The pBT and pTRG vectors carrying insert coding for LGF2 and Gal11P respectively 
were used to express the respective fusion proteins as a further positive interaction control pair. 
 
In order to establish selection conditions of the B2H genetic system for a detection 
of low affinity interactions of EVH1 domains the bait and target plasmid pairs pBT-VASP (1-115) 
/ pTRG-ActA (332-344)F, pBT-VASP (1-115) / pTRG-ActA (332-344)W, pBT-VASP (1-115) / 
pTRG-ActA (332-344)A were co-transformed into competent cells of the E. coli XL1-Blue hisB 
MRF′ Kanr strain. Co-transformants were analysed for 3-AT resistant colony growth by plating on 
selective screening medium containing increasing concentrations of 3-AT viz., 0 mM, 0.25 mM, 
0.5 mM, 1.0 mM, 2.0 mM, 3.0 mM, 4.0 mM and 5.0 mM. Colony growth was observed at 3-AT 
concentrations up to 5 mM for co-transformants of pBT-VASP (1-115) with the pTRG-plasmids 
encoding the cognate ActA peptides i.e. ActA (332-344)F and ActA (332-344)W (Fig. 14). The 
non-binding mutant peptide ActA (332-344)A failed to support such growth even at the lowest 3-
AT concentration tested. The yeast LGF2 and Gal11P interaction pair used as a further positive 
control showed a similar 3-AT resistance phenotype but plated at a five fold higher plating 
efficiency due to their more robust interaction behaviour (Fig. 14).  
Expression levels of λcI-VASP EVH1 and λcI-Spred2 EVH1 were analysed 
immunologically in western blots with an anti-λcI polyclonal antibody. This antibody however 
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could not detect an expression of λcI-VASP EVH1 and λcI-Spred2 EVH1 fusion proteins even 
after using different minimal and rich media and various host strains. Yet, the anti-λcI antibody 
activity was confirmed by the λcI-LGF2 positive control. No EVH1 antiserum was available for an 
independent detection of the fusion proteins. It was concluded that although the expression levels 
of the EVH1 fusion proteins were below the detection limit of the anti-λcI antibody their local 
intracellular concentrations were nevertheless high enough to be detected genetically as assayed by 
transcriptional activation of the reporter gene cassette.  
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Figure 14: Establishment of B2H system for EVH1 domain interactions. Plating efficiency (percentage of cfu per 
ng of transformed plasmid) at increasing concentrations of 3-AT for co-transformants expressing appropriate fusion 
proteins either VASP EVH1 and two different ActA peptides (332SFEFPPPPTEDEL344 ( ) or 
332SFEWPPPPTEDEL344 ( )) or a pair of robustly interacting yeast proteins (LGF2 and Gal11p( )) is shown here. 
These data show the utility of the bacterial two-hybrid system for in-vivo detection of interactions between an EVH1 
domain and its binding peptides that have previously [24] been well-characterized in-vitro. 
 
 As a further test the potential for partner-independent self activation of each of the 
recombinant constructs was studied by transforming into the E. coli XL1-Blue hisB MRF′ Kanr 
reporter strain the recombinant plasmid encoding the chimeric protein together with its empty 
partner plasmid (pBT-X / pTRG empty plasmid; pBT empty plasmid / pTRG-Y) and assaying for 
colony growth on 3-AT selective and non-selective medium. Colony growth on non-selective 3-AT 
free medium plates confirmed that co-transformation of both bait and target plasmid confers double 
antibiotic resistance to the host cell to allow its growth in the presence of both antibiotics. No 
colony growth was observed on 3-AT selection plates showing the incapability of chimeric protein 
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alone to activate HIS3 gene transcription and thus confirming the lack of self activation for each of 
these genetic elements. 
In summary, the data from these experiments clearly demonstrate that an interaction 
of an EVH1 domain with its cognate binding motif which has been well-characterized in-vitro [24, 
29] could be successfully recorded in-vivo in a heterologous bacterial expression system which 
utilizes transcriptional activation of a reporter gene cassette to monitor these interactions. 
Specifically the data provide evidence that in the B2H system an EVH1 domain and its ligand can 
be co-expressed at levels sufficiently high to detect their physical interaction inside the bacterial 
cell with a genetic assay. We concluded that concentrations at and above 1 mM 3-AT are suitable 
selection pressures for detection of EVH1 domain-peptide interactions and the B2H system of 
Joung et al. should be a suitable interaction cloning system for identification of unknown EVH1 
domain-peptide interactions. 
 
5.2.4. Human brain cDNA library screening for candidate sequences harbouring binding 
epitopes of the Spred2 EVH1 domain and their physical and genetic characterization 
  A commercially available pTRG expression plasmid library of human brain cDNA 
in E. coli XL1-Blue MRF′ Kanr with an average insert size 1.08 kb and 1.65x106 cfu of primary 
clones was screened for candidate sequences harbouring binding epitopes of the Spred2 EVH1 
domain. Therefore the plasmid pool was isolated after amplification of the library without 
distortion of its sequence complexity and used for co-transformation with pBT-Spred2 (1-124) 
(Fig.15). Small scale pilot co-transformation experiments of pBT-Spred2 (1-124) and the pTRG 
clone pool from the amplified plasmid library into E. coli XL1-Blue MRF´ Kanr reporter strain 
were performed to determine the scale of transformation reactions required to fully cover the 
library’s sequence complexity for a comprehensive search of Spred2 EVH1 binding proteins.  
Two primary screenings of the library co-transformed with pBT-Spred2 (1-124) 
were performed at a selection stringency of 1 mM and 5 mM 3-AT. Colonies were grown on 
selective histidine-free medium containing 3-AT. Co-transformants were also plated on non-
selective 3-AT free medium to determine the co-transformation efficiency. Large number of 
colonies was obtained at the low stringency screen. Replica plating of several of these colonies 
under higher initial selection stringencies viz., 3 mM and 5 mM 3-AT again showed 3-AT resistant 
growth and did not lower the number of isolates significantly. Another library screening performed 
at higher initial selection stringency i.e. 5 mM 3-AT gave 291 colonies which were collected 
during the incubation at successive time periods of appearance i.e. early, intermediate and late 
appearing colonies. However the later result was not only due to an increased selection intensity, as 
Results 
 
84 
control transformations done in parallel revealed an unexpectedly low competence state of cell 
preparations used in this second experiment. 
 
1. EcoR I      2. Xho I       3. EcoR I + Xho I
4254 bp
M     1      2       3     M     1      2      3      M     1   2      3     M
 
Figure 15: Amplification and characterization of the human brain cDNA expression library. A 150 mm LB-
tetracycline plate of the amplified cDNA plasmid library after 48 hours of incubation at 37°C is shown here. The 
isolated pool of amplified clones is shown on a 1% agarose gel after single or double digestion with EcoRI and XhoI. 
The expression plasmids are shown at three different concentrations to identify the insert pool in the double digested 
samples (shown as lane ‘3’ in each set of concentration) showing its broad molecular size distribution. (‘M’ is 
molecular weight markers) 
 
The 3-AT resistant colonies selected in the primary screenings at 1 mM and 5 mM 
3-AT were further analysed by a secondary screening using a dual selection pressure i.e. 5 mM 3-
AT together with streptomycin (12.5 µg/ml) in histidine-free minimal medium. Replica plating of 
colonies from the primary library screenings again showed growth on this dual selection medium 
and no further differentiation of these clones with respect to their growth phenotype was possible 
with this strategy (Fig.16). Colonies with the positive control plasmid pairs pBT-VASP (1-115) / 
pTRG-ActA(332-344)F, pBT-VASP (1-115) / pTRG-ActA(332-344)W and pBT-LGF2 / pTRG-
Gal11P were used throughout this protocol and confirmed the efficiency of the dual selection. 
Colonies which arose at different time points of incubation (early, intermediate and late) in the 5 
mM primary screening showed no difference in growth behaviour in this secondary screening. 
Therefore, the secondary screening experiment was not found to be helpful in further selection of 
isolates obtained from primary screenings at 1 mM and 5 mM 3-AT. Physical characterization of 
20 dual resistant colonies from each library screening by colony PCR and restriction enzyme 
digestion analysis of their isolated target plasmids showed the expected heterogeneity in the insert 
size distribution with a molecular size range from 500 bp to 2000 bp indicating the clonal origin of 
each isolate (Fig. 17).  
Isolated target plasmids were further subjected to a genetic screening by a panel of 
genetic assay (Fig.18). Individual target plasmids of this clone collection were investigated against 
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a panel of bait expression plasmids to test linkage of the 3-AT resistance phenotype to the isolated 
plasmid, its EVH1 specificity of interaction and the absence of transcriptional self-activation by the 
target alone. Each target plasmid was co-transformed with pBT-Spred2 (1-124), pBT-VASP (1-
115) and an empty pBT plasmid into the E. coli XL1-Blue MRF′ Kanr reporter strain and analysed 
quantitatively for 3-AT resistant growth by determining its plating efficiency (PE value). If the 
growth phenotype is linked to the isolated target plasmid, the same phenotype should be observed 
after co-transformation of the target plasmid with pBT-Spred2 (1-124). Co-transformants of the 
same target plasmid with either the VASP EVH1 bait plasmid or an empty bait plasmid should not 
exhibit any 3-AT resistance phenotype above background if the target clone is specific for the 
Spred2 EVH1 domain and did not show any self activation. The plasmids pBT-LGF2 / pTRG-
Gal11P and pBT-VASP (1-115) / pTRG-ActA(332-344)F were used as positive control pairs in this 
experiment and the empty pBT / pTRG-Gal11P plasmid combination was used to determine the 
background PE value in this experiment. The bait plasmid encoding the Spred2 EVH1 domain 
together with either a target plasmid expressing Gal11P or the ActA (332-344)F peptide were used 
as non-cognate interaction pairs to determine the PE values of non-specific interactions. 
 
VASP EVH1 +
ActA (332-344)F
VASP EVH1 +
ActA (332-344)W Gal 4 + Gal 11P 
VASP EVH1 +  
ActA (332-344)A
 
Figure 16: Secondary screening of primary isolates from cDNA library screening. Dual resistant colonies were 
obtained after replica plating on secondary screening minimal medium of the 3-AT resistant clones from the primary 
library screening. EVH1 control interacting pairs pBT-VASP EVH1 / pTRG-ActA(332-344)F and pBT-VASP EVH1 / 
pTRG-ActA(332-344)W, system positive control pair pBT-Gal4 / pTRG-Gal11P and the negative interacting pair pBT-
VASP-EVH1 / pTRG-ActA (332-344)A were also spotted on the same plate. 
 
The number of co-transformants (cfu) obtained per µg of DNA on non-selective 3-AT free 
screening medium and the number of 3-AT resistant colonies on selective screening medium were 
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determined to asses the efficiency of co-transformation (XFE) and the plating efficiency (PE). The 
latter is considered as a measure of the interaction strength between an interaction partner pair and 
was estimated by calculating the percentage of co-transformants able to grow on 5 mM 3-AT 
plates. PE values determined for each of the 20 target plasmid isolates should enable us to identify 
 
(b)
Target plasmids Target plasmidsM M
1000 bp
500 bp
M M M M MTarget plasmids Target plasmids
3000 bp
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500 bp
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Figure 17: Physical characterization of plasmid target isolates from the cDNA library screening. The expression 
target plasmids of dual resistant colonies from secondary library screening were physically characterized by enzyme 
digestion (Fig. a) after separation from the bait plasmid and colony PCR (Fig. b) using the primers flanking insert 
cloning sites. In Fig. a and b, the expected heterogeneity in the insert size distribution is seen after 1% agarose gel 
electrophoresis. In fig a and b, ‘M’ represents the molecular weight marker. 
 
by these genetic assays candidates for the Spred2 EVH1 binding proteins in this clone collection 
and give a first estimate of the false positive rate inherent to the experiment. A plasmid pair 
encoding interaction partners with a very high interaction strength should achieve nearly maximal 
PE values i.e. almost every co-transformed colony will also grow in the presence of 3-AT. A non-
interacting pair should give a background PE value ideally not larger than 0.1% while a plasmid 
pair of intermediate interaction strength could achieve any PE value in between this range. Due to 
its low binding affinity, an EVH1-ligand pair is expected to give PE values in the lower range but 
significantly above background as it has been determined for the positive control pair of the VASP 
EVH1 mediated interaction. This experiment should therefore identify among the dual resistant 
clone collection candidate target plasmids capable of specific interaction with the Spred2 EVH1 
domain which will be analysed by sequencing (Table.8). The empty pBT / pTRG-Gal11P plasmid 
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pair had scored at a background value of 0.5% and the pBT-LGF2 and pTRG-Gal11P plasmid pair 
which served as a positive control achieved PE values of 57% which is nearly 100 fold above the 
background. The pBT-VASP (1-115) / pTRG-ActA(332-344)F plasmid pair serving as a EVH1 
interaction control scored at 9.2% which is nearly 5 fold below the maximal activity and thus 
nearly 20 fold above the background. None of the pTRG isolates showed evidence for 
transcriptional self activation. However none of the 3-AT resistant pTRG isolates showed Spred2 
EVH1 specific PE values in a range similar to that observed for the VASP EVH1 domain. Only 
one out of 10 pTRG isolates (pTRG-II-4 in Table.8) showed a PE value sufficiently above the 
background and with a Spred2 EVH1 specific interaction. However it encodes an out-of-frame 
fragment of NADH dehydrogenase. All of the other dual resistant target plasmids were also 
sequenced and they did not show any in-frame inserts. 
 
αN gene transcription ?
pBT Spred2 (1-124)
His3 Streprλ Operator
λcI
pTRG-X
αN gene transcription ?
His3 Streprλ Operator
λcI
pTRG-X
αN gene transcription ?
His3 Streprλ Operator
λcI
pBT-Y pTRG-X
(a) Assay for linkage of growth phenotype to isolated pTRG -X
(b) Assay of bait specificity of target plasmid pTRG -X using 
non-cognate baits ‘Y’ (VASP EVH1, non-EVH1 domain)
(c) Assay for self activation of target plasmid pTRG -X using empty pBT
YES
NO
NO
Transcriptional activity 
of  reporter genes
 
Figure 18: Validation of target plasmid isolates from library screenings by three different genetic assays.  
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5.2.5. Summary 
  The B2H system successfully recorded the physically well characterised interactions 
of the VASP EVH1 domain with its ligands by a dose-dependent 3-AT resistant growth of the 
respective clones which were used as positive controls throughout the experiments. Screenings of a 
human brain cDNA expression plasmid library for Spred2 EVH1 ligands performed at two 
different selection stringencies did not detect Spred2 EVH1 specific interactions among the clones 
characterized and thus seems to be completely dominated by false-positive isolates. These isolates 
which were identified as positives after the primary and secondary screenings did not show PE 
values significantly above background and carry target peptide sequences with stop codons. The 
panel of genetic assays developed in the context of validating candidate clones was found to be 
efficient and useful in assaying isolates of the library screening. The PE values of the target 
plasmid isolates clearly indicate them as false positives since the PE values of the linkage assay are 
in the same low range as those observed for the non-cognate interactions. Therefore it is not clear if 
the bacterial two-hybrid experiments had been performed at selection stringencies either too low or 
already too high for a detection of Spred2 EVH1 specific interactions as of course no data are 
available on binding affinities of this domain. Binding to this domain might well occur at affinities 
much lower then those known for VASP EVH1 class 1 ligands in which case it would be almost 
impossible to detect such interaction strengths in a B2H screen as shown by our experimental 
results. Searching a cDNA library with its large insert sizes for small candidate binding epitopes of 
an EVH1 domain might be particularly challenging due to the presence of the large background 
sequence information which is unrelated to the targets searched for. A biased or incorrect folding 
of host proteins upon heterologous expression in a bacterial cell might be another possible reason 
for missing any domain-specific interactions in this in-vivo interaction cloning approach (i.e. its 
suspected false-negative rate). Controlled in-vitro affinity selection with the purified and natively 
folded protein domain for short peptide target epitopes exposed on phage particles would be an 
alternative approach for detecting Spred2 EVH1 binding epitopes. Therefore a phage display 
library screening experiment was performed. 
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Target plasmid          Bait plasmid PE value Genetic assay
pTRG-Gal11p pBT 0.5 % (-) control
pTRG-Gal11p pBT-LGF2 57 % (+) control
pTRG-ActA (332-344)F pBT-VASP EVH1 9.2 % (+) control
pTRG-Gal11p pBT-Spred2 EVH1 0.9 % S
pTRG-ActA (332-344)F pBT-Spred2 EVH1 0 % S
pTRG-I-2 pBT-Spred2 EVH1 0.3 % L
pTRG-I-2 pBT-VASP EVH1 1.5 % S
pTRG-I-4 pBT-Spred2 EVH1 1.0 % L
pTRG-I-4 pBT-VASP EVH1 1.0 % S
pTRG-II-1* pBT-Spred2 EVH1 0.6 % L
pTRG-II-1* pBT-VASP EVH1 0.4 % S
pTRG-II-4§ pBT-Spred2 EVH1 2.4 % L
pTRG-II-4§ pBT-VASP EVH1 0.9 % S
pTRG-II-5& pBT-Spred2 EVH1 0.8 % L
pTRG-II-5& pBT-VASP EVH1 0.3 % S
pTRG-II-6 pBT-Spred2 EVH1 2.0 % L
pTRG-II-6 pBT-VASP EVH1 2.4 % S
pTRG-II-7 pBT-Spred2 EVH1 1.4 % L
pTRG-II-7 pBT-VASP EVH1 2.8 % S
pTRG-II-12 pBT-Spred2 EVH1 0.4 % L
pTRG-II-12 pBT-VASP EVH1 0.7 % S
pTRG-II-18 pBT-Spred2 EVH1 0.7 % L
pTRG-II-18 pBT-VASP EVH1 1.9 % S
pTRG-II-25 pBT-Spred2 EVH1 0.4 % L
pTRG-II-25 pBT-VASP EVH1 0.9 % S
No target clone shows transcriptional self-activation (0.01 % < PE < 0.5 %)
* in-frame insert, §, & out-of-frame insert
 
Table 8: Summary of genetic assays on target plasmid isolates to determine the linkage to growth phenotype [L] 
and EVH1 specificity of interaction [S]. Target plasmids from dual resistant clones of library screenings were 
isolated after physically separation from bait plasmid and assayed by a panel of genetic assays as shown in Fig. 18. In 
these assays, the interaction strength was determined quantitatively as the plating efficiency values (PE). No target 
isolates shown transcriptional self-activation (data not shown). pTRG-Gal11P / pBT-LGF2 and pTRG-ActA (332-344)F 
/ pBT-VASP EVH1 plasmid pair were used as positive control. pTRG-Gal11P / pBT empty plasmid was used as 
negative control interaction pair. 
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5.3. In search for binding epitopes of the Spred2 EVH1 domain: Genetic screening using a 
phage display library  
 
5.3.1. Motivation for the experimental approach chosen 
  The identification of candidate sequences encoding Spred2 EVH1 binding proteins 
based on a cDNA expression library screening by the bacterial two-hybrid system of Chapter 5.2 
was only of limited success despite the proper use of a control panel of interaction clones and the 
careful calibration of selection conditions. The results obtained were dominated by a unexpectedly 
high false-positive rate with a complete missing of any Spred2 EVH1 specific clones isolated as 
assayed by a set of genetic tests performed on random selections of these primary isolates in 
conjunction with a sequence characterization of their inserts. Based on our knowledge of EVH1 
domain-ligand interactions (see Chapter 2.2) one possible explanation for these negative findings 
might be related to the rather small target sizes of the expected Spred2 EVH1 binding epitopes 
which have to be identified in the highly complex sequence space spanned by a cDNA expression 
library. Any discrimination of sequence stretches coding for such small candidate binding epitopes 
among these large collections of naturally occurring cDNA sequences would thus be expected to be 
very demanding due to the presence of the large background sequence information unrelated to the 
targets. A further biological problem to cope with by any in-vivo interaction cloning approach 
might be based on the limited accessibility to the domain of interest of the candidate binding 
epitopes which could be due to a biased or incorrect folding of their host proteins upon 
heterologous expression in a bacterial cell. 
  In recent years, phage display technology has evolved into a powerful and 
independent research tool providing several advantages to define natural protein-protein 
interactions and to delineate ligand binding motifs for different adaptor domains (see Chapter 
2.3.3) [199] [200]. In contrast to B2H system technology which operates as an in-vivo binding 
assay between heterologously expressed proteins, phage display allows for an in-vitro screening of 
peptide libraries of restricted target sizes which are displayed on the surface of individual phage 
particles. This set-up provides not only a direct physical link between the expressed target peptides 
and their encoded genetic information in the viral genomes but also facilitates target accessibility to 
the bait protein. Libraries displayed on the phage virion surface however are repertoires of mostly 
non-natural peptide sequences which are generated by randomization to cover a comprehensive set 
of sequence combinations. It was successfully applied to identify peptide ligands for a number of 
SH3 domains and discovered first insights into the molecular determinants of SH3 domain affinity 
and selectivity [201]. Furthermore, recent studies have demonstrated the utility of this approach in 
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identifying the specificity profiles for proline rich motifs (PRM) of PDZ domains from phage 
display peptide libraries [154]. It is well-known from the other EVH1 domain classes that they bind 
to short proline rich epitopes. Expression and display of such short target peptides on phage virions 
not only restricts the target size but also favourably limits the sequence space complexity compared 
to the situation in a B2H system. An important feature of phage display is that conditions can be 
designed for screening of phage with either modest (Kd as high as 500 µM) or high (Kd as low as 5 
pM) affinity for the target [202]. Therefore, phage display library screening was considered as a 
complementary and independent experimental approach for identification of Spred2 EVH1 binding 
epitopes which are in general expected to interact with low affinity. However in-vitro screening of 
such phage display peptide libraries by affinity selection requires a purified and biologically active 
bait protein. Heterologous expression of the bait domain as a fusion protein is thus a prerequisite 
for possible identification of its binding epitopes provided the protein is natively folded and 
biologically active in order to retain its binding region in a binding competent state to interact with 
target epitopes. The Spred2 EVH1 domain fused to a GST tag was successfully expressed and 
purified in our laboratory from E. coli in a physical state suitable for NMR structure determination 
of this domain. The purified Spred2 EVH1 protein has thus proven to be properly folded and is 
therefore expected to be in a biologically active conformation (Fig.24). Hence, the GST fused 
Spred2 EVH1 domain prepared according to these protocols was used for a phage display peptide 
library screening to search for its binding epitopes. Since the peptides displayed on phage virions 
may interact with different possible target regions available on the bait protein’s surface including 
the fusion partner, appropriate control proteins have to be used in order to assess the specificity of 
interaction. Screening of phages populations are therefore controlled by using suitable negative and 
positive controls to monitor the enrichment of phage variants interacting with the Spred2 EVH1 
protein.  
 
5.3.2. Introduction to phage display technology and overview of the experimental procedure 
Several phages are described in the literature for use as vectors with phage display 
experiments including filamentous phage M13 as well as the icosahedral phages such as T4 and 
T7. Most of the protein engineering tools using phage display are developed for filamentous phage 
M13. The native M13 phage particles are of thin, cylindrical shape, usually 930 nm long and 6–7 
nm in diameter with a single stranded DNA genome (6,400 nucleotides in length) encoding 11 
genes, of which five codes for the coat proteins. The major coat protein pVIII present in almost 
2,700 copies is responsible for encapsulating the phage DNA. The distal end of the phage particle 
is capped by five copies each of pVII and pIX and the proximal end contains four to five copies of 
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each of pVI and pIII [148, 153](Fig.19). Upon infection of E .coli cells possessing F-pili, the 
single-stranded genome of M13 first replicates to a double-stranded form which serves as a 
template for production of viral proteins and single-stranded DNA progeny. The single stranded 
DNA eventually is extruded from the host cell through the inner membrane and is encapsulated by 
the five coat proteins residing in the outer membrane during the release [153] [148]. pIII and pVIII 
are most commonly used to display peptides/domains/proteins or even libraries of antibodies [149]. 
The repertoire of peptides expressed as N-terminal fusion partners to the phage coat protein is 
based on a viral gene library constructed in a phagemid vector system which enables screening of 
large collections of phage variants for the target of interest (Fig.19). Display of peptides on the 
major coat protein pVIII offers high copy numbers of target sequences for high throughput 
screening, though only short peptides of length up to 9 amino acids could be displayed using this 
fusion partner [158].  
Ff origin
AmpR
gene VIII(xxx)n
Phagemid
pVIIpIII pVIII Fused peptidepV pVI
M13 filamentous phage
 
Figure 19: Overview of the phage display system. Peptides are displayed using plasmid based “phagemid” vectors 
that contain a gene encoding only one of the phage’s capsid proteins (gene VIII as shown in figure), an Ampicillin 
resistance gene and Ff origin to allow production of single-stranded vector DNA for subsequent encapsidation into 
phage particles. The gene of the peptide to be displayed (shown as (xxx)n in figure) is cloned into the phagemid to fuse 
it N-terminally to the capsid protein. When E. coli cells containing the phagemid are infected with helper virus which 
lack package capability, wild type phage proteins from the helper phage genome as well as a small amount of fusion 
protein encoded by the phagemid are expressed and the phagemid DNA get packaged into viral particles that display 
both wild-type and fusion capsid proteins. 
 
Although there are several different potential variations of the phage display 
approach, many investigators have used cloning systems in which the DNA sequences encoding 
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the coat protein target-peptide fusions are carried within a plasmid or phagemid that also contains a 
filamentous phage origin of DNA replication (Fig.19). Consequently, when permissive E. coli 
strains containing these plasmids/phagemids are later infected with helper phages supplying the 
other native phage proteins, the resulting phagemid constructs are efficiently packaged into phage 
particles (see Chapter 2.3.3). Protocols for affinity selection of phages on the basis of their 
specificity and affinity for the bait protein are focused on screening to progressively enriched 
phage variants. A basic affinity selection protocol for phage binding requires immobilization of the 
purified and biologically active bait protein via its tag to a matrix, addition of the phage variants, 
washing away those variants that did not bind to the bait, elution of the bound phages and their 
amplification by infection of host bacteria for subsequent rounds of selection. This process of 
selection of phages by binding, washing and elution on an immobilized bait protein is called 
‘panning’. For immobilization of the bait protein, there are a variety of assay formats and a number 
of commercially available supports including suspended resins or beads. After immobilization of 
the bait to the support, the remaining sites on the support are generally blocked with unrelated 
proteins such as BSA or powdered milk. Bound phage variants are eluted from immobilized bait in 
general by simply reducing pH followed by a neutralization step. Each cycle of binding, washing 
and elution then results in a subpopulation of phages being enriched for interaction with the bait at 
the expense of those variants which bind with decreased affinity. As enrichment of binding-
competent phages increases in the course of selection, its stringency could be increased. By using 
multiple washing steps and increased washing times, phages encoding binding peptides with lower 
dissociation rate constants can be selected. Thus, even relatively rare binding phage variants can 
finally be rescued from large library repertoires by the combination of in-vitro affinity selection 
and in-vivo amplification. An identical selection procedure against the tag alone which is used to 
immobilize the bait protein serves as a negative control and any enrichment of phages against this 
fusion protein or the matrix is considered as a background signal. A well-characterised adaptor 
domain whose interacting target peptides have already been characterized by using the same library 
serves as a positive control to monitor panning rounds, washing and eluting procedures. After each 
panning round, the titers (pfu) of the phage variants eluted from either the bait protein or the tag 
moiety alone are determined by infection of E. coli to calculate an enrichment factor achieved in 
each panning round. The enrichment factor for a bait protein is the pfu ratio of the phages eluted 
from that protein to the phages eluted from the tag moiety alone. As enrichment of phages binding 
to the bait protein is expected to increase in successive panning rounds, the enrichment factor 
should also increase depicting a specific interaction of the bait protein with its cognate target 
peptides. Specific target binding and successful phage propagation in a phage display screening are 
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thus tracked by monitoring the enrichment factor and its final saturation. After several rounds of 
selection the eluted phage populations are cloned into single plaques for further physical analysis 
of phagemids encoding individual target peptides. 
 
 Receptor-Coated
Beads
Panning Wash Unbound Phage
Elute Bound
Phage
Repeat the panning with eluted phages
Phage display library  
Figure 20: Affinity selection by phage display methodology. The most commonly used selection method in phage 
display is affinity based and is usually referred to as “panning”. Typically the query protein is immobilized on a solid 
support and the phage display library is then incubated with the support to allow binding between the immobilized 
query protein and the appropriate phages. Unbound phages are then removed by washing steps. Elution of the 
specifically bound phages can be accomplished by brief incubation at low pH. This process is repeated using the same 
query protein with the eluted phages for further rounds of selection to enrich more specifically bound phages. 
 
Phage display peptide library screening for Spred2 EVH1 binding epitopes has been 
carried out by using a 9mer peptide library fused N-terminally to the major capsid protein, pVIII of 
M13 (Fig.19). It was donated by Dr. Cesareni’s group [158]. As the majority of the EVH1 domain 
family members are known to bind short epitopes containing proline-rich motifs of 4–6 amino 
acids long (see Chapter 2.2), this 9mer randomised library was expected by us to be suitable for 
determining peptide motif epitopes even for a new class of the EVH1 family such as the Spred2 
EVH1 domain. The same library has already been used successfully in determining the short target 
epitopes for one of the SH3 domains [203].  
 
5.3.3. Preparation and characterization of the bait fusion protein and its controls 
The GST-fused Spred2 EVH1 domain was used for phage display library screening 
experiments. It was expressed from the recombinant pGEX-4T-2-hSpred2 EVH1 (1-124) plasmid 
in E. coli BL-21 cells in 2 X YT medium after induction with IPTG. The expressed fusion protein 
was isolated from the harvested cell lysates by GSH affinity column chromatography and further 
purified by gel filtration chromatography on a Sephadex 75® column through FPLC. The protein 
obtained after each chromatography step was analysed by SDS-gel electrophoresis (Fig.21). The 
protocols used for expression and purification of GST-Spred2 EVH1 were the same as used for 
preparation of isotopically labelled samples utilized in NMR structure determination of domain 
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(Fig.24). The natively folded conformation of freshly expressed GST-Spred2 EVH1 domain fusion 
protein was assayed by 1H NMR spectroscopy after treating the protein sample with D2O in 1:10 
ratio (v/v). The NMR spectrum confirmed that the sample of GST fusion protein used as bait in the 
phage display library screenings was natively folded and is expected thus to be biologically active 
(Fig.21). Target binding regions required for the interaction with a ligand should therefore be 
exposed on the surface of the bait protein. GST fused Fyn-SH3 domain and the GST moiety alone 
were expressed, purified and certified for their biologically active form according to the protocol 
used in Dr. C. Freund’s laboratory. They were used as positive and negative control proteins 
respectively during phage display library screening experiments with the Spred2 EVH1 domain. 
The GST-Fyn-SH3 fusion protein had already been successfully screened with the same M13 
X9mer peptide library [204] and it could thus be used as a well-defined positive control protein to 
monitor the panning rounds also against the GST-Spred2 EVH1 domain in our experiments. 
GST-Spred2 EVH1
36 kDa
45 kDa
 
Figure 21: Isolation and characterization of the bait fusion protein. The 1H NMR spectrum shows the natively 
folded conformation of freshly purified GST-Spred2 EVH1 domain fusion protein which is expected thus to be 
biologically active in the experiments. Inset figure: A 10% SDS gel electrophoresis showing GST-Spred2 EVH1 
purified consecutively by GSH-affinity column chromatography and gel filtration chromatography on a Sephadex 75® 
column through FPLC after expression and harvest from cell lysates. The protein was loaded after serial dilution and 
shows the expected molecular weight. 
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5.3.4. M13 phage display peptide library screening for binding epitopes of the Spred2 EVH1 
domain and physical characterization of phagemids from the isolated phage variants 
The GST-Spred2 EVH1 fusion protein had been immobilised to GSH-Sepharose 
beads and panning was performed by using the M13 X9mer peptide library in order to select phage 
variants expressing its binding epitopes [156]. GST fused Fyn-SH3 domain [204] and GST alone 
were used aside as appropriate positive and negative control protein respectively. Phages eluted 
after binding from each round of panning were used for a successive round against the same query 
protein after their amplification by infection of E .coli along with the packaging-defective helper 
phages (Fig.20). After each panning round, titers (pfu) of phages bound to the GST-Spred2 EVH1 
and the GST-Fyn-SH3 fusion proteins were determined to estimate the enrichment factor achieved 
for the domain of interest (see Chapter.4.2.5). Three successive panning rounds were performed for 
the GST-Spred2 EVH1 domain in our phage display screening experiments.  
 
 
Enrichment factor Panning 
round GST-Fyn-SH3 
(Positive control)
GST-Spred2 EVH1 
(Bait protein) 
1 0.4 820 
2 300 500 
3 5 x 103 1 x 104 
4 2 x 104 -  
Table 9: Enrichment factors achieved during phage display experiments. Enrichment factor for GST-Fyn-SH3 
protein used as a positive control and GST-Spred2 EVH1 protein used as bait are shown until different rounds of 
panning against M13 X9mer phage display library. 
 
In general as described above, the first round of panning would enrich very low 
numbers of specifically bound phages against any protein of interest due to the highly diverse 
peptide repertoire of the phage library. This value should increase in the next rounds of panning if 
specifically bound phages could be enriched further by eliminating non-binding and non-
specifically binding phages. The positive control protein GST-Fyn-SH3 showed a continuous 
increase in enrichment for bound phages with every round of panning until saturation. The first 
round showed an enrichment factor of 0.4 and then 300 in the second round of panning. Finally, it 
has reached almost a saturation value after four rounds (5x103 in third and 2x104 in fourth round of 
panning) indicating a domain-specific peptide interaction (See second column in Table. 9). These 
results demonstrate a successful performance of the phage display screening experiment according 
to the protocols used. In contrast, the GST-Spred2 EVH1 domain fusion protein showed an 
abnormally high enrichment factor i.e. 820 for bound phages against the same M13 X9mer peptide 
Results 
 
97 
library already in the first round of panning suggesting highly non-specific interactions. The next 
panning round for this domain showed a slightly decreased enrichment factor i.e. 500 which is 
however in the same range as observed for the positive control protein at this stage of the 
experiment (See third row in Table.9). Unexpectedly, the third round of panning against the GST-
Spred2 EVH1 domain fusion protein achieved a high enrichment factor of 1x104 which is in the 
same saturation range as observed for the GST-Fyn-SH3 protein (Table.9). Similar panning rounds 
of the eluate phages from the bait protein of interest against the GST moiety alone showed a 
declining enrichment in successive steps indicating that neither the GST tag nor the matrix 
unspecifically bind phages of the library used here. Phages eluted from the other two bait proteins 
are then physically characterised. 
 
(a) GST-Fyn SH3, after 3rd round
(b) GST-Spred2 EVH1, after 3rd round
M C
Positive
Negative
Query phagemids
Query phagemidsM C
Positive
Negative
 
Figure 22: Physical characterization of isolated phagemids. Inserts of the phagemids of the elute phages after the 
third round of panning were amplified by colony PCR after infecting E. coli cells and the products were analysed on a 
1% agarose gel. In lane ‘C’ of both Fig. a and b, upper band with nearly 50 bp higher molecular weight than the lower 
band represents an amplified product of a positive recombinant phagemid carrying an insert and lower band represents 
negative phagemids without any inserts. All the phagemids of phages selected against GST-Fyn SH3 protein (Fig. a)  
showed inserts of the expected size as shown in lane ‘C’ where as majority of the phagemids of phages selected against 
GST-Spred2 EVH1 protein were devoid of any inserts (Fig. b). 
 
Therefore eluted phages after the third round of panning against both proteins were 
analysed by colony PCR of single plaques which amplifies the phagemid insert regions of 
individual isolates in order to identify phagemids with inserts encoding binding motifs. Bacteria 
infected with the eluted phage population were grown on LB-amp plates and plaques were used to 
perform colony PCR with primers flanking the insert cloning sites of the phagemid (see Chapter 
4.2.5). PCR products of these phagemid isolates were analysed on a 2% agarose gel to differentiate 
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by a slightly higher molecular weight those isolates carrying inserts from empty phagemids without 
any insert. The molecular mass difference between the PCR products of a recombinant vs. an 
empty phagemid is less than 50 base pairs due to the short insert sizes which nevertheless can be 
well differentiated on a 2% agarose gel. Insert-harbouring positive phagemid isolates recognised on 
the agarose gel were then further characterised by sequence analysis of their inserts. 
 
Clone 3:   M L S F A A E G E F D A L * T L R H Q-----------D P A K A A 
Clone 8:   M L S F A A E G E F K P G T P A P * T -----------D P A K A A 
Clone 19: M L S F A A E G E F R T S L S H G Y T ---------- D P A S I L R A 
Clone 25: M L S F A A E G E F G A R P V P P P P V G S S D P A K A A 
Clone 34: M L S F A A E G E F P * P T A R I A P ------------ D P A K A A *
Clone 37: M L S F A A E G E F * D Q A A C S V T -----------D P A K A A 
Clone 40: M L S F A A E G E F * ----------------------------------D P A K A A *
Clone 43: M L S F A A E G E F * ----------------------------------D P A K A A *
Clone 44: M L S F A A E G E F Q N * N A G R F M ----------D P A K A A 
Clone 48: M L S F A A E G E F * * P A V S H L R------------- D P A K A A 
Clone 49: M L S F A A E G E F L P K * P K A H L------------D P A K A 
 
Figure 23: Sequence alignment of insert coding sequences of the positive phagemid isolates. The recombinant 
phagemids recognised as positives in the colony PCR were isolated and their inserts were sequenced. Sequence 
alignment of this region is shown in the figure. The amino acids shown in bold gave insert coding sequences of 
recombinant phagemids and * represents the position of stop codons.  
 
All the phagemid isolates obtained from a sample of eluted phages of the third round 
of panning against the GST-Fyn-SH3 domain showed a higher molecular weight than an empty 
control phagemid in this colony PCR amplification (Fig.22a). This result indicates a successful 
enrichment achieved in the panning with this query protein and is in line with the titration results 
described above. Colony PCR of clones obtained from phages of the third round of panning against 
the GST-Spred2 EVH1 protein however shows that the majority of their phagemids (90%) did not 
contain any insert to express a peptide (Fig.22b). Recombinant phagemids from colonies of the 
remaining 10% of insert-contained phages form the third round eluates against the Spred2 EVH1 
domain were then isolated, sequenced and analysed for their insert coding sequences. The sequence 
results of this subpopulation showed an assortment of recombinant phagemids carrying either stop 
codons or short peptide encoding sequences or even empty phagemids (Fig.23). Two positive 
phagemids with inserts having a continuous ORF without a stop codon were found among nine 
negative clones (see clone 19 and 25 in Fig.23). Surprisingly one of them contained a larger than 
9mer insert and shows a 13mer proline-rich sequence. The other phagemid with continuous ORF 
contained an unrelated sequence that exhibits no proline-rich peptide motif. Isolation of a 13mer 
sequence selected in this phage display peptide screening was unexpected given that the library 
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was initially constructed to expresses 9mer peptides. No further similar sequences to support this 
ligand motif could be enriched in our phage display library screening for Spred2 EVH1 binding 
epitopes. 
 
5.3.5. Summary 
The phage display screening experiment for Spred2 EVH1 binding epitopes was not 
very informative and revealed unexpected results. When compared to the positive control screening 
experiment using the GST-Fyn SH3 protein, the highly non-specific performance of the former 
screening was evident. Positive phage enrichment seems not to be possible for the Spred2 EVH1 
domain due to the high number of phages obviously interacting non-specifically with this domain. 
The majority of phages isolated against the Spred2 EVH1 domain surprisingly either carried no 
insert or inserts with stop codons suggesting a dramatic lack of specificity in the interactions with 
this domain compared to the Fyn-SH3 domain and the GST moiety alone. The results obtained 
seem to suggest that the pVIII major coat protein is not an inert scaffold protein with respect to the 
Spred2 EVH1 protein and its N-terminal fragments might already display sticky epitopes that 
interact with the Spred2 EVH1 domain. No such behaviour is observed for the Fyn SH3 domain or 
GST alone. However, detection of a 13mer proline rich sequence from the Spred2 EVH1 screen 
was particularly surprising in this context as it might have been possible only if there was a 
sufficiently strong interaction of the Spred2 EVH1 domain with this target peptide leading to its 
selection. Even though the phage display peptide library screening experiment did not perform in 
the expected manner for the Spred2 EVH1 domain, this 13mer sequence identified in the screen 
might be helpful as an initial cue for further analysis by SPOT scan and amino acid substitution 
assays. Taken the results obtained from screening of an in-vivo expression library and an in-vitro 
peptide display library seriously, our working hypothesis on the peptidergic nature of a Spred2 
EVH1 ligand might be questioned. Non-peptidergic interactions were therefore considered for this 
domain in further experiments as already described in other adaptor domains of the SH3 class [120, 
205].  
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5.4. In search for binding epitopes of the Spred2 EVH1 domain: Biochemical screening using 
in-vitro binding assays for non-peptidergic interactions 
 
5.4.1. Motivation of the experimental approach chosen 
  Two interaction cloning strategies employing a bacterial two-hybrid and a phage 
display system has been used in the course of this work for binding epitope identification of the 
Spred2 EVH1 domain. Both approaches were based on the assumption that Spred EVH1 ligands 
will form peptidergic epitopes. The two-hybrid system utilizes in-vivo co-expression of the Spred2 
EVH1 domain from a low copy number expression plasmid vector together with a target cDNA 
expression library under conditions of growth indicative of a productive protein interaction. The 
phage display system in contrast relies on in-vitro interaction of the purified and natively folded 
Spred2 EVH1 protein with a repertoire of short peptides exposed on the surface of phage particles 
followed by enrichment of interacting phages from these display libraries. Both approaches were 
shown in our experiments to be capable of detecting domain: peptide interactions successfully in 
appropriate controls run in parallel. However the experimental results of both the bacterial two-
hybrid and the phage display library screens for Spred2 EVH1 binding epitopes were found to be 
dominated by false-positive isolates precluding a reliable identification of candidate clones 
although probably for different biological reasons. The inability to find Spred2 EVH1 ligands with 
these genetic techniques has therefore cast some doubt on the underlying assumption that a Spred2 
EVH1 ligand will form a peptide. Analysis of the newly available NMR structure of the Spred2 
EVH1 domain (accession number “2JP2” and Fig.24) revealed an unusual surface charge 
distribution showing patches of pronounced positive charge distribution in the putative binding 
cleft region which is not observed in the other EVH1 classes (Fig.24). We therefore considered an 
interaction of this domain with a negatively charged ligand probably of non-peptidergic nature to 
counterbalance this unique charge pattern. Some non-EVH1 adaptor domains like the C-terminal 
SH3-C domain of the Adhesion and degranulation-promoting adapter protein (ADAP) [120], PDZ 
domains of syntenin-1 and syntenin-2 [206], the PH domain of phospholipase C-δ1 [207] also 
showed a positive surface charge distribution and were found experimentally to interact with 
phospholipid molecules. We therefore studied a possible interaction of the Spred2 EVH1 domain 
with several types of phospholipids using biochemical in-vitro binding assays. 
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(a) (b)
(c) (d)
 
Figure 24: NMR structure of the hSpred2 EVH1 domain. The NMR structure of human Spred2 EVH1 domain has 
been resolved recently and submitted under the accession number “2JP2” by SGC (Oxford) in collaboration with our 
Institute. Fig. a shows a back view, Fig b, c and d show the front view of the domain highlighting its binding surface. 
The domain is composed of a C-terminal α-helix and seven β-sheets. The binding groove for accommodating the still 
unknown ligands is seen in the front view. Electrostatic surface potential revealed patches of positive surface charge in 
the binding groove shown in blue colour in Fig. c. Distribution of surface hydrophobicity as shown in Fig. d points to 
an involvement of hydrophobic residues in the organisation of this ligand binding site. Hydrophobic patches are shown 
in yellow and hydrophilic patches are shown in green colour coding in Fig. d. 
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5.4.2. Introduction to protein-phospholipid binding assays and overview of the experimental 
procedure 
Protein: phospholipid binding assays were performed in our study in a solid phase 
overlay format or a liquid phase binding format. The solid phase overlay assay is carried out by 
using a GST fusion construct of the Spred2 EVH1 domain binding to a solid phase membrane 
carrying different types of pre-spotted phospholipids [208] (Fig.25a), hence it is also considered as 
a SPOT test. This assay can determine not only the type of phospholipids but also the 
phosphorylation pattern of their isomers involved in interaction with a protein module of interest. 
Membrane-bound protein molecules interacting with a specific phospholipid are detected 
immunologically after blocking non-specific binding sites by an anti-GST primary antibody 
followed by HRP tagged secondary antibody and a chemiluminescence signal. The N-terminal SH3 
domain of human ADAP protein fused to a GST tag (GST-ADAP SH3-N) was used as a negative 
control in our phospholipid overlay experiments since it is known to be inactive to the array of 
phospholipids analysed here. 
GST-Spred2 (1-124)
10 µg/ml 
Negative control
PtdIns(3,5)P2
PtdIns (3)P 
PtdIns(4)P 
PtdIns(5)P 
(a)
(b)
 
Figure 25: Protein:phospholipid solid phase overlay experiment. (a) Scheme depicting a membrane strip with 
different phospholipids spotted on it. (b) Such membrane was incubated with GST-Spred2 EVH1 protein and the 
bounded protein was detected by immunoblotting with a primary antibody against GST. The Spred2 EVH1 showed 
interaction with phosphatidyl inositol phosphorylated preferably at its 3’, 4’ and 5’ sites. ADAP SH3-N protein used as 
negative control had shown no interaction with the same phospholipids. 
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Another assay format for studying protein:phospholipid interactions is available in 
liquid phase by a liposome sedimentation assay. Liposomes are artificially generated spherical 
vesicles dispersed in aqueous phase that consist of an aqueous core enclosed by one or more 
amphiphilic layers of the phospholipid to be tested along with phosphatidylcholine (PC) and 
phosphatidylserine (PS) to mimic plasma membrane’s lipid composition. Liposomes can vary in 
charge and size depending on the method of preparation and the composition of the lipids used. 
There are different types based on their size viz., multi-lamellar vesicles (MLV, size range 0.1–5.0 
µm), small uni-lamellar vesicles (SUV, size range 0.02–0.05 µm) and large uni-lamellar vesicles 
(LUV, size range from 0.06 µm). Protein: phospholipid interaction studies using liposomes have 
been performed to reveal biological relevant interactions like those of the ADAP SH3-C domain 
with phosphatidyl inositol phosphates in a mixture of phosphatidylcholine (PC)/phosphatidylserine 
(PS) [205] [120, 172]. This assay analyses in a quantitative manner binding of a biologically active 
bait protein in solution to different concentrations of liposomes containing a small fraction of a test 
phospholipid. Free unbound and phospholipid-bound protein fractions are separated by differential 
centrifugation of the reaction mixture into a liposome-free supernatant and the liposome-containing 
pellet respectively (Fig.26). Unbound protein remaining in the supernatant is detected by its 
tryptophan fluorescence or by SDS gel electrophoresis of equivalent amounts of pellet and 
supernatant fractions. A reaction mixture without liposomes but the same amount of bait protein as 
in the binding reactions is used as the blind value giving the protein concentration maximally to be 
present in the supernatant if no binding at all occurs. Natively folded bait protein without any 
fusion tag is required in a mono-disperse preparation for these experiments and Spred2 EVH1 
protein was prepared accordingly. The C-terminal SH3 domain of human ADAP protein (ADAP 
SH3-C) which is known to interact with phosphatidyl inositol phosphorylated at 3, 4 and 5 sites 
was used as a positive control in our experiment [120, 205]. Not only due to the quantitative 
information obtained from it but also due to the physical state of its binding substrates the liposome 
sedimentation assay is considered as a more sensitive and less error-prone assay format compared 
to the semi-quantitative overlay assay which can at best only provide initial evidence for binding.  
 
5.4.3. Preparation and characterization of the Spred2 EVH1 domain and the control proteins 
The Spred2 EVH1 domain was used either as a GST- fusion protein or alone for the 
phospholipid interaction experiments. The GST-Spred2 EVH1 domain fusion protein was 
expressed and purified from the pGEX- 4T-2-hSpred2 (1-124) recombinant plasmid in E. coli BL-
21 cells as described in Chapter. 5.3.3. The natively folded conformation of freshly expressed 
GST-Spred2 EVH1 domain fusion protein was assayed by 1H NMR spectroscopy after treating the 
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protein sample with D2O in 1:10 ratio (v/v). The NMR spectrum confirmed that the sample of GST 
fusion protein used as bait in the phospholipid overlay assay was natively folded and is expected 
thus to be biologically active (Fig.21). For the liposome sedimentation assay, Spred2 EVH1 protein 
was prepared by digesting the GST-Spred2 EVH1 fusion protein with Thrombin to cleave-off the 
GST tag and further purified by Sephadex 75® column chromatography through FPLC. The 
purified protein samples were verified by SDS gel electrophoresis and spectrophotometry to 
determine purity, molecular size and concentration. The control GST-ADAP SH3-N and ADAP 
SH3-C proteins were prepared in Dr. C. Freund’s laboratory according to their standard expression 
protocols. 
 
Differential 
centrifugation
Pellet = Protein bound to liposome
Supernatant = Unbound protein
= Liposome = Protein
 
Figure 26: Protein:phospholipid liposome sedimentation assay. A quantitative protein-phospholipid interaction 
assay was performed by liposome sedimentation assay. The artificially prepared liposomes of test phospholipid at 
different concentrations are incubated with constant amount the query protein and the free unbound and phospholipid-
bound protein are separated by differential centrifugation of the binding reaction mixture. Unbound protein remaining 
in the supernatant is detected by its tryptophan fluorescence or by SDS gel electrophoresis of equivalent amounts of 
pellet and supernatant fractions.  
 
5.4.4. Biochemical screening for phospholipid interactions of the Spred2 EVH1 domain 
Phospholipid overlay experiments were performed using the purified GST-Spred2 
EVH1 fusion protein and fifteen different phospholipids immobilized on a membrane strip 
(Fig.25a). The GST- ADAP SH3-N was used as a negative control. The results show an interaction 
of the Spred2 EVH1 domain at decreasing intensity with the spots of phosphatidyl inositol 5-
phosphate [PtdIns(5)P], phosphatidyl inositol 3-phosphate [PtdIns(3)P], and phosphatidyl inositol 
4-phosphate [PtdIns(4)P] (Fig.25b). The abundant cell membrane phospholipids, 
phosphatidylcholine (PC) and phosphatidylserine (PS), which are known to interact with other 
adaptor domains, did not interact with the Spred2 EVH1 domain. The negative control protein did 
not show interaction with any of the fifteen phospholipids spotted on the membrane (Fig.25b).  
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The results obtained with these phospholipids immobilised on a membrane were 
further analysed by using the liposome sedimentation assay which supplies the binding substrates 
under more native conditions. Large uni-lamellar vesicles were therefore prepared of those test 
phospholipids observed to interact in the overlay assay together with PC and PS in a composition 
similar to that found in the plasma membrane while taking care to equalise the total negative 
charge of different vesicle preparations. Increasing concentrations (100 µM to 1200 µM) of 
vesicles were incubated with a fixed concentration (2 µM) of Spred2 EVH1 protein and the ADAP 
SH3-C was used as a positive control in this experiment. A liposome-free solution of these proteins 
served as a concentration standard. 
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Figure 27: Results of the liposome sedimentation assay for the Spred2 EVH1 domain. (a) Percentage of unbound 
protein present in the supernatant fraction after differential centrifugation of phospholipid-protein binding reaction 
mixture was calculated by considering the unbound protein present in the negative control (liposome-free) as the 
maximal protein concentration present in the binding reaction and values are plotted in the graph against increasing 
liposome vesicle concentration for each phospholipid. Values higher than 100% are the experimental errors occurring 
during spectrophotometric measurement and pipetting steps. (b) The protein amount present in the pellet and 
supernatant after differential centrifugation of a binding reaction of Spred2 EVH1 and PtdIns(3)P were analysed by 
SDS gel electrophoresis. Positive control protein ADAP SH3-C had shown specific interaction with the phospholipid 
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(Fig. a) and was detected in the pellet fraction after differential centrifugation (Fig. b). In the similar assay, the Spred2 
EVH1 domain was detected in the supernatant due to a  lack of interaction with respective phospholipids (Fig. b). 
 
The liposome sedimentation assay for ADAP SH3-C showed a dose-dependent 
interaction with vesicles of PtdIns(3)P, PtdIns(5)P and PtdIns(3,5)P2 phospholipids as revealed by 
differential centrifugation (Fig.27a). Phosphatidyl inositol mono-phosphates PtdIns(3)P and 
PtdIns(5)P completely bound protein even at the lowest concentration (100 µM) studied thus 
depicting the high binding affinity of ADAP SH3-C. The phosphatidyl inositol bis-phosphate 
PtdIns(4, 5)P2 showed a concentration corresponding to half-maximal binding which was three 
times higher (300 µM) than  that observed for the mono-phosphates (Fig.27a). The qualitatively 
similar results were observed by SDS gel electrophoresis with the protein found in the pellet 
fraction after differential centrifugation (Fig.27b). These data obtained with the positive control 
protein showed the correct preparation of vesicles and the proper performance of the assay which 
was therefore used with the unknown protein. However, the liposome sedimentation assay for the 
Spred2 EVH1 domain did not show any interaction with vesicles containing PtdIns(3)P, 
PtdIns(4)P, PtdIns(5)P, PtdIns(3,5)P2 and PtdIns(4,5)P2 even at the highest concentration tested (up 
to 1200 µM) (Fig.27a). No difference in binding was observed compared to the carrier 
phospholipids PC and PS, used in the preparation of the liposomes (Fig.27a). The amount of 
protein detected in the supernatant fractions after differential centrifugation of these binding 
reactions was almost the same independently of the concentrations of liposomes used and did not 
differ from that of the liposome-free control reactions. Similar results were observed by SDS gel 
electrophoresis of pellet and supernatant fractions (Fig.27b). Taken together these results with the 
liposome sedimentation assay are at variance with the initial observations for binding of the Spred2 
EVH1 domain obtained from the overlay experiments.  
 
5.4.5. Summary 
Two different biochemical assays were performed to study the interaction of the 
Spred2 EVH1 domain with several phospholipids including phosphatidyl inositol phosphates. 
Whereas in a solid phase overlay assay an interaction was observed with immobilized PtdIns(3)P, 
PtdIns(4)P and PtdIns(5)P, no such interaction could be detected when these lipids and their bis-
phosphate derivates PtdIns(3,5)P2 and PtdIns(4,5)P2 were supplied in solution as vesicular 
preparations to study Spred2 EVH1 binding activity in a quantitative manner by a liposome 
sedimentation assay. The later assay format was considered to be a more sensitive and less error-
prone one compared to the more qualitative overlay assay. Due to its physiological conditions 
supporting protein lipid interactions we therefore consider the liposome sedimentation assay to 
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supply the more reliable data and conclude that the Spred2 EVH1 domain does not interact in 
solution with vesicles containing in a small mole fraction PtdIns(3)P, PtdIns(4)P, PtdIns(5)P, 
PtdIns(3,5)P2 and PtdIns(4,5)P2 as individual test lipids (Table.10). 
 
Phospholipid Protein Interaction 
PtdIns(3)P ADAP SH3-C Positive 
PtdIns(5)P ADAP SH3-C Positive 
PtdIns(3,5)P2 ADAP SH3-C Positive 
PtdIns(3)P Spred2 EVH1 Negative 
PtdIns(4)P Spred2 EVH1 Negative 
PtdIns(5)P Spred2 EVH1 Negative 
PtdIns(3,5)P2 Spred2 EVH1 Negative 
PtdIns(4,5)P2 Spred2 EVH1 Negative 
PC:PS Spred2 EVH1 Negative 
 
Table 6: Summary of phospholipid interaction experiments. Different types of phospholipids with different 
phosphorylation sites were tested against control domain (ADAP hSH3C) and query domain (Spred2 EVH1) for 
protein-phospholipid interactions by the liposome sedimentation assay and the results are shown in the table. 
 
In summary neither a peptide nor a phospholipid of the chemical classes studied here 
could be identified as a ligand of the Spred2 EVH1 domain. Experiments for ligand identification 
were done by genetically screening a cDNA expression library and a phage display library or by 
biochemically screening several phospholipid binding candidates. In each of these experimental 
approaches appropriate sets of positive and negative controls were used to asses their proper 
experimental performance. Biological consequences of these results with regard to the nature of the 
still elusive Spred2 EVH1 ligand(s) and its probable complementarity to a Spred2 EVH1 
interaction interface described recently at an atomic scale will be addressed in the Discussion 
section.
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6. DISCUSSION 
 
6.1. Protein interactions of the EVH1 domain containing proteins VASP and Spred2 
Protein interactions are of central importance for virtually every process in a living 
cell by mediating signals from the exterior to the inside of the cell. A protein may either interact 
with another protein just to modify it covalently (like a protein kinase adding enzymatically a 
phosphate group to a target protein) or proteins might interact only non-covalently to form part of a 
protein complex (like a modulator or suppressor protein interacting with its binding partner). 
During covalent modifications such as phosphorylation, phosphate groups are transferred to 
effector proteins under the control of secondary messengers to alter their binding activities whereas 
non-covalent interactions regulate the signal-dependent formation of protein complexes between 
interacting molecules. However, both covalent modification and non-covalent binding contribute to 
the signal transduction processes that trigger events inside the cell. The EVH1 domains are such 
protein-protein interaction adaptor modules essential for connecting their host proteins to various 
signalling pathways. In our study, protein interactions of the two EVH1 domain host proteins 
VASP and Spred2 were studied according to their involvement in different signal transduction 
pathways. EVH1 domains hold a unique binding pocket for their peptide epitopes and so far, the 
VASP EVH1 domain and its binding partners were well studied. Since VASP localizes as part of 
the actin cytoskeleton, it interacts specifically with different actin network proteins and also acts as 
a substrate for covalent modifications by PKA and PKG. The signalling pathways of many 
candidate protein kinases which could be involved in phosphorylation of VASP are not yet 
analysed. A majority of these signalling pathways can be triggered by stimulation of the cell with 
serum and therefore candidate protein kinases involved in phosphorylation of VASP during serum 
stimulation are disclosed in this study (see below). An entirely new class of the EVH1 domain 
family, consisting of the Spred2 EVH1 domain, carries a characteristic putative binding cleft region 
containing a subfamily specific triad of surface exposed aromatic amino acid residues which by 
homology are expected to bind unique sequences of its unknown peptide ligand(s) via non-covalent 
protein-protein interactions. The search for these unknown binding epitopes for the Spred2 EVH1 
domain was therefore performed as a part of our study addressing protein interactions of two EVH1 
domain containing proteins. The results from these interaction studies are discussed here with 
regard to the elucidation of candidate protein kinases involved in serum stimulated VASP 
phosphorylation and the identification of binding epitopes for the Spred2 EVH1 domain. 
The different signalling pathways leading to a possible phosphorylation of VASP 
during serum stimulation were predicted from literature knowledge and summarized into an 
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interaction network graph model forming the theoretical basis of our study (Fig.8). The external 
stimulation, the expected mediators of the external signal and the target substrates of the network 
including the final destiny were categorised into three hierarchical levels to model the process. The 
key players of each layer were represented as nodes in the interaction graph. The biochemical role 
of multiple nodes in this interaction network graph model was assessed experimentally by using 
different immunological tools and a pharmacological perturbation analysis in a well-defined cell 
line model. After treating the cells with pharmacological drugs acting as either activators or 
inhibitors of the target nodes in the interaction graph that represent different candidate protein 
kinases, the phosphorylation of VASP at its specific phosphorylation sites was studied by using 
phosphosite-specific antibodies for VASP as molecular probes. By mapping the results of the 
perturbation analysis into the interaction network graph model, un-affected nodes could thus be 
excluded and a subnet of the interaction graph was subsequently developed to model those 
candidate protein kinases involved either directly or indirectly in the phosphorylation of VASP 
during serum stimulation of the cells. 
The search for the unknown binding epitopes for the Spred2 EVH1 domain was 
performed by independent and complementary genetic and biochemical approaches using a cDNA 
or a peptide library together with libraries of candidate compounds. Two genetic interaction 
cloning strategies employing a bacterial two-hybrid and a phage display system were used for 
binding epitope identification of the recombinantly expressed Spred2 EVH1 domain. The atomic 
structure of this domain was recently solved by protein NMR spectroscopy. It revealed patches of 
positive surface charges on its putative binding pocket and thus raised the issue of interactions with 
negatively charged ligand molecules. Hence, we also searched for Spred2 EVH1 domain 
interactions with a panel of phospholipid candidate ligands. This study of two EVH1 domain 
containing proteins therefore covers both techniques and biological concepts for pathway 
elucidation in complete interaction networks and for an identification of direct binding partners of a 
single protein in such networks. However due to the different cellular function of VASP and 
Spred2 the networks studied belong to different and non-overlapping signal transduction pathways 
of the cell. 
 
6.1.1. Deciphering the serum stimulated VASP phosphorylation at Ser-157 
A number of proteins such as VASP, vinculin, talin, α-actin are associated with focal 
adhesions at the intracellular face of the plasma membrane [209]. In a functional cytoskeleton, all 
these molecules are forming complex connective networks with interactions at different levels 
either directly or indirectly. Earlier studies have shown that VASP binds to F-actin and co-localize 
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with stress fibres, focal contacts and highly dynamic membrane structures. It is a known fact that 
VASP is a major substrate for PKA and PKG, which phosphorylate VASP at Ser-157, Ser-239 and 
Ser-278 [2] and few recent research articles described PKC and AMP-activated protein kinase to 
phosphorylate VASP too [3, 4].  
From our study, we made the observation utilizing a serum starvation and 
stimulation protocol of mouse cardiac fibroblast (+/+) and mouse mesangial cells that VASP is 
phosphorylated at Ser-157 on stimulation of these cells as detected in cell lysates by electrophoretic 
mobility shifts and phosphorylation site-specific monoclonal antibodies (Fig.6 and 7). As this 
conditional phosphorylation had been observed in two different cell lines, this response is 
considered not to be a cell specific activity. VASP phosphorylation at Ser-157 by serum induced 
cell stimulation is a time dependent process whose kinetics was determined with a prominent 
activity nearly 90 min after treatment of starved cells with serum. It persists at a steady state level 
even after 10 hours. These observations clearly establish that serum stimulation induces VASP 
phosphorylation at Ser-157 in a time dependent manner after a lag time of 90 min. 
Generally, upon stimulation of cells with serum many protein kinases like MAP 
kinases, Rho kinases and PKC are activated which regulate cytoskeletal reorganisation in the cell. 
Of these three kinases, Rho kinase and PKC are known to interact with the actin cytoskeleton and 
focal adhesions where VASP also interacts with. An important isoform of Rho kinase, ROCK, 
mediates intracellular serum responses to the cytoskeleton by finally inhibiting actin polymerisation 
in a treadmilling process where VASP is also known to have a prominent role [210]. PKC is also 
one of the major protein kinases known to regulate focal adhesions and actin cytoskeleton 
contractions during serum stimulation [209]. Since these biological molecules show some overlap in 
activity and regulation with regard to serum response, we have investigated a possible role of these 
two protein kinases in the observed phosphorylation of VASP at Ser-157 during serum stimulation 
of cells. Based on published data of these and other protein kinases, an interaction network graph 
model of signalling pathways possibly phosphorylating VASP during serum stimulation was 
developed as described in Chapters 5.1.1 and 6.1 (Fig.8) with individual pathways numbered for 
convenient reference. In this network, the direct interaction between different nodes is in general not 
known and therefore we represent such interactions as multiple arrow lines keeping in mind that 
there might be further mediators involved in these signal passages. In our experimental work we 
have looked for a role of these target nodes in terms of VASP phosphorylation as shown in the 
network graph and internal mediators were not searched for in our study. Combinatorial treatment 
with activators and inhibitors of different target nodes of the network allows us in defined 
perturbation experiments to determine the key players involved in this cascade. A major issue which 
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needs to be carefully addressed in such type of experiments is the specificity profile of the 
pharmacological substances used to target the proteins of interest. Most of the protein kinase 
inhibitors have been developed based on competitive activity either against the secondary 
messengers that regulate the protein kinases or their common substrate ATP. The inhibitors 
developed for a particular kinase can therefore disturb the activity of several other protein kinases 
either partially or completely in a chosen concentration range due to their isomeric chemical 
structure. Similarly activation of one protein kinase by its respective activator should in general not 
interfere with other protein kinases since this response pattern would misguide results obtained by 
activating the targeted signalling pathway. To overcome such experimental limitations in the 
chemical dissection of an unknown signalling cascade, careful control experiments that complement 
the pharmacological approach are necessary and have been performed here. 
 
Inhibitory targeting of the two nodes “Rho kinase” and “PKC” in the interaction 
network graph model by the drugs Y-27632 and Ro-31-8220 respectively had shown that only 
PKC but not Rho kinase participates in phosphorylation of VASP at Ser-157 upon stimulation of 
cells with serum (Fig.9a). These data thus rule out any pathways mediated by Rho kinase in this 
process i.e. those pathways numbered as [4, 4´, 4´´] in our interaction network model (Fig. 8). 
However due to their specificity profile these inhibitors may also interrupt the activity of those 
nodes (PKA and PKG) of the interaction network which are already known from literature data to 
phosphorylate VASP at Ser-157 by cyclic nucleotide dependent pathways. Hence, we examined the 
activity of the PKC and Rho kinase inhibitors used here with regard to their sensitivity towards 
PKA and PKG. We found that these inhibitors are not unspecifically interrupting a PKA and PKG 
mediated VASP phosphorylation (Fig.9b) and our data therefore suggests that these inhibitors act 
specifically to only inhibit the addressed target nodes under the experimental conditions used here. 
This data proved a role of PKC in phosphorylation of VASP at Ser-157 upon stimulation of cells 
with serum and we therefore studied its function in more detail. 
It is known from the literature that activation of PKC with phorbol ester induces 
focal adhesions and cell contraction due to remodelling in the cell cytoskeleton [211]. The phorbol 
ester activates only classical isoforms of PKC that regulate the activity of the cytoskeleton. Hence, 
we asked whether classical isoforms of PKC mediate serum stimulated VASP phosphorylation. 
Activity of these phorbol ester sensitive classical isoforms could be inhibited specifically by using 
the compound Bis I [175]. An optimal concentration (10 μM) of Bis I was found to prominently 
inhibit serum stimulated VASP phosphorylation at Ser-157 under the experimental conditions used 
(Fig.11a) demonstrating that Bis I sensitive classical isoforms of PKC are involved. We then 
Discussion 
 
112 
looked at the effect of the phorbol ester PMA on VASP phosphorylation. Our experimental results 
showed that PMA phorbol ester stimulation which activates classical isoforms of PKC induced 
VASP phosphorylation (Fig.11b). It is well known from the literature that phorbol ester treatment 
initially up-regulates PKC activity followed in the long run by its down regulation due to a 
translocation of PKC to the cell membrane [185]. Upon phorbol ester treatment, VASP 
phosphorylation showed a similar temporal pattern of activation and inactivation as that reported 
for activated PKC alone upon PMA stimulation. There is a transient phosphorylation of VASP at 
Ser-157 after 2 min of PMA stimulation which persisted no longer than 8 min after stimulation 
probably due to a down regulation of PKC activity by the phorbol ester (Fig.11b).  
Since classical PKC isoforms were identified to mediate serum stimulated VASP 
phosphorylation at Ser-157, it was necessary to elucidate if this signalling cascade is also 
dependent on the well known protein kinases PKA and PKG which have already been found to 
phosphorylate VASP (See interaction graph model in Fig.8) under different experimental 
conditions. In consecutive experiments, we therefore looked at a role of PKA and PKG in VASP 
phosphorylation at Ser-157 upon stimulation of cells with serum. The PKG inhibitor Rp-8-Br-
cGMPS used in our experiments was not observed to disturb serum stimulated VASP 
phosphorylation at Ser-157 and it was subsequently found based on immunological detection that 
MCFB cells (+/+) even lack PKG (Fig.10b). Hence, we concluded that PKG most probably has no 
role in serum stimulated VASP phosphorylation at Ser-157. This result is in line with our 
observations showing an absence of phosphorylation of VASP at Ser-239 during serum 
stimulation, which is the preferable site for PKG in this substrate (Fig.7b). These data is in 
accordance with previously published ones for the same cell line [182]. With this information at 
hand, it was possible to experimentally exclude the involvement of a further node and its associated 
pathway (numbered as [3] of our interaction network graph model in Fig.8) i.e. PKG was shown 
not be involved in serum stimulated VASP phosphorylation at Ser-157. A similarly designed 
experiment with H89 used as inhibitor of PKA showed a clear-cut inhibition of serum stimulated 
VASP phosphorylation at Ser-157 (Fig.10a). This result suggests a role for PKA in serum 
stimulated VASP phosphorylation at Ser-157. H89 can also inhibit PKG [177] but this is clearly 
not of concern here as our cells lack this enzyme. Our experiments showed that H89 can be used as 
a PKA-specific inhibitor in MCFB cells (+/+) at an optimal concentration of 10 µM. Furthermore 
these results are consistent with previous data obtained under different conditions of cellular 
stimulation identifying Ser-157 of VASP as the phosphorylation site preferred by PKA (see Fig.1). 
So far after excluding any involvement of Rho kinases and PKG, our experimental 
results have identified PKC and PKA as major protein kinases participating in VASP 
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phosphorylation at Ser-157 upon stimulation of MCFB cells (+/+) with serum. This 
phosphorylation at VASP Ser-157 by a combined action of PKC and PKA seems to utilize a 
signalling pathway which is clearly different from that of a PKA induced VASP phosphorylation at 
the same site under different stimulatory conditions. The data obtained on the two candidate protein 
kinases involved left us however with the question how PKA mediated VASP phosphorylation at 
Ser-157 upon serum stimulation relates to the serum-induced signalling cascade mediated by PKC 
upon phosphorylation of the same site of the VASP molecule. Control experiments with regard to 
specificity have also identified Bis I and PMA as useful tools for modulating in intact cells the 
activity of PKC by either inhibition or activation. Similar control experiments showed that for 
modulating the PKA activity the drugs H89 and Forskolin could be used in experiments with intact 
cells for either directly inhibiting or indirectly activating this enzyme. Summarizing the data 
obtained we therefore came up with a reduced model of the possible interaction network pathways 
as shown in Fig.28a with PKA and PKC identified as the main nodes together with the set of 
inhibitors and activators targeting each of them. The model is still ambiguous with regard to PKC 
and PKA participating in either a serial or a parallel order of action with regard to VASP 
phosphorylation in serum-stimulated cells. However with the characterized tools available it was 
now further elucidated experimentally by a combinatorial in-vivo modulation of the network target 
nodes involved in serum stimulated VASP phosphorylation i.e. a simultaneous activation and 
inhibition of these protein kinases. Specifically experiments using various drug combinations were 
therefore designed to activate either PKC or PKA instead by serum stimulation with their 
respective activators (PMA or Forskolin) in the presence of the protein kinase inhibitors (Bis I or 
H89) targeting either the same or the alternative node of the network. 
Using a combination of Bis I and Forskolin together we found that the PKC specific 
inhibitor Bis I did not inhibit VASP phosphorylation at Ser-157 during Forskolin stimulation of the 
collateral node which activates the adenylyl cyclase and thus PKA (Fig.12b). The complementary 
experiment was performed with activation of PKC by short term treatment with PMA in the 
presence of the PKA inhibitor H89. VASP phosphorylation was found to be inhibited under these 
conditions (Fig. 12c). Taken together these results strongly suggest that the signalling pathway is 
not organised in the direction from PKA to PKC but instead PKA seems to participate in the 
process of VASP phosphorylation after initial stimulation of PKC. Thus the pathway numbered 
[e+2´+1] in the reduced model as shown in Fig.1a could be excluded experimentally and the data 
are compatible with a pathway organization summarized as [b+1’+2] in the model. The 
insensitivity of Forskolin stimulated VASP phosphorylation to a PKC inhibitor and the successful 
inhibition of PMA stimulated VASP phosphorylation by a PKA inhibitor is fully explained by the
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Figure 28: Final model of the signalling pathways contributing to serum stimulated VASP phosphorylation. Possible pathways for serum stimulated VASP phosphorylation 
involving the protein kinases PKC and PKA are shown in Fig. a of this experimentally reduced version of our interaction graph model. Pathways given with unbroken lines show 
direct interactions. The pathways involving PKC and PKA (with pathway numbers [1] and [2]) were further analysed experimentally by a combinatorial use of specific activators 
and inhibitors of these protein kinases to elucidate their order of action. The results of these experiments are summarized in the model of Fig. b. Cumulative data suggest that PKC 
acts upstream of PKA in serum stimulated VASP phosphorylation at Ser-157. 
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proposed pathway in the final model of Fig.28b with PKC acting upstream of PKA. Additional 
support was observed in the following experiment. After down regulation of PKC by phorbol ester 
long term treatment, Forskolin treated cells showed undisturbed phosphorylation of VASP at Ser-
157 as mediated by PKA (Fig.11c) emphasing again the proposed pathway organisation. Moreover, 
the interpretation of our experimental results given here is also in line with information from the 
literature showing that it is PKA that prefers Ser-157 as a phosphorylation site on VASP [2](see 
Fig.1). However it is still not yet understood how PKC and PKA interact under these conditions 
and how a signal is mediated between these two kinases. In particular the internal regulation of 
PKA after receiving the signal from PKC during serum stimulation either by secondary messengers 
or any other regulator to phosphorylate VASP at Ser-157 is not settled from the experimental 
results presented here. Some published studies are supporting directly and indirectly that PKC and 
PKA can interact during various signal transduction processes [212, 213]. PKC has been shown to 
activate many other cytoskeletal proteins including associated protein kinases during its activity. It 
is known to modulate focal adhesions and stress fibres through numerous mechanisms. The α 
isoform of PKC is translocated to focal adhesions upon activation of the fibronectin receptor, αIIbβ3 
after stimulation by serum or growth factors, and it is reported that PKC phosphorylates focal 
adhesion proteins such as vinculin and talin [214, 215]. Additionally, PKC modulates the cellular 
cytoskeleton through the regulation of intermediate filaments and stress-fiber related proteins, 
including vimentin, CPI-17, myosin light chain kinase, tau protein and numerous others [215]. It is 
still a matter of debate how PKC exerts its influence on VASP. Recent published data supplied 
preliminary information from different cell models that PMA activation of PKC induces VASP 
phosphorylation either directly [4, 52] or indirectly by activating PKG [216]. However this type of 
interaction can be excluded in MCFB cells (+/+) since they lack PKG. These discrepancies in 
signalling pathway organisation seem to be due to cell type or organism specific expression 
patterns of signalling networks.  
In conclusion based on our experimental results and literature information, we 
hypothesize that PKC receives an external stimulatory signal upon serum stimulation of MCFB 
(+/+) cells which is passed either directly or indirectly to PKA which finally phosphorylates VASP 
at Ser-157. PKA is thus positioned downstream of PKC in serum stimulated phosphorylation of 
VASP and is probably located most proximal to its substrate VASP giving the following pathway: 
serum stimulation →→ PKC → → PKA → phospho Ser-157 VASP as shown in the final model of 
Fig.28b.  
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6.1.2. Identification of unknown binding epitopes for a new class of EVH1 domains 
In a cell, modular proteins involved in signal transduction utilize a limited number 
of highly conserved, non-catalytic, ‘adaptor’ domains to mediate their non-covalent interactions 
during the formation of transient, multi-protein signalling complexes [99]. Such adaptor domains 
recognise surface-exposed sites on their binding partners such as proline-rich-, phosphorylated- or 
C-terminal motifs. For example, domain families namely EVH1, SH3, GYF, UEV and WW 
domains and the single domain protein profilin are known to recognise highly conserved clusters of 
proline rich motifs (PRM)[86]. Further, some of the modular domains (mostly in apoptotic 
signalling proteins) undergo homo- or heterotypic domain-domain interactions rather than binding 
short peptide motifs [99]. Sometimes, certain cytoskeletal modular domains like the pleckstrin 
homology (PH) or SH3 domains bind to different phosphorylated head groups of phospholipids 
[99, 120]. 
The EVH1 domains regulate their interactions via a unique recognition pocket 
exposed on their surface due to a set of three aromatic amino acids which bind to peptides that are 
usually 6-13 amino acids long and contain proline-rich motifs of 4-6 amino acids. The recently 
discovered Spred proteins harbour a new class of EVH1 domains at their N-terminus whose atomic 
structure was recently been determined by NMR spectroscopy [33]. The atomic structure of the 
domain revealed patches of positive surface charge in its putative binding cleft region and thus 
suggests interactions with negatively charged ligand molecules. Since the Spred2 EVH1 domain is 
expected to bind unique ligand(s), search for its binding epitopes had been performed in our study.   
As protein-protein interactions are so important there are a multitude of high-
throughput methods available to detect them [126]. Each of the approaches has its own strengths 
and weaknesses, especially with regard to the sensitivity and specificity of the method. These 
approaches may for instance select clones that have an apparently positive readout phenotype but 
that when further analysed are not of physiological relevance. Such clones are usually referred to as 
“false-positives” [217]. In some cases, expected interacting clones may escape from a library 
screening which are then referred to as “false-negatives”. In general a high sensitivity of a method 
used suggests that many of the interactions that occur in reality can be detected by the screen 
giving a low false-negative rate while a high specificity approach indicates a low false-positive rate 
with most of the interactions detected by the screen actually occurring in reality [218]. Detection of 
protein interactions is complicated by the fact that protein themselves are chemically distinct 
entities with differing charges, numerous secondary and tertiary structural folds that may include a 
wide variety of post translational modifications. Selection of a method suitable to detect an 
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interaction depends on the protein for which the interactions are to be screened and several 
methods are available as already described in Chapter 2.3.  
The majority of protein-protein (peptidergic) interaction studies were done by in-
vivo two-hybrid systems and in-vitro bacterial-based phage display methods [219]. Since few 
years, these methods have been scaled up in screening entire complements of proteins or peptides 
in large library formats. The in-vivo two-hybrid systems have been well-established in yeast and 
their more advanced developments allowed biologists to test inference about the functional aspects 
of entire protein networks [139]. Over the past few years, analogous to the embodiment of the yeast 
two-hybrid systems, similar genetic assays were developed in E. coli to facilitate a more rapid 
analysis of even larger libraries due to the higher transformation efficiency and faster growth rate 
of this organism [136, 137]. A bacterial two-hybrid (B2H) system thus offers a number of 
potentially significant advantages over analogous yeast based two-hybrid methods in identifying 
and characterizing protein-protein interactions from large scale cDNA expression libraries [137, 
187]. In particular, it does not require a nuclear localisation of the interaction partner or any export 
of proteins to the cell membranes and it is possible to study proteins that are toxic to yeast [137]. 
Furthermore, an E. coli based two-hybrid screening reduces the chance that the host harbours any 
closely related homologues of an interacting partner. The in-vitro selection technique of phage 
display in contrast enables small protein fragments with desired properties with respect to binding 
of a target protein to be identified from large collections of peptide variants displayed on the 
surface of filamentous phages such as M13. Since phage M13 is a non-lytic phage which can be 
produced in high titres and secreted from the infected bacterial host cell without their killing or 
lysis, it also greatly simplifies phage purification steps and thus peptide identification by DNA 
sequencing of the isolated clones. 
After considering different approaches for detection of peptidergic interactions, two 
interaction cloning approaches employing a bacterial two-hybrid and a M13 phage display system 
were used in our study for in-vivo screening of a cDNA library and in-vitro screening of a M13 
9mer peptide library respectively to search for the unknown binding epitopes of the Spred2 EVH1 
domain. These two genetic technologies are considered as orthogonal i.e. independent and 
complementary approaches suitable for a detection of protein interactions solely based on the 
assumption that Spred2 EVH1 ligands are of peptidergic nature. The B2H screening system used in 
our studies was based on a HIS3 gene reporter system developed by Joung et al [137, 188] whereas 
the peptides displayed on the surface of phage are fused N-terminally to the major capsid protein, 
pVIII of phage M13 [158]. Both genetic systems had to be established in our study for Spred2 
EVH1 binding interactions using well-characterized positive controls to survey experimental 
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conditions most likely to detect unknown EVH1 domain interactions. Based on those experimental 
conditions and guided by the control experiments performed in parallel, the search for binding 
epitopes of the Spred2 EVH1 domain was performed by us. 
The B2H system was first of all established for a physically well characterized 
VASP EVH1 and ActA peptide interaction pair [24] which was used as a tool to calibrate the 
system for the genetic detection of low affinity interactions which are characteristic of EVH1 
domains. The HIS3 based B2H system offers the advantage to be easily regulated at different 
selection stringency levels by varying the concentration of 3-AT as the selection agent. This results 
in a 3-AT dose-dependent growth of resistant clones as reflected in their differential plating 
efficiency. Recombinantly expressed ActA peptides with different binding strengths as determined 
in-vitro against the VASP EVH1 domain [24] were used as target peptides in doubly transformed 
bacterial cells also expressing the latter protein. 3-AT resistant growth indicating VASP EVH1 and 
ActA peptide in-vivo interaction was observed for those clones expressing a wild type ActA 
peptide 332SFEFPPPPTEDEL344 or its tighter binding mutant 332SFEWPPPPTEDEL344 at 3-AT 
concentrations even up to 5 mM (Fig.14). The non-binding mutant peptide 332SFEAPPPPTEDEL344  
as observed from in-vitro data [24] failed to support 3-AT resistant growth of the reporter strain 
even at the lowest concentrations tested. These experimental results clearly showed to us that the 
B2H system records successfully in-vivo an interaction of an EVH1 domain with its cognate 
binding motif which has already been well-characterized in-vitro at the structural and energetic 
level [24, 29]. We thus expect the B2H system of Joung et al. to be a suitable tool for the genetic 
identification of unknown peptide binding epitopes of the Spred2 EVH1 domain.  
A human brain cDNA expression plasmid library was then chosen for a binding 
epitope screen by the B2H system since the Spred protein is known to be ubiquitously expressed in 
brain and neural tissues [79]. The cDNA library screening performed at a selection stringency of 1 
mM 3-AT using a λcI fusion protein with the Spred2 EVH1 domain as the bait gave thousands of 
3-AT resistant colonies. A further library screening was therefore performed by increasing the 
selection stringency to 5 mM 3-AT. This higher selection stringency tremendously reduced the 
population of 3-AT resistant colonies. However, replica plating of 3-AT resistant colonies to a 
secondary screening medium and thus selection based on transcriptional activation of the aadA 
gene which is located downstream of HIS3 reporter gene and responsible for Streptomycin 
resistance could not further differentiate among colonies. Target plasmid isolates from resistant 
colonies of both screenings were physically characterized showing that these plasmids carry insert 
target fragments (Fig.17). Inserts selected by the Spred2 EVH1 domain from the cDNA library 
showed a heterogeneous molecular weight distribution demonstrating clonal heterogeneity of the 
Discussion 
 
119 
isolates obtained. Positive target plasmid isolates were then further validated genetically by a panel 
of genetic assays designed to asses (a) their potential for transcriptional self-activation in the 
absence of the bait plasmid (b) the linkage of the growth phenotype to the target plasmid isolated 
and (c) Spred2 EVH1 specificity of interaction by comparison against a VASP EVH1 bait plasmid 
(Fig.18). Positive and negative interaction control plasmid pairs were used in this panel of genetic 
assays during validation of the target plasmid isolates. The 3-AT resistant growth phenotype 
observed in these assays were analysed quantitatively by determining the plating efficiency (PE) of 
the clones and thus comparing these with the panel of interaction control pairs. PE values are 
expected to directly correlate to the interaction strength at a defined selection stringency for a 
fusion protein pair tested [198]. None of the target isolates showed self activation by expression of 
a 3-AT resistant phenotype in the absence of the bait plasmid. Surprisingly the majority of the 
positive target isolates assayed in these genetic assays scored at PE values not higher than the 
background value corresponding to a non-specific interaction with a query domain (Table.8). 
Sequence analysis of those few positive candidates of target isolates showing PE values similar to 
that of the VASP EVH1 and ActA interaction pair revealed however that they were not carrying in-
frame coding sequences for expression of target peptides which would interact with the Spred2 
EVH1 domain. Overall, screenings by the B2H system of a human brain cDNA expression plasmid 
library performed at two different selection stringencies for binding epitopes of the Spred2 EVH1 
domain did not detect any Spred2 EVH1 specific interactions. The library screening experiments 
performed under these experimental conditions seemed to be completely dominated by false-
positive isolates. 
Although two-hybrid methods are generally considered to be highly sensitive in 
particular to detect domain-mediated interactions [139], our experimental results showed its 
reduced specificity in search for Spred2 EVH1 ligands leading to high numbers of false positives. 
The selection stringencies used might thus be either too low or too high for the detection of Spred2 
EVH1 domain specific interactions. Of course no data about its binding affinities are available to 
evaluate these alternatives. If the selection stringency used here is above the threshold level for 
Spred2 EVH1 domain interactions, high false-negative rates are expected in these experiments and 
vice-versa with false-positive isolates. For an unknown interaction pair it is impossible to predict 
threshold selection stringency. Based on the structural information revealed from X-ray 
crystallography [76] and the NMR-spectroscopy of the Spred2 EVH1 domain (accession number 
“2JP2” and Fig.24), it was speculated that the domain might bind its ligands at affinities lower than 
those known for other EVH1 ligands. If this expectation is true then according to our results it 
would be difficult to detect such interaction strengths in a B2H based screen. If however Spred2 
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EVH1 ligand interactions occur at higher affinities than the well characterized EVH1 class 1 
interactions probably due to binding of extended epitopes similar to those described for the WASP 
EVH1 class 3 ligands (see Chapter.2.2.2.3) [33], selection stringencies as applied in our library 
screenings are not expected to be high enough to screen for such interactions.  
Several retrospective analyses of published protein-protein interaction data obtained 
at a genomic scale, mainly in yeast, have shown that the actual results deviate strongly from the 
gold standards of optimal specificity and selectivity and normally show unexpectedly high levels of 
false-positive and false-negative rates [142]. Binding epitope discovery can be viewed as “a needle 
in a haystack” problem [220] that is small target sizes of the expected Spred2 EVH1 binding 
epitopes are to be identified in a highly complex sequence space spanned in our case by a 
collection of large cDNA fragments as represented in an expression library. Discrimination of 
sequence stretches coding for such small binding epitopes against a huge background by cDNA 
sequences is thus a challenging problem. Another biological problem to cope with by any in-vivo 
interaction cloning approach using heterologously expressed proteins might be based on the limited 
accessibility of candidate binding epitopes. This could be due to a biased or incorrect folding of 
their host proteins upon heterologous expression in a bacterial cell. Furthermore heterologous 
eukaryotic protein expressions in a prokaryotic host cell might not accomplish the required post-
translational modification which might be a necessary factor supporting the interaction. By 
considering a posteriori all these complications in principle inherent to a B2H system, we expected 
that screening of target peptide libraries under in-vitro conditions using a purified bait protein 
would be an alternative approach to identify the Spred2 EVH1 domain binding epitopes. 
An in-vitro screening of repertoires of non-natural short target peptides exposed on 
the surface of phage virions seems to be superior for a precise target access and the corresponding 
affinity selection for Spred2 EVH1 binding epitopes. Thus, a phage display library screening for 
Spred2 EVH1 ligands of a M13 X9mer peptide library displayed N-terminally to the pVIII major 
capsid protein was performed by using purified, natively folded GST-Spred2 EVH1 protein as 
assessed by NMR spectroscopy. A GST-Fyn SH3 protein was used as a positive control for this 
library screening since its binding epitope has already been determined by screening the same 
phage display library which is used in our study [203]. Hence, this positive control domain would 
help us to calibrate the screening conditions for the GST-Spred2 EVH1 protein. Progressive 
enrichment of a positively interacting phage population with immobilized bait protein was 
calculated as a series of enrichment factors in each round of panning. For the positive control 
protein the enrichment factor reached saturation after four rounds of panning against this domain in 
our experiments. As observed by colony PCR, the phage populations enriched consists entirely of 
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phage particles with inserts coding for the expected size of the specific target peptide (Fig 22a). 
This result demonstrates a successful establishment of the experimental protocol for a phage 
display screening. In contrast, similar panning with the same library using the GST-Spred2 EVH1 
protein revealed an irregular enrichment during successive rounds (Table.9). Analysis of phages by 
colony PCR after infecting to E. coli cells showed that the majority of the isolates did not carry any 
inserts and thus will not express any target peptides fused to and displayed with the capsid protein. 
Sequencing of those small sample set of insert containing phages identified a population mainly 
containing stop codons. Only two isolates harbor in-frame ORF fusions, one of which contains a 
13mer proline-rich sequence. The significance of this observation is however unclear not only in 
the context of the non-specific overall performance of the phage display library screening 
experiment with the Spred2 EVH1 domain but also in light of the fact that the library used had 
been constructed for 9-mer insert sizes. Selection of phages containing in majority either no inserts 
or even stop codons suggests that already an N-terminal fragment of the pVIII major coat protein 
might display sticky epitopes that non-specifically interact with the Spred2 EVH1 but not with the 
Fyn SH3 domain. Therefore the phage display peptide library screening for identification of 
binding epitopes for the Spred2 EVH1 domain was of only limited over-all success despite the 
isolation of a promising candidate binding clone. Several factors could have been responsible for 
the non-specific performance of our phage display screening experiments. A partial occlusion of 
the Spred2 EVH1 binding surfaces by the GST moiety of the fusion construct should be 
considered. Although an alternative small fusion tag would be preferably such as a hexahistidine 
peptide, increased binding affinity of phages to a Ni-NTA matrix compared to a GSH-Sepharose 
matrix should be considered in view of artefacts which could arise by selection of Ni+2 binding 
phages [157]. Since the phage display assay involves in-vitro affinity selection, the system can 
obviously not support any post-translational modifications. Finally the Spred2 EVH1 domain might 
be too sticky for a phage M13 based screening approach. 
In general, EVH1 domains bind to proline-rich core motifs of 3-6 amino acids 
present in the binding epitope of target peptides. Further affinity- and specificity-increasing 
interactions are then formed between additional domain regions and 'core-flanking' peptide 
residues [85]. For this reason, we had used a 9mer peptide phage display library based on the 
expectation that binding epitopes for the Spred2 EVH1 domain are similar to those of the VASP 
EVH1 domain (see Chapter 2.2.2.1). However the Spred2 EVH1 domain does not seem to be able 
to bind with sufficient affinity to our phage display 9mer peptide library thus probably suggesting a 
requirement for still larger epitope sizes in a more stable ligand binding. The isolation of a 13mer 
proline-rich sequence by the Spred2 EVH1 domain from a 9mer library might suggest a preference 
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of this domain for 13mer peptides probably containing several core-flanking residues. But such 
larger peptide sequences could probably not be enriched in large amounts from this library due to 
its construction based which was based on short peptides. A single 13mer proline-rich isolate alone 
is certainly not enough to determine the binding specificity of the Spred2 EVH1 domain. However, 
we consider this 13mer proline-rich peptide as a first cue which could be followed up by further 
screening experiments like SPOT scans to identify in detail the Spred2 EVH1 domain binding 
motif. 
The inability to find Spred2 EVH1 ligands so far not only with a B2H system but 
also by phage display library screening experiments raised doubts about a peptidergic nature of the 
ligand. It was therefore necessary to consider additionally a non-peptidergic nature of the still 
elusive binding ligand. The atomic structure of the Spred2 EVH1 domain showed patches of 
positive surface charge in the region of the expected binding epitope recognition site which are not 
observed in any of other EVH1 classes whose structures have been determined so far (Fig.24). It is 
already known from adaptor domains like pleckstrin homology (PH) or SH3 domains that 
positively charged surface regions bind to negatively charged phosphorylated phospholipids of 
different composition [99, 120]. To assess binding interactions of the Spred2 EVH1 domain with 
candidate phospholipids, solid phase overlay and liquid phase sedimentation assays were 
performed in the course of this study. The N-terminal and C-terminal SH3 domains of the ADAP 
protein were used as negative and positive controls respectively in our experiments to follow up 
their performance. As a prerequisite a natively folded conformation of the bait protein is required 
for assaying its interaction. Hence, the bait protein independent of the GST moiety was analysed by 
1H NMR and found to be actively folded in the protein preparations used. 
Protein-phospholipid solid phase overlay assays performed against natively folded 
Spred2 EVH1 protein with membrane strips carrying 15 different, biologically active, pre-spotted 
phospholipids showed a positive interaction of decreasing apparent binding intensity with 
phosphatidyl inositol 5-phosphate [PtdIns(5)P], phosphatidyl inositol 3-phosphate [PtdIns(3)P], 
and phosphatidyl inositol 4-phosphate [PtdIns(4)P] (Fig.25). Further analysis however of these 
binding activities by liquid phase sedimentation assay of the phospholipids including their bis-
phosphates phosphatidyl inositol 3,5-bisphosphate [PtdIns(3,5)P2] and phosphatidyl inositol 4,5-
bisphosphate [PtdIns(4,5)P2] did not show any interactions of the Spred2 EVH1 domain with 
liposomal vesicles of up to 1.2 mM concentration (Fig.27). In contrast, the positive control domain 
showed a strong interaction even at the lowest concentrations tested for the expected phospholipids 
and thus confirmed the correct preparation of liposomes and its handling. The reason for a different 
interaction behaviour of a protein in two different assay formats against the same set of 
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phospholipids is currently unclear. Of the two tests performed, the solid phase overlay assay is 
considered to be at best a semi-quantitative one whereas the more sensitive liquid phase 
sedimentation assay is a truly quantitative assay performed at different lipid concentrations. It thus 
permits determination of affinities in dose dependent experiment with a low error rate in terms of 
binding specificity. The interactions detected in the solid phase overlay assay are considered 
therefore as false positives without biological relevance and are probably due to non-specific 
electrostatic interactions between a positively charged protein molecule and the negatively charged 
phospholipids spotted on the membrane. Such interactions will be excluded in the liquid phase 
sedimentation assay where different concentrations of liposomes are incubated with the protein 
assaying after separating unbound protein for its physical contact in liquid phase. Since the 
technically more reliable liquid phase sedimentation assay did not show any interaction of the 
phospholipids tested with the Spred2 EVH1 domain, we concluded from this study that the Spred2 
EVH1 domain does not interact with the negatively charged phospholipids tested despite its 
positive surface charge. These results seem to exclude a non-peptidergic nature of the ligand for the 
Spred2 EVH1 domain at least with regard to the common classes of phospholipids analysed here. 
 
6.2. Conclusions and open questions 
In the first part of our study, the protein kinases involved in the serum stimulated 
VASP phosphorylation in MCFB cells (+/+) are identified as classical isoforms of PKCs and PKA. 
However the nature of an exchange of signals from PKC to PKA remains unclear; a direct 
interaction or any further mediators could be involved. The signal transmitted between these two 
molecules might be based on a low-molecular activator to be identified. It was not possible to 
address this question from the experimental setup of our study. It will also be necessary to study 
the newly detected signalling pathway in different cell models using further pharmacological 
compounds. A major limitation of any signal transduction study based on perturbation analysis is 
the choice of the appropriate pharmacological drugs since their specificity is often highly 
dependent on the biological context. If the signalling pathway detected in our study is of a more 
general nature, it should be reproducible in other biological models of cellular serum stimulation. 
We have proved so far this signalling process in two different cell models i.e. mouse cardiac 
fibroblast cells and mouse mesangial cells. Although we have performed our experiments with 
properly designed experimental controls, there is always a need to retest a pathway in future 
experiments whenever any new pharmacological drugs to target it may arise. 
In the second part of our study, the cumulative evidence suggests to us a peptidergic 
nature of negatively charged Spred2 EVH1 ligands since a phospholipid mediated interaction to 
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this domain seems highly unlikely. In principle a peptidergic binding epitope of an adaptor domain 
or a receptor could form one of the following types: it could be a short or extended, linear or 
conformational, continuous or discontinuous, post-translationally modified or unmodified peptide 
sequence with or without any cofactor requirement. Although an in-vivo B2H and an in-vitro phage 
display system offer a wide range of library screening formats, they will not detect any post-
translationally modified ligands including phosphorylated recognition motifs. Eukaryotic proteins 
studied in E. coli based library screenings are expected to lack co-factors or post-translational 
modifications which however could occur in yeast for determining potential interactions [134]. In 
general proteins can be altered by a diverse set of post-translational modifications that include 
phosphorylation, methylation, acetylation, ubiquitylation and hydroxylation [221]. A post-
translational modification attached to one amino acid can antagonise or favour the ability of 
adjacent residues to recruit a binding partner. Some modular domains like SH2, PTB, WW or 14-3-
3 domains recognise target core motifs containing phosphorylated residues [99, 221]. Due to the 
pronounced positive surface charge of the Spred2 EVH1 domain as revealed by its atomic 
structure, hydrophobic phosphopeptide binding motifs would be attractive candidates to think of in 
next steps of a study. Considering tools like phosphopeptide SPOT scans or yeast two-hybrid 
systems which may identify interactions of the Spred2 EVH1 domain with post-translationally 
modified epitopes would be an attractive option for future experiments. 
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8. Abbreviations      
 
3-AT   3-amino-1, 2, 4-triazole 
8pCPT-cGMP  8-(para-Chlorophenylthio) guanosine-3’,5’-cyclic monoposphate 
aadA    Aminoglycoside 3`adenyltransferase 
Abl    Ableson tyrosine kinase 
AC    Adenylate cyclase 
ADAP   adhesion- and degranulation-promoting adaptor protein) 
AMPK   AMP activated protein kinase 
APS    Amonium persulfate 
Arp 2/3   Actin related protein 2/3 complex 
ATP    Adenosine triphosphate 
B2H system  Bacterial two-hybrid system 
Bis I    Bisindolylmaleimide I 
Bis V    Bisindolylmaleimide V 
DMEM   Dulbecco’s Modified Eagle Medium 
DMSO   Dimethyl Sulfoxide 
ECL    Enhanced chemoluminiscence 
EDTA   Ethylendiamine tetraacetic acid 
EGF    Epithelial growth factor 
EVH1    Ena/VASP homology 1 
EVH2    Ena/VASP homology 2 
EVL    Ena/VASP–like 
F-actin   Filamentous actin 
FCS    Foetal Calf Serum 
Fyb/SLAP   Fyn binding protein/SLP76 associated protein 
G-actin   Globular actin (monomeric actin) 
IP3    Inositol-1,4,5-triphosphate 
IPTG    Isopropyl-β-D-Thiogalacto(pyrano)side 
KBD   c-Kit binding domain 
LPA    Lysophosphatidic acid 
LPP   Lipoma preferred partner 
MAP Kinase   Myosin activated protein kinase 
MARCKS   Myrostylated alanine-rich C-kinase substrate 
MCFB   Mouse cardiac fibroblast 
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Mena    Mammalian enabled 
MINT   Molecular INTeraction database 
MLC    Myosin light chain 
MLCK   Myosin light chain kinase 
NMR   Nuclear magnetic resonance 
PBS    Phosphate buffered saline 
PC   phosphatidylcholine 
PEG   Poly ethylene glycol 
PKA    Protein kinase A 
PKC    Protein kinase C 
PKG    Protein kinase G 
PMA    Phorbol 12-Myristate 13-Acetate 
PRM   Proline rich motif 
PRR    Proline rich region 
PS   phosphatidylserine 
PtdIns(3)P  phosphatidyl inositol 3-phosphate 
PtdIns(5)P  phosphatidyl inositol 5-phosphate 
RACKS   Receptor for activated C-kinases 
Robo    Roundabout 
Rp-8-Br-cAMPS  8- Bromoadenosine- 3', 5'- cyclic monophosphorothioate, Rp-isomer 
SDS    Sodium dodecyl sulphate 
SEMA6A-1   semaphoring 6A-1 protein 
SGC   Structural genomic consortium 
SH3    Src homology domain 3 
SNP    Sodium nitro prusside 
SPR    Sprouty related 
Spred   Sprouty related with an EVH1 domain 
SRE    Serum Response Element 
SRF    Serum Response Factor 
TEMED   N,N,N’,N’-tetramethylendiamine 
VASP    Vasodilator Stimulated phosphoprotein 
WASP   Wiskott Aldrich Syndrome protein 
WH1    WASP homology 1 
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